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Abstract 
Burkholderia is a multi-talented genus of Gram-negative bacteria that has been recently shown 
to be a promising, untapped source of antibiotics with the potential to overcome antimicrobial 
resistance. An antimicrobial activity screen of a clinical isolate, B. gladioli BCC0238, identified a 
novel polyketide macrolide antibiotic, gladiolin, that is structurally related to a known antibiotic 
etnangien and exhibits potent activity against Mycobacterium tuberculosis. Gladiolin shows 
significantly increased stability towards light and air compared to etnangien, due to the absence 
of a highly unstable hexaene moiety present in the side chain of etnangien, which is the key 
structural difference between the two metabolites. Comparison of the polyketide synthases 
(PKSs) responsible for the biosynthesis of gladiolin and etnangien, however, reveals a strikingly 
similar domain architecture. This thesis reports the elucidation of the catalytic origins for the 
main structural differences between the two metabolites, revealing a trans-acting enoyl 
reduction event involved in shutting down a programmed iteration in gladiolin biosynthesis, 
which is proposed for the polyene formation in etnangien biosynthesis.  
In addition to gladiolin, a set of lipopeptodiolides, known as icosalides, which were originally 
reported as fungal metabolites, were also discovered from B. gladioli BCC0238. The non-
ribosomal peptide synthase (NRPS) responsible for the biosynthesis of icosalides exhibits an 
unprecedented domain architecture revealing two directly adjacent condensation (C) domains 
embedded in the middle of the NRPS. In this study, the enzymology of these C domains has been 
investigated in vitro, elucidating an unusual double chain initiation mechanism for asymmetric 
peptidolide biosynthesis. Additionally, efforts towards in vitro reconstitution of the entire 
icosalide NRPS is reported, which may allow access to novel antibiotic analogues. 
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Chapter 1  
Introduction 
1.1 Burkholderia 
1.1.1 The diversity and versatility of Burkholderia  
Burkholderia is a genus of Gram-negative β-proteobacteria. Species belonging to this genus which 
occupies remarkably diverse ecological niches, ranging from environmental water, soil, the 
rhizosphere of plants to animals and humans.1,2,3 The first described species from this genus was 
identified by William Burkholder in 1950 as a plant pathogen that caused sour rot of onion and 
named as Pseudomonas cepacian due to the phenotypic similarity to Pseudomonas species.4 The 
Burkholderia species were included in the Pseudomonas genus till 1992 when the new genus 
Burkholderia was generated.5 This genus underwent a rapid expansion subsequently and now 
composes over 80 identified species, which are classified into two major clades.6 A particular 
important group of species is the Burkholderia cepacia complex (Bcc) located in clade I. Bcc is a 
collection of genetically distinct but phenotypically similar Burkholderia species, which have 
attracted considerable attention from researchers due to their challenging taxonomy, particular 
importance in clinical epidemiology as well as exceptional metabolic versatility among 
Burkholderia species.7  
Burkholderia species are now known as one of the most versatile groups of Gram-negative 
bacteria that are capable of forming a variety of complex interactions with hosts.1 These 
interactions form the basis of both the problematic and beneficial traits of Burkholderia species 
as shown in Figure 1.1. Apart from some species identified as plants pathogens, for example B. 
plantarii causes seedling blight of rice8 and B. andropogonis causes stripe disease of sorghum9, 
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several species are also capable of infecting animals and humans. The primary pathogens include 
B.mallei and B. pseudomallei which cause glanders mainly in horses and melioidosis in both 
animals and humans respectively.10,11 Species like B. gladioli, B. fungorum and Bcc are 
opportunistic pathogens that are considered as serious threats to vulnerable individuals, 
especially cystic fibrosis (CF) patients.12,13,14   
In contrast to the pathogenic traits that led to the original identification, some Burkholderia 
species have been demonstrated to develop beneficial interactions with plants leading to a 
general growth promotion of crops. These species are able to fix atmospheric nitrogen, such as 
B. vietnamiensis and B. tropica,15,16 or produce bioactive metabolite to protect seedling plants 
from attack by pathogenetic fungi and nematodes or insects.17,18,19 Additionally, several species 
have also showed great biotechnological potential as bioremediation agents, due to their ability 
to degrade polyaromatic hydrocarbon pollutants, such as B.cepacia20,21.  
 
Figure 1.1 Beneficial and problematic traits of the Burkholderia species (reproduced from ref.22). The 
pathogenicity to plants, animals and humans, particularly evident for cystic fibrosis (CF) patients, represent the 
problematic traits of Burkholderia species. The ability to biodegrade pollutants and promote plant growth via 
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nitrogen fixing or producing antimicrobial metabolites form the beneficial basis of this genus. 
1.1.2 Natural products discovery in Burkholderia  
Burkholderia species exhibit a remarkable ability to produce a variety of specialized metabolites 
with diverse bioactivities (Figure 1.2), the majority of which are antimicrobial metabolites, such 
as antibiotic cepacins 123 and enacyloxins IIa 524 and antifungal agent pyrrolnitrin 625 and 
occidiofungin 226 . 
 
Figure1.2 Representative examples of bioactive natural products produced by Burkholderia species. 
In recent years, the availability of vast genome sequence data from Burkholderia species has 
uncovered their surprisingly huge genetic capacity with the genome size ranging between 6 and 
9 Mb, which underpins their extraordinary specialized metabolic potential.27 Aided by the 
advances in genomic-driven natural product discovery technologies, numerous natural product-
linked as well as cryptic biosynthetic gene clusters have been identified from Burkholderia species, 
proving them as an untapped and promising source of novel natural products. 
1.1.3 Discovery of gladiolin from Burkholderia gladioli BCC0238 
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During previous screens of Burkholderia clinical isolates for antimicrobial metabolite production 
in the Mahenthiralingam group, B. gladioli BCC0238, isolated in 1996 from the sputum of a cystic 
fibrosis patient, was found to exhibit a broad spectrum of antimicrobial activity.28 HPLC 
purification coupled with structural elucidation of the active metabolite from B. gladioli BCC0238 
resulted in the identification of a novel polyketide macrolide, named gladiolin 7 (Figure 1.3) by 
the Challis group.28 Gladiolin is structurally similar to the known polyketide antibiotic etnangien 
8 (Figure 1.3), produced by Sorangium cellulosum.29,30 Structural comparison of gladiolin and 
etnangien reveals three differences: 1) an extra methyl group at C6 in etnangien, 2) the C38-C39 
double bound in etnangien is saturated at the corresponding C34-C35 position in gladiolin and 3) 
the C26-C31 triene moiety in etnangien is replaced by saturated a C26-C27 bond in gladiolin. The 
conjugated hexaene moiety in the etnangien side chain significantly destabilizes the molecule, 
making it prone to light-induced isomerization and rapid oxidative degradation.30 Gladiolin 
lacking this moiety and thus has significantly increased stability towards light and air. However, 
the lactone of gladiolin is prone to rearrangement/hydrolysis (detailed in section 2.1.1.1). 
 
Figure 1.3 Structural comparison of gladiolin 7 and etnangien 8. Structural differences are highlighted in red 
(gladiolin) and blue (etnangien).  
Etnangien was reported to be active against a broad panel of Gram-positive bacteria, including 
Mycobacterium smegmatis (MIC = 1 μg/ml), a non-pathogenic species, which is phylogenetically 
close to a known tuberculosis causing pathogenic species, Mycobacterium tuberculosis. As an 
analog of etnangien, gladiolin was also tested against mycobacteria, revealing it possesses potent 
activity against M. tuberculosis (MIC = 0.4 μg/ml against the H37Rv strain).28 Both compounds 
have been shown to be capable of inhibiting the mycobacterial RNA polymerase, which is a 
validated drug target of M. tuberculosis, while having low mammalian cytotoxicity.28-31 With the 
significantly increased stability towards light and air compared with etnangien, potent activity 
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including against several isoniazid and isoniazid/rifampicin-resistant clinical isolates of M. 
tuberculosis,28 gladiolin offers more promise for development of novel drug to confront 
multidrug-resistant tuberculosis. 
1.1.4 Re-discovery of icosalides from Burkholderia gladioli BCC0238 
In the process of screening for other bioactive metabolites from B. gladioli BCC0238 in the Challis 
Group, a set of lipopeptodiolides, known as icosalides A1 (9), A2 (10) and B (11) (Figure 1.4) were 
identified from the extracts of this strain. Interestingly, icosalides were originally isolated from 
the extract of a fungi species32. 
 
Figure 1.4 Structures and activities of icosalide A1 (9), A2 (10) and B (11). The amino acid building blocks are 
denoted, with the different configurations of the second leucine residue highlighted in green. The incorporated 
3-hydroxyacyl units are highlighted in red and blue.  
Structurally, all three icosalide analogs contain two serine and two leucine amino acid residues, 
with two fatty acid-derived 3-hydroxyacyl units incorporated as part of the central twenty-
member ring. A distinguishing feature of icosalide A1 is the presence of a single D-Leucine residue, 
whereas A2 and B universally contain L-configured amino acid residues. Besides, icosalides A1 
and A2 integrate eight and ten carbon 3-hydroxyacyl chains into the cyclic core generating an 
asymmetric peptolide, whereas icosalide B obtains structural symmetry via incorporation of two 
eight carbon 3-hydroxyacyl units. With these structural differences, the three Icosalide analogs 
display very different bioactivities: icosalide A1 shows modest antimicrobial activity against 
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Streptococcus pyogenes, S. pneumoniae, and Enterococcus faecalis while icosalides A2 and B are 
cytotoxic to replicating Madin-Darby canine kidney (MDCK) cells. 
1.2 Polyketides  
1.2.1 Polyketide natural products 
Polyketides (PKs) are a large family of natural products that possess impressive structural 
complexity and diversity, as well as a broad range of biological activities, such as antibiotic 
erythromycin A 12, antifungal agent amphotericin B 13, anti-cancer agent epothilone B 16, 
cholesterol-lowering agent lovastatin 14, immunosuppressant rapamycin 15 and pesticide 
spinosyn A 17 (Figure 1.5). Their pharmaceutical and economic value have motivated interest in 
novel structure discovery, elucidation of the enzymology and structure of biosynthetic 
machineries as well as genetic and chemical engineering of novel derivatives for the last three 
decades.    
 
Figure 1.5 Representative bioactive polyketide natural products. 
1.2.2 Polyketide biosynthesis  
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Despite polyketide natural products having remarkable structural diversity, they are all assembled 
from simple acyl-coenzyme A (CoA) derived building blocks by a group of enzymes called 
polyketide synthases (PKSs).33 Three distinct types of PKSs exist in various organisms, including 
bacteria, fungi and plants, and are responsible for biosynthesis of different classes of polyketides, 
including aromatic and complex polyketides.34 This study focuses on the bacterial polyketides 
complex, the majority of which are assembled by type I modular PKSs.  
1.2.1.1 Type I modular polyketide synthases 
Type I modular PKSs are large multifunctional enzyme complexes, in which the catalytic domains 
are organized into multiple sequential modules, whereby a module is responsible for one 
catalytic cycle of the building block selection and installation.35 The best studied type I modular 
PKSs is the 6-deoxyerythromycin B synthase (DEBS) involved in erythromycin biosynthesis, which 
cotains six chain extension modules flanked by a loading and module and a chain releasing 
thioesterase (TE) domain into three gigantic multienzymes (DEBS 1, DEBS 2 and DEBS 3) as shown 
in Figure 1.6.  
 
Figure 1.6 Schematic view of the type I modular PKS responsible for erythromycin A biosynthesis. The 
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correspondence between the structures of the assembled intermediates and final structure id highlighted by the 
color coding the domain organization of the PKS. 
1.2.1.2 Biosynthetic overview of type I modular PKSs  
Type I modular PKSs employ the biosynthetic logic resembling that of mammalian fatty acid 
synthases (FASs). In general, both biosynthetic machineries incorporate the simple acyl-CoA 
building blocks in an assembly line fashion through three steps: chain initiation, chain extension 
and chain termination (Figure 1.7).  
Chain assembly is normally initiated by an acyltransferase (AT) domain in the loading module 
selecting and loading a starter unit from the corresponding CoA thioester (commonly acetyl-CoA) 
onto the phosphopantetheinyl (PPant) moiety of an acyl carrier protein (ACP) domain. This PPant 
moiety is attached to the ACP domain by a phosphopantetheinyl transferase (PPase) prior to 
polyketide assembly. An alternative chain initiating mechanism involves an AT domain loading a 
malonyl or methylmalonyl unit, followed by a decarboxylation catalyzed by a ketosynthase 
domain (KS) variant KSQ (discussed in section 1.2.2.5 ‘Ketosynthase domains’). 
In each chain elongation step, a KS domain catalyses a decarboxylative Claisen condensation 
between the starter unit or the growing polyketide chain it accepts from the upstream ACP 
domain and the extender unit (commonly methymalonyl- or manlonyl-CoA) loaded on the 
downstream ACP domain by the adjacent AT domain. The minimal chain elongation module thus 
consists of KS, AT and ACP domains which extend the polyketide backbone by one ketide unit. 
The resulting β-keto-acyl thioester can undergo optional modification by ketoreductase (KR), 
dehydratase (DH) and enoyl reductase (ER) domains, leading successively to β-hydroxyl, α,β-
unsaturated and fully saturated intermediates respectively. The polyketide chain is passed along 
the assembly line between ACP domains and KS domains and built up through repeated chain 
extension.  
The chain assembly is normally terminated by a TE domain located at the end of the PKS releasing 
the product by hydrolysis or more commonly macrocyclization. Further post-PKS modifications, 
such as glycosylation, methylation and hydroxylation are sometimes employed to introduce 
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additional structural complexity and diversity.  
 
Figure 1.7 Schematic overview of chain initiation, extension and termination by type I modular PKSs (adapted 
from ref.36). 
1.2.1.3 Subdivision of type I modular PKSs 
Given the above biosynthetic logic employed by type I modular PKSs, the structures of their 
polyketide products are often found to be directly correlated to their domain organizations 
(Figure 1.6). This correlation is referred to as ‘colinearity’ and has been applied to effective 
prediction of final product structure from the PKS architecture.37  
In recent years, however, another class of modular system has emerged, in which the colinearity 
is normally not conformed to. In these particular systems, the most obvious feature is that 
integrated AT domains are absent from the assembly lines. Instead, the AT activity required by 
every module is supplied by one or more trans-acting AT domains.38 They are thus termed as 
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trans-AT PKSs, with DEBS representing modular systems termed as cis-AT PKSs.38 Examples of 
trans-AT PKSs include those responsible for the biosynthesis of pederin,39 bacillaene,40 
viginamycin41 and leinamycin 1942 (Figure1.8). 
 
Figure 1.8 Schematic view of the trans-AT PKS responsible for leinamycin biosynthesis. 
In addition to trans-acting AT domains as a distinguishing feature, trans-AT PKSs exhibit several 
other non-canonical architectural and enzymatic characteristics. These include unusual domain 
architectures, modules split into across subunits, inactive domains or and trans-acting enzymes 
other than AT domains as shown in Figure 1.8. Phylogenetic studies have revealed that the cis- 
and trans-AT PKSs have distinct evolutionary origins, with the former believed to evolve through 
module duplication and domain diversification while the latter has evolved via horizontal gene 
transfer.43,44  
1.2.1.4 Iterative module use in type I modular PKSs 
In type I modular PKSs, a molecular ratchet mechanism is typically employed to govern the 
unidirectionally of the assembly line.45 However, iterative usage of individual modules has been 
observed as either an aberrant or a programmed event in several modular PKS systems (Figure 
1.9). The discovery of a ring expanded 6-dEB analogue 20 as a minor product of DEBSs resulting 
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from iteration in module 4 represents the first example of module ‘stuttering’ (Figure 1.9 A). A 
similar phenomenon was found during epothilone biosynthesis, which iteratively use module 5 
and module 6 to generate 6 different ring expanded analogue.46 On the other hand, programmed 
module iterations are demonstrated to be required for the biosynthesis of stigmatellin, 
aureothin,47 (each two iterations) borrellidin,48 and etnangien31 (each three iteration) (Figure 1.9 
B). 
 
Figure1.9 Examples of module iteration in type I modular PKSs. (A) Module ‘stuttering’ occurs in module 4 of 
the 6-dEB PKS leading to a minor ring-expanded product is an example of aberrant module iteration. (B) Iterative 
usage of module 1 of the aureothin PKS is required for the biosynthesis of the final product, representing the 
programmed iteration.  
Current understanding of programmed module iteration in modular PKSs is mainly based on 
investigations of aureothin biosynthesis. Since modular PKSs exist as homodimers, it has been 
proposed that the iteration occurs by retrotransfer of the intermediate from the ACP domain 
onto the KS domain located on the opposite polypeptide strand49. In addition evidence was 
provided to show that iteration is controlled by several factors, including a ‘gate-keeper’ function 
and downstream KS domains and the kinetics of chain acylation of and elongation by the KS 
domains.50 
1.2.1.5 Catalytic domains of type I modular PKSs 
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Acyltransferase domains 
The AT domains catalyze the transfer of the acyl unit from CoA to the downstream ACP domain 
via a ‘ping-pong bi-bi’ mechanism which involves two half reactions: acylation of the active site 
serine residue of the AT domain followed by transfer to the ACP domain51,52 (Figure 1.10).  
 
Figure1.10 Mechanism of acyl transfer reaction catalyzed by the AT domains from modular PKSs. The AT 
domains catalyse starter unit (e.g. malonyl- or 2S-methylmalonyl-CoA) loading via an acyl-O-A T intermediate 
The AT domains from modular PKSs play a crucial role in conserving the fidelity of the assembly 
line through their specificity towards the substrates. The extender AT domains mainly select 
primary metabolism originated malonyl- and (2S)-methylmalonyl-CoA,53 with trans-acting AT 
domains normally specific for malonyl-CoA.38 However, some examples of extender AT domains 
incorporating unusual acyl building blocks, such as hydroxyl- and aminomalonyl-CoA have been 
observed, which contribute to the structural diversity of polyketides.53 In contrast, the AT 
domains associated with the loading module utilize a variety of acyl-CoAs as starter units, such 
as acetyl-, propionyl-, isobutyryl-, crotonyl- and isopentyl-CoA.54,55 Structural and bioinformatic 
studies on several AT domains have allowed the identification of the conserved motifs that 
correlates the with substrate specificity.36  
Ketosynthase domains 
KS domains catalyse carbon-carbon bond formation through two half reactions, including 
transthiolation and decarboxylative Claisen condensation. Reported structures of modular PKS 
KS domains showed they form homodimers with each monomer adopting a thiolase-like fold.56,57 
The substrate binding channel is split into a well-conserved PPant arm binding region and a more 
variable thioester substrate binding site. Bioinformatics analysis combined with structural studies 
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revealed a conserved Cys-His-His catalytic triad is harbored that all chain elongating KS domains 
contain.56,57,58 Firstly, the transthiolation proceeds via nucleophilic attack of the thiol group in the 
active site Cys residue on the carbonyl group of the starter unit or polyketide thioester tethered 
to the upstream ACP domain, forming an acyl-S-KS complex (Figure1.11). Following release of the 
upstream ACP domain, the KS domain catalyses decarboxylation of the extender unit delivered 
by the PPant arm of the downstream ACP domain. This enables the resulting enolate to attack 
the carbonyl group of the acyl-S-KS intermediate, thereby generating a two-carbon elongated β-
keto-acyl-ACP thioester product. One of the histidine residues within the catalytic Cys-His-His 
triad stabilizes the enolate intermediate while the other histidine residue is hypothesized to 
promote decarboxylation via activation of a water molecule to towards nucleophilic attack on the 
carbonyl group extender unit.59,60    
 
Figure 1.11 Mechanism of KS domain catalyzed chain elongation reaction in modular PKSs. The KS domain 
catalyzed chain elongation reaction involves a transthiolation and a decarboxylative condensation steps. 
Biochemical studies of KS domains from cis-AT PKSs revealed they exhibit varying levels of 
substrate specificity61 while KS domains from trans-AT PKSs are more selective towards the 
structure of the functional group at the β-position, especially in the chain elongation step.62,63 
The substrate specificity prediction of trans-AT PKS KS domains has been facilitated by 
phylogenetic analysis, which demonstrated that evolutionarily close trans-AT KS domains usually 
have similar substrate specificity.44 These insights have greatly facilitated the biosynthetic 
assignment of trans-AT PKSs which are normally difficult using colinearity-based predictions. 
In addition to chain elongating KS domains, other two variants of KS domains exist in modular 
PKSs. The first is located in the loading modules of cis-AT PKSs and catalyses the decarboxylation 
of a starter unit (malonyl or methyl-malonyl unit) due to a catalytic cysteine to glutamine 
mutation, and are thus termed KSQ domain.64 The other ones are found as a characteristic feature 
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of trans-AT PKSs. These lack an active site histidine residue which is essential for chain elongation, 
and are thus termed non-elongating KS (KSo) domains.38 KSo domains have been postulated to 
pass the growing polyketide chain to the next module but the reason this is needed is unclear.   
Ketoreductase and Dehydratase domains  
Ketoreductase domains in type I modular PKSs belong to the short-chain 
dehydrogenase/reductase (SDR) family and catalyse stereospecific reduction of β-keto-acyl-ACP 
thioester intermediates to the corresponding β-hydroxy-acyl-ACP thioester using NAD(P)H as a 
cosubstrate.65 They consist of a structural and a catalytic subdomain with a conserved Tyr-Ser-Lys 
triad in the active site participating in catalysis. 66,67 The reaction proceeds via the transfer of 4-
pro-S hydride from NAD(P)H to the β-carbon of the substrate, followed by the protonation of the 
resulting alkoxide by the active site tyrosine residue. Based on the stereochemistry of the 
resulting β-hydroxy group, KR domains are classified into A-type (for L-configuration) and B-type 
(for D-configuration) (Figure 1.12 A) KR domains.68 The stereochemistry of the product is thought 
to be determined by the binding orientation of the substrate relative to the NADPH, which is 
influenced by the relative position of amino acid residues in the active site amino acids.68 
 
Figure 1.12 Catalytic and stereo control mechanisms of KR and DH domains from modular PKSs. (A) KR domains 
catalyzed ketoreduction proceeds via 4-pro-S hydride transfer from NADPH to the β-carbonyl carbon followed by 
α-position protonation by a catalytic Tyr residue. A type and B type KR domains lead to different stereo outcome 
at C3, determined by the binding orientation of the substrate relative to the NADPH. (B) A Syn elimination 
mechanism that involves the catalytic His-Asp diad is applied by modular PKS DH domains to achieve stereo 
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control with 3R-hydroxy groups resulting in trans double bonds while 3S-hydroxy groups resulting in cis. 
Dehydratase domains from modular PKSs catalyse elimination of water from the β-hydroxy-acyl-
ACP substrate and typically result in formation of a trans (E)-α, β-double bond, however, cis(Z)-α, 
β-double bond has been observed69. Structurally, they are organized as dimers with each 
monomer forming a double hot dog (DHD) fold and bearing a conserved His-Asp catalytic dyad 
at the active site.70,71,72 The dehydration reaction has been proposed to proceed via 
deprotonation at the α-position by the His residue and elimination of the β-hydroxy group, 
promoted by protonation by the Asp residue (Figure 1.12 B).70,71 Biochemical and evolutionary 
evidence have suggested most double bonds formation by modular PKS DH domains share a 
common syn elimination mechanism.73,74,75 The geometry of the double bond is hypothesized to 
be mainly determined by the chirality of the β-hydroxy group, with 3R-hydroxyl group generated 
by A-type ketoreduction leading to trans double bond, and 3S-hydroxyl group generated by B-
type ketoreduction giving cis-double bound.76 
Cis-acting enoyl reductase domains 
The modular PKS integrated ER domains catalyse cis-acting NADPH-dependent reduction of an 
enoyl-ACP to an α, β-saturated acyl-ACP.77 Current understanding of the mechanism involves two 
processes: the transfer of the 4-pro-R hydride of NADPH to the C3 position of the enoyl acyl-ACP, 
followed by a stereospecific protonation of the C2 position by either a general acid or solvent 
(Figure 1.13 A). Multiple sequence alignment of cis-acting ER domains combined with 
mutagenesis studies revealed that a conserved tyrosine residue confers the S configured stereo 
specificity at the C2 position protonation process, whereas a valine (occasionally alanine or 
phenylalanine) at the corresponding position led to 2R configured products (Figure 1.13 A).78,79  
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Figure 1.13 Catalytic mechanism, stereo control and structural overview of of cis-acting ER domains from type 
I modular PKSs. (A) cis-acting ER domains catalyse enoyl reduction via transfer of the 4-pro-R hydride from 
NADPH to the C3 position of the enoyl-ACP thioester, followed by a stereospecific protonation at C2, resulting in 
2S- (when conserved Tyr present) or 2R-configurated products (when the conserved Tyr is replaced by 
Val/Ala/Phe). (B) Crystal structure of the SpnER2 domain shows the NADPH binding site located in a cleft between 
the two subdomains and the conserved catalytically important residues (K422, Y241 and D444) located close to 
the nicotinamide moiety (Figure adapted from ref.80).   
Like their counterparts in mammalian FASs, cis-acting ER domains belong to the Medium-chain 
Dehydrogenases/Reductases (MDR) family that typically comprise of a C-terminal NADPH binding 
subdomain with a Rossman fold and a N-terminal substrate binding subdomain.81 The only 
reported crystal structure of an ER domain from a modular PKS is SpnER2 (solved as a KR-ER 
didomain) from the spinosyn PKS. It showed, unlike other homodimeric members of the MDR 
family, that the SpnER2 domain exists as a monomer with the NADPH binding site located in a 
cleft between the two subunits (Figure 1.13 B).80 Within its active site, three conserved residues 
Y241, K422, and D444 were observed with in ~6 Å of the nicotinamide 4-pro-R hydrogen atom, 
indicating they may be involved in substrate protonation.80However, both previous in vivo 
mutagenesis study on RapER13 domain (in rapamycin PKS)82 and the structural guided in vitro 
mutagenesis study on SpnER279 concluded that no single residue is essential for catalytic activity. 
PhD Thesis: Xinyun Jian  Chapter 1 
17 
Trans-acting enoyl reductase domains 
In addition to the embeded cis-acting ER domains, another phylogenetically distinct type of ER 
domain in trans-AT PKSs is the stand-alone trans-acting ERs.38 In some cases these are fused to 
the N-terminus of AT or AH domains. Trans-acting ERs clade with stand-alone ER domains (PfaD) 
employed by polyunsaturated fatty acid synthases and close to non-canonical bacterial FAS ER 
(FabK), fungal FAS ER (fFAS ER) and Corynebacteria, Mycobacteria, and Nocardia (CMN)-FAS ERs 
(Figure 1.14 A).83 While cis-acting ER domains directly reducing substrate tethered on the 
adjacent ACP domain using NADPH as cosubstrate, this type of ER performs enoyl reduction in a 
trans-acting manner using FMN to mediate hydride transferring from NAD(P)H to substrate 
(Figure 1.14.B). The trans-acting enoyl reduction activity of a PksE ER domain involved in 
dihydrobacillaene biosynthesis was biochemically characterized, showed it engaged in a specific 
interaction with its cognate ACP domain.84 Other homologues are found in several trans-AT 
polyketide biosynthetic clusters, such as kalimantacin/batumin,85 leinamycin86 and 
myxovirescin87. 
 
Figure 1.14 Phylogenetic, functional and structural overview of trans-acting ER domains from type I modular 
PKSs. (A) Phylogenetic tree and distribution of modular PKSs trans-acting ER related proteins among bacteria and 
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fungi showing trans-acting ERs form trans-AT PKS are phylogenetically close to PfaD, FabK, CMN-FAS ERs and 
fungal FAS ERs (Figure reproduced from ref.83) . (B) Trans-acting ERs catalyse enoyl reduction using FMN to 
mediate the transfer of hydride from NAD(P)H to the substrate. (C) Crystal structure of DifA ER domain shows it 
forms a homodimer with FMN (highlighted in green) bound to the TIM barrel subdomain and contains additional 
loops and helix insertions compared to FabK (highlighted in purple and yellow) which are proposed to serve as 
interdomain interaction interfaces (Figure reproduced from ref.83). The dimerization tip is highlighted in red.    
The first structural insights into trans-acting ERs was provided by the crystal structure of the DifA 
ER domain (excised from an AT-ER didomain), which is involved in the biosynthesis of difficidin.83 
The DifA ER domain exists as a homodimer with each monomer consisting of a triosephosphate-
isomerase (TIM) barrel domain with FMN bound and an inserted α-helical substrate-binding 
domain (Figure 1.14 C).83 Though highly structurally homologous to FabK, the DifA ER domain 
contains additional loops and helix insertions (highlighted in purple and yellow), which were 
proposed to serve as interdomain interaction interfaces.83 However, the detailed catalytic 
mechanism of trans-acing ERs and the molecular basis underlying their specific interactions with 
cognate ACP domains remain unclear.   
Thioesterase domains 
TE domains fused to the C-termini of modular PKSs catalyze polyketide chain release via a two-
step reactions.88 The highly conserved serine residue located within the active site initiates the 
reaction by nucleophilic attack on the C=O bond of the assembled polyketide chain tethered via 
a thioester linkage to the adjacent ACP domain, resulting in formation of an acyl-O-TE 
intermediate. This intermediate subsequently undergoes hydrolysis from the TE domain or a 
regio-specific macrocyclization via attack of internal nucleophilic.89,90 In addition to the TE 
domains fused to the C-termini of modular PKSs (termed type I TE domains), standalone type II 
TE domains are also usually associated with modular PKSs.91,92 This type of TE domain catalyses 
cleavage of aberrant acyl chains from ACP domains to ensure the assembly line remain 
catalytically active.93  
Acyl carrier protein domains and their interactions with other domains 
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Acyl carrier protein domains are small (  8̴0-100 aa) non-catalytic domains involved in all of the 
catalytic steps of polyketide chain assembly. Structurally, they consist of four-helix bundles, 
stabilized by inter-helical hydrophobic interactions.94,36 Inactive apo-ACP domains are converted 
to their functional holo forms by a dedicated PPTase, which catalyses post-translational 
attachment of a PPant moiety of CoA to a conserved the serine residue located in the DSL motif 
(Figure 1.16 A).95,96  
 
Figure 1.16 Schematic view of PPtase catalyzed post-translational modification of ACP domains (A) and the 
distinct interfaces that mediate KS-ACP interactions (B). Chain elongation (orange and red) and chain transfer 
(blue) epitopes lie on entirely different faces of the DEBS ACP2 domain (figure reproduced from ref.97) 
The PPant moiety of ACP domains serves as a  2̴0 Å long and flexible arm that allows the shuttling 
of covalently-bound building blocks or assembled intermediates to and between different 
catalytic domains.57 ACP domains also engage in the specific protein-protein interactions with 
partner domains through distinct interface. The conserved DSL motif in helix II has been 
demonstrated be a universal recognition site for interacting with other catalytic domains.98 
Recent work has showed the docking sites for intramodular KSn-ACPn interaction (in chain 
elongation step) and intermodular ACPn-KSn+1 interaction (in chain translocating step) are located 
at distinct regions of ACP domains, with the former located in Helix I and the latter located in 
Loop I (Figure 1.16 B).97,45 These specific KS-ACP protein-protein interactions play an important 
role in conserving the unidirectionally of the assembly line.36  
1.2.3 Biosynthesis of gladiolin and etnangien 
Complete genome sequencing of B. gladioli BCC0238 and S. cellulosum So ce56, in combination 
with targeted gene inactivation experiments, have facilitated the identification of the 
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biosynthetic gene clusters for gladiolin and etnangien.28,99 Both clusters harbor six large trans-AT 
PKS-encoding genes, associated with a conserved set of genes encoding trans-acting polyketide 
processing enzymes and export related proteins (Figures 1.17).28,31 
 
Figure 1.17 Comparison of the gladiolin and etnangien biosynthetic gene clusters.28 The proposed functions of 
genes are indicated in color corresponding to the annotation at the bottom and the homology between the genes 
from the two clusters is indicated by the colored shading. 
BLAST searches revealed that these two trans-AT PKSs share remarkably similar domain 
organizations, with the only difference identified as the substitution of an ACP domain in module 
1 of the etnangien PKS with an ER (GbnD1 ER1) domain in the gladiolin PKS (Figure1.18). The 
proposed biosynthetic pathways for gladiolin and etnangien show that the main structural 
differences between the two compounds are incorporated by the first five modules of their 
respective assembly lines.28,31 Both are proposed to utilize a succinyl-CoA starter unit, which 
subsequently undergoes chain elongation with a malonyl unit catalyzed by the KS domain in the 
first module (Figure 1.19). A β-branch is then incorporated. This is catalyzed by a cassette of trans-
acting enzymes (‘HCS cassette’), including a 3-hydroxymethylglutaryl synthase (HMGS)-like 
enzyme, standalone KSQ and ACP domains, and two enoyl-CoA hydratase (ECH)-like enzymes, and 
results in a β-methyl, α, β-unsaturated intermediate (Figure 1.19). The α, β-double bond is 
predicted to be saturated by the ER (GbnD1 ER1) domain in module 1 of the gladiolin PKS. The 
GbnD1 ER1 domain is substituted with an ACP domain in the etnangien PKS. Thus, this α, β-
double bond remains in the final product, accounting for one of the structural differences 
between the two compounds (Figure 1.19).
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Figure1.18 Comparison of the trans-AT PKSs responsible for etnangien and gladiolin assembly28,31,100. Domain and module organization of the gladiolin and etnangien PKS, showing 
the proposed structure of chain-elongation intermediates attached to the ACP domain in each module. Structural differences between intermediates and final products are shown 
in red (gladiolin) and blue (etnangien). The GbnD1 ER1 domain is highlighted in green as the sole difference between the two PKSs. The predicted iterative EntE module 5 is highlighted 
in gold. The configurations of the stereocenters are predicted based on sequence analysis of the KR domains. Acyl transferase (AT)/hydrolase (AH) domains acting in trans with their 
predicted specificities are indicated. Putative trans-acting ERs, non-elongating KSs and HMGS enzymes cassette are indicated. ‘HCS cassette’ interacting ACPs are labeled with ‘+’. 
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Figure 1.19 Comparison of the proposed biosynthesis in the first module of gladiolin (red box) and etnangien 
(blue box) PKSs. β-branching event is highlighted in gray box. ACP domains labeled with ‘+’ denotes the integrated 
ACP domains, while without denotes the ACP domain belongs to the trans-acting ‘HCS cassette’ enzymes.  
The resulting intermediate from module 1 of each assembly line is then transferred to module 2 
and subsequently module 3 and 4 for identical chain elongation and modification reactions. 
According to the key structural differences between the two metabolites, module 5 of the 
etnangien PKS (EntE Module 5) is predicted to be iteratively used for three times while the 
corresponding iteration does not occur at this biosynthetic stage of gladiolin chain assembly. In 
addition, an enoyl reduction is proposed to take place in module 5 of the gladiolin PKS (GbnD2 
Module 5) which does not occur in EntE Module 5 (Figure. 1.18). Interestingly, the corresponding 
ER domains is absent from GbnD2 Module 5. This ER activity has been postulated to be provided 
by the GbnD1 ER1 domain. However, according to the proposed biosynthetic pathways, a trans-
acting ER activity is also required by module 10 of both assembly lines (Figure 1.18). The trans-
acting ER activities of standalone GbnE and EntL in each cluster have been predicted based on 
their homologies to the putative trans-acting ER (BatK) involved in the Kalimantacin/Batumin 
biosynthesis28,101. Therefore, GbnE could be the other candidate to provide the ER activity in 
GbnD2 Module 5.  
After the chain assembly process has passed module 5 in each PKS, β-branching is employed 
again in module 6 of both assembly lines. Interestingly, while the etnangien assembly line uses 
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only one set of ‘HCS cassette’ enzymes to carry out two β-branching events, two sets of ECH 
enzymes (GbnI/J and GbnR/S) are found in the gladiolin biosynthetic gene cluster. The 
subsequent biosynthetic steps appear to be identical for etnangien and gladiolin, except that an 
methyl group is predicted to be installed in module 15 of the former, even though no C-MT 
domain is present in the module.  
As gladiolin and etnangien PKSs are striking similar, the catalytic origins of the structural 
differences between the two compounds is a very intriguing aspect of their biosynthesis. The 
shorter side chain of gladiolin indicates a different chain length control mechanism is employed 
by its assembly line in compare to etnangien, which is possibility linked to an additional enoyl 
reduction in the module 5. 
1.3 Non-ribosomal peptides 
1.3.1 Non-ribosomal peptide natural products 
In addition to polyketides, non-ribosomal peptides (NRPs) represent a second major superfamily 
of natural products and have also been exploited in the development of numerous therapeutically 
important agents, such as antibiotics (e.g. vancomycin 22, tyrocidine A 24 and daptomycin 26), 
anticancer agents (e.g. bleomycin A2 23) and immunosuppressants (e.g. cyclosporin A 25) as 
shown in Figure 1.20.102 The broad range of the bioactivity of NRPs reflects their remarkable 
structural complexity and diversity, which is greatly expanded by various chemical modifications, 
including incorporation of fatty acid moieties, nonproteinogenic amino acids (including as D-
amino acids), sugars and heterocycles as well as methylation and halogenation. The biological 
functions of NRPs are closely associated with their structural features, which often play an 
important role in constraining the peptide in its biologically active conformation. It is the unique 
conformation of each peptide that ensures its selective binding to a dedicated molecular 
target.103,104 
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Figure 1.20 Representative bioactive non-ribosomal peptides. Examples of diverse structural modifications are 
highlighted with coloured ovals. 
1.3.2 Non-ribosomal peptide biosynthesis  
1.2.1.6 Non-ribosomal peptides synthetases 
The majority of non-ribosomal peptides are assembled from simple amino acid building blocks 
by the modular non-ribosomal peptide synthetases (NRPSs), which are large multienzyme 
complexes containing catalytic domains organized in an assembly line fashion (Figure 1.21). 
NRPSs adopt a similar biosynthetic logic to type I modular PKSs to assemble the peptide through 
chain initiation, elongation and termination processes. 
 
Figure 1.21 Schematic view of the representative modular NRPS that responsible for vancomycin biosynthesis. 
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The order and number of NRPS modules corresponds to the sequence and number of amino acids in the final 
product. 
1.2.1.7 Chain elongation and core domains 
The core domains required for peptide chain extension consist of an adenylation (A), peptidyl 
carrier protein (PCP) and condensation (C) domains. As shown in Figure 1.22, during each peptide 
chain extension cycle, the A domain first selects and binds the cognate amino acid building block 
and then activates it as the corresponding aminoacyl-AMP via reaction with ATP. The amino acyl 
adenylate intermediate is subsequently attacked by the thiol group of a 4’-phosphopantethiene 
arm that is post-translationally coupled to the adjacent PCP domain, resulting in a PCP domain-
bond aminoacyl thioester. The aminoacyl substrate is then condensed with the peptidyl or 
aminoacyl thioester tethered to the upstream PCP domain by the C domain from the same 
module via a peptide bond formation. The elongated peptide intermediate is then provided as 
the substrate for further chain extension by the downstream module.103,105 
 
Figure 1.22 Schematic overview of non-ribosomal peptide chain elongation reactions catalyzed by the three 
core domains. (1) The A domains select and activate the amino acid (aa) using ATP to generate the corresponding 
aminoacyl-AMP. (2) The aminoacyl-AMP undergoes a nucleophilic attack from the thiol group of the PPant 
prosthetic group of the PCP domain forming an aminoacyl thioester. (3) The C domain subsequently catalyses a 
condensation reaction between the α-amino group of the PCP-bound acceptor amino acid with the thioester of 
the upstream PCP-bound donor amino acid or peptide. 
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Adenylation domains  
A domains (  5̴50 aa) function as the initial gate-keeper of the NRPS assembly lines as a 
consequence of their substrate specificity. Though A domains catalyse very similar chemistry as 
aminoacyl tRNA synthetases, which are part of the protein biosynthetic machinery, they are 
structurally and evolutionally distinct.106 Several crystal structures of A domains have been 
determined, such as phenylalanine-activating PheA from the gramicidin S NRPS107 and 2,3-
dihydroxybenzoic acid specific DhbE from the bacillibactin NRPS108. They share significant 
structural similarity to enzymes from the adenylate-forming-superfamily, which includes acetyl 
CoA synthetases (ACS) 109 and acyl-CoA ligases. 110 The overall structure of A domains comprises 
a large N-terminal subdomain and a small flexible C-terminal subdomain with the active site 
located at the interface. Bioinformatic analysis combined with extensive structural and 
mutagenesis studies allowed the identification of 8-10 residues within the substrate binding 
pocket, which were shown to be crucial for substrate recognition.111,112,113 Some of these residues 
interact with the carboxy and α-amino moiety of the substrate, whereas others interact with the 
substrate side chain. Aided by computational design, these insights have been exploited to 
rationally engineer the selectivity of A domains for novel NPRs biosynthesis.113,114 
Peptidyl carrier protein domains 
PCP domains are small (  ̴100 aa) non-catalytic domains located downstream of A domains. Like 
ACP domains in PKSs, a conserved serine residue is found by all PCP domains. It is covalently 
modified via attachment of the a 4’-PPant moiety from CoA, a post-translational modification 
catalyzed by PPTases.115 In doing so, the PCP domain is converted from the inactive apo form to 
the functional holo form with the thiol group of the flexible 4’-PPant arm serving as an anchor to 
covalently bind aminoacyl and peptidyl intermediate substrates. PCP domains are central in 
mediating NPR biosynthesis by shuttling biosynthetic intermediates between catalytic 
domains.104 PCP domains are four-helix bundles with the conserved serine residue located in 
helix 2. Three distinct conformations of PCP domains were observed: A state (apo), H state (holo) 
and A/H state(apo/holo) as shown in Figure 1.23.116 It was proposed that the transitions between 
the conformations contribute to further flexibility of the 4’-PPant arm of PCP domains in 
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interacting with different partner catalytic domains.104 
 
Figure 1.23 Ribbon diagrams of the solution NMR structures of the TycC3-PCP (from tyrocidine A synthetase) 
showing three conformers in the A, A/H, and H states (figure reproduced from ref.116). 
Condensation domains 
C domains normally contain  ̴450 aa and are located at the N-terminus of elongation modules. 
Bioinformatic analysis revealed C domains bear a conserved HHXXXDG motif and share sequence 
similarity with acyltransferases.117 Comprehensive mutagenesis studies of the TycB1 C domain 
(from the tyrocidine A NRPS) and EntF C domain (from the enterobactin NRPS) highlighted the 
putative role of the second Histidine residue in the conserved HHXXXDG motif as a general 
base.118,119 The catalytic mechanism of the C domains is proposed to involve deprotonation of 
the α-amino group of the acceptor aminoacyl-substrate thioester by the second histidine residue 
in the conserved motif to promote nucleophilic attack on the thioester of the acyl donor.118,119   
Based on the crystal structures of the stand-alone C domain VibH (from the vibriobactin NRPS)120 
and the TycC PCP-C didomain (from the tyrocidine NRPS)121 as well as several further 
structures,122,123 C domains were found to be monomeric enzymes that are composed of N and 
C-terminal subdomains organized in a V-shape with the conserved HHXXDG active site located at 
the junction between them. A tunnel running through the active site was observed at the 
interface providing the entry to the donor and acceptor PCP-bond substrates (Figure 1.24 A).120 
A structure of the calcium-dependent antibiotic (CDA)-C1 domain with a substrate covalently 
tethered in the active site provided further insights to the role of the second His within the 
catalytic motif (H157).124 In addition to the previously proposed catalytic role, H157 was observed 
to be critical for substrate positioning via forming a hydrogen bond with the α-amino group of 
acceptor aminoacyl substrate (Figure 1.24 B).124 
PhD Thesis: Xinyun Jian  Chapter 1 
28 
 
Figure 1.24 Crystal structure and detailed view of active site of CDA-C1 domain. (A) A Model of CDA-C1 domain 
with PCP domains bound showing the active site tunnel based on the crystal structures of CDA-C1 (highlighted in 
green, PDB:4JN3) with the position of acceptor PCP domain (shown in dark blue) modeled from PDB:2VSQ and 
the position of donor PCP domain (shown in light blue) modeled from biochemical data (figure reproduced from 
ref.125). (B) Active site of CDA-C1 domain, containing engineered E17C mutation with bromoalkylamine analogue 
covalently bound to mimic the substrate delivery by PCP domain, shows the important role of H157 in positioning 
α-amino group of the substrate for nucleophilic attack via forming a hydrogen bond (figure reproduced from 
ref.124 ). 
Several bioinformatic and phylogenetic studies show C domains clade according to their 
biochemical activity.126,127 Subtypes were found as shown in Figure 1.25 A : The subtype LCL 
catalyses the condensation between L-configured amino acid building blocks tethered on PCP 
domains; DCL domains link the acceptor L-aminoacyl substrate with a D-configured donor;128 
starter C domains, situated at the priming position of the NRPS, acylate the first loaded amino 
acid a the 3-hydroxyacyl unit hijacked from fatty acid biosynthesis;129 dual E/C domains first 
epimerize the C-terminal amino acid in the donor peptide chain and subsequently condense it to 
with the acceptor aminoacyl substrate;130 the Cy domain first performs the condensation 
between aminoacyl/peptidyl-PCP donors and serinyl-/threoninyl-/cysteinyl-PCP acceptors, and 
then catalyses the cyclodehydration between the thiol or hydroxyl side chains of the donor 
residues and the carbonyl group of the newly-formed peptide bond, resulting in incorporation of 
a heterocycle into the growing peptide chain.131 Profile Hidden Markov Models (pHMMs) for the 
sequence motifs as well as for the entire sequences of C domain subtypes were provided as 
shown in Figure 1.25 B, the determined specificity conferring positions of which have greatly 
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facilitated C domain subtype identification and engineering.  
 
Figure 1.25 Classification of NRPS C domains based on phylogenetic and bioinformatic analysis (reproduced 
and adapted from ref.127) . (A) Phylogenetic tree of C domains showing the subtypes. (B) Hidden Markov Models 
(HMMs) of the C domain subtypes. Yellow bars indicate significant specificity determining positions in LCL, Starter 
and DCL domains with the most significant residues highlighted with a red star. 
1.2.1.8 Chain modification  
In addition to the core domains catalysing chain elongation, NRPSs can contain a variety of chain 
modification domains to introduce other chemical features, which enrich the structural diversity 
and complexity of NRPs (Figure 1.20). As well as the dual E/C domains, introductino of D-
configured amino acid residues into the peptide chain can be mediated by individual 
epimerization (E) domains, through epimerization of newly incorporated L-amino acid with the 
growing peptide chain.132,133 The thiazolines and oxazolines incorporated by Cy domains can be 
further oxidized to the corresponding thiazoles and oxazoles by oxidation (Ox) domains using 
FMN as a cofactor, as in the biosynthesis of bleomycin and epothilone.134,135 These heterocycles 
could be alternatively reduced to thiazolidines and oxazolidines respectively by a NADPH-
dependent reductase (R) domains, for example during pyochelin assembly.136 Both N-methyl and 
C-methyl groups are also commonly installed into the NRPs, such as cyclosporin,137 
actinomycin138 and yersiniabactin.139 The methylations are catalyzed by N-methyl transferase (N-
MT) and C-methyl transferase (C-MT) domains using methyl donor, S-adenosyl methionine (SAM) 
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as methyl donor.  
1.2.1.9 Chain initiation and release  
Peptide assembly is usually initiated by the activity of an A domain located in the loading module, 
which normally lacks a C domain. However, in the biosynthesis of lipopeptides, such as surfactin, 
fengycin and gliadobactin, a starter C domain (discussed previously) is always found at the N-
terminus of the loading module.126 In this kind of chain initiation mechanism, the starter C 
domain catalyses N-acylation of the loaded amino acid with a 3-hydroxylacyl unit.129 The loading 
modules of NRPS sometimes contain additional chain modification domains, for example a E 
domain is located in first module of the Gramicidin S assembly line.140  
Once the peptide chain has been fully assembled, it is released from the assembly line either as 
a linear product, such as vancomycin, or more commonly as a macrocyclic product, such as 
surfactin. This process is normally accomplished by a C-terminal TE domain, which utilizes a 
similar catalytic mechanism to type I TE domains from modular PKSs (discussed in the previous 
section).141,142 Alternatively, in some cases, the product is liberated as a linear aldehyde or alcohol 
via NADPH-dependent reduction catalyzed by a C-terminal thioester reductase (TR) domain.143 
1.3.3 Biosynthesis of icosalides 
Genome sequencing of B. gladioli BCC238 identified a single  ̴15 kb gene encoding an NRPS 
proposed to be responsible for the biosynthesis of icosalides(Figure 1.26 A). Within the NRPS, 
four adenylation domains were identified, with their predicted substrate specificities in 
agreement with amino acid residues incorporated into the icosalides (A1: Leucine, A2: Serine, A3: 
Leucine, A4: Serine). Five C domains and a cyclising TE domain were assigned to the six bond-
forming reactions required for the assembly of the 20-membered cyclic core of the icosalides. 
Phylogenetic analysis of the five C domains revealed they clade into the following subtypes 
(Figure 1.26 B): C3 and C5 are LCL domains, C2 is a dual E/C DCL domain and C1 and C4 are starter 
C domains. The dual epimerization-condensation activity of the C2 domain accounts for the 
existence of the D-configuration of the Leu residue in the final product. The presence of the two 
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starter C domains, C1 and C4, is also in agreement with the incorporation of two 3-hydroxy acyl 
chains into the icosalides. Inactivation of icoA abolished production of the icosalides, confirming 
the involvement of the NRPS in the icosalides biosynthesis (Figure 1.26 C)The biosynthetic 
pathway proposed for the icosalides is shown in Figure 1.27. 
 
Figure 1.26 Identification of the gene encoding the icosalide NRPS biosynthetic gene and phylogenetic analysis 
of the C domains (unpublished data from Challis group). (A) Schematic of the ~15 kb icoA NRPS biosynthetic 
gene. The sequence of enzymatic domains within the NRPS is shown below. (B) phylogenetic analysis of the C 
domains of IcoA NRPS. 3-hydroxyacyl unit incorporating starter C1 and C4 domains are highlighted in red. (C) 
Insertional mutagenesis of icoA abolishes icosalide A1 production in B. gladioli BCC0238.  
 
Figure 1.27 NRPS and proposed biosynthesis of icosalides. Domain and module organization of the icosalide 
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NRPS showing the proposed structure of chain elongation intermediates. The two starter condensation domains 
are highlighted by red numbers. The starter condensation domain C4 is ‘embedded’ in the predicted NRPS. 
Substrate specificity of each adenylation domain is denoted above each domain. 
The icosalide NPRS exhibits an unprecedented domain architecture, with the chain initiating C 
domain IcoA C4 situated in the middle of IcoA and directly adjacent to the IcoA C3 domain. The 
IcoA C4 domain is believed to be the first example of a starter condensation domain that is 
internal to an NRPS. The domain organization of module 3 also indicates IcoA C3 domain and 
IcoA C4 domain are required to co-operate for accomplishing a second round of chain initiating 
event as well as a chain elongation event in this module, the biosynthetic mechanism of which is 
of considerable interests. 
1.4 Study aims  
The aims of this study were to gain a better understanding of gladiolin and icosalides biosynthesis 
in B. gladioli with a long-term goal of employing the obtained insights to engineer their and 
related biosynthetic pathways. 
The first aim was to uncover the biosynthetic origins for the key structural differences between 
gladiolin and etnangien. This included identification of the enoyl reductase required by module 
5 of the gladiolin PKS and probing the molecular basis for the non-iteration of this module. 
The second aim was to investigate the double chain initiation mechanism underpinned by the 
unprecedented domain organization of the icosalide NRPS. This involves characterization of the 
internal starter and the adjacent ‘normal’ condensation domains in module 3 of icosalide NRPS. 
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Chapter 2 
Characterization of cis- and trans-acting 
enoyl reductases in the gladiolin polyketide 
synthase 
As discussed in section 1.2.3, the gladiolin and etnangien PKSs possess strikingly similar domain 
architectures, yet produce quite different biosynthetic products. A key structural difference is the 
hexaene moiety of etnangien (absent in gladiolin), which is likely installed by the iterative activity 
of EtnE Module 5 resulting in the three double bonds between C26-C31, and contributes to the 
inherent instability of etnangien (Figure 2.1A). The corresponding region in gladiolin is a saturated 
centre between C26-C27, suggesting an enoyl reduction event has halted the formation of a 
polyene (Figure 2.1B). Intriguingly, the corresponding module 5 of the gladiolin PKS does not 
harbor an ER domain to catalyze the reduction of the α,β-unsaturated intermediate. 
 
Figure 2.1 Partial biosynthetic pathways of the gladiolin (A) and etnangien (B) PKSs. The iterative module 5 of 
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the etnangien PKS is highlighted in gold. The missing ER required for the additional enoyl reduction event in 
module 5 of the gladiolin PKS is denoted. The substituted ER domain in module 1 of the gladiolin PKS is highlighted 
in green. Structural differences in the intermediates and final products resulted from the two additional events 
and iteration and non-iteration of module 5 are highlighted in red (gladiolin) and blue (etnangien). 
In order to investigate this phenomenon, the ER required by module 5 of the gladiolin PKS is 
needed to be first identified. Building upon the previous detailed analyses of the gladiolin and 
etnangien biosynthetic gene clusters, the most likely candidate was assigned as the sole 
difference between the two PKSs architecture, the substituted ER (GbnD1 ER1) domain in module 
1 of the gladiolin PKS (Figure 2.2). Here, the GbnD1 ER1 domain would be predicted to act dual-
functionally that catalyzes the enoyl reduction in GbnD1 module1 in an intra-modular manner, 
and in GbnD1 Module 5 in an inter-modular manner. Another feature identified from 
bioinformatics analysis of both clusters is the presence of a putative trans-acting enoyl reductase 
GbnE/EntL are proposed to reduce the intermediate in module 10 of their PKSs according to the 
structure of the final products (Figure 2.2). However, with this knowledge, it is feasible that GbnE 
could be the second candidate supplying dual-functional trans-acting ER activity in module 5 
apart from in module 10. 
This chapter describes efforts to elucidate the ‘cryptic’ ER activity in the module 5 of the gladiolin 
PKS. Using a combination of in vivo genetic engineering and in vitro biochemical assays, the 
function of the aforementioned two candidate ERs in the gladiolin biosynthesis are investigated. 
 
Figure 2.2 Comparison of catalytic domain architectures of gladiolin and etnangien PKSs showing the 
hypothetic catalytic origin of the additional enoyl reduction event in module 5 of the gladiolin PKS. 70 out 71 
catalytic domains are identical between the two assembly lines. The two candidates for the ER required by 
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module 5 of the gladiolin PKS are denoted as: 1) the sole domain architecture difference, the substituted GbnD1 
ER1 domain in the gladiolin PKS (highlighted in green), and 2) the putative trans-acting ER GbnE (highlighted in 
purple). The counterpart of GbnE in the etnangien PKS is shown as EntL. 
2.1 Characterization of the GbnD1 ER1 domain  
2.1.1 In vivo characterization of the GbnD1 ER1 domain 
2.1.1.1 In-frame deletion of gbnD1 ER1  
An in vivo inactivation approach was first employed to investigate the function of the GbnD1 ER1 
domain in gladiolin biosynthesis. In-frame deletion of the DNA-encoding region for the GbnD1 
ER1 domain was considered to be the most direct strategy to inactivate this domain. This 
approach also aimed to mimic the catalytic domain organization of the etnangien PKS at the 
sequence level (minus an ACP domain), in attempt to elicit etnangien-like biosynthesis.  
In-frame deletion of targeted chromosomal regions in B. gladioli were achieved by the 
homologous recombination mutagenesis system, based on the yeast homing endonuclease I-
SceI144 (Figure2.3). The system involves cloning the sequences flanking the chromosomal region 
targeted for deletion into the suicide plasmid pGPI-SceI that cannot replicate in Burkholderia 
strain and carries the I-SceI recognition site. This plasmid is then transferred to Burkholderia by 
tri-parental mating, resulting in its targeted insertion into the chromosome via homologous 
recombination and the introduction of a single crossover mutant allele. The second plasmid pDAI-
SceI that constitutively expresses the I-SceI nuclease was then introduced into the single 
crossover mutant allele. I-SceI causes a double strand break into the inserted plasmid sequence, 
which stimulates intramolecular homologous recombination between the flanking region on 
plasmid and chromosome. The resolution of this cointegrate can either restore the parental allele 
or cause a gene deletion, depending on the site of the crossover. 
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Figure 2.3 Work flow of the mutagenesis system applied in in-frame deletion in Burkholderia. Blue and red box: 
5’ and 3’flanking regions, green box: targeted gene, grey box: SceI nuclease encoded in pDAI-SceI, orange and 
purple box: trimethylprime and tetracycline resistance gene, yellow box: counter selection marker SacB, arrow 
on pDAI: constitutive promoter, blue cross marks are referred to homologous recombination events. 
As the previous trial of gene deletion in the original gladiolin producer B. gladioli BCC0238 
resulted in failure due to its spontaneous resistance to the antibiotic for the mutant selection, 
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the in vivo investigation was then carried out in another gladiolin producing isolate B. gladioli 
BCC1622, which harbors the identical biosynthetic gene cluster (99.5% identity of DNA 
sequences). Metabolite profiling of wild type B. gladioli BCC1622 by LC-MS also observed another 
two gladiolin related compounds which present in the extract of B. gladioli BCC0238. Structural 
elucidation (by Dr. Lijiang Song) confirmed one of them is the iso-gladiolin 28, generated via 
rearrangement, and the other is the linear gladiolin 29 due to hydration of gladiolin28 (Figure 2.4). 
 
Figure 2.4 Structure comparison of gladiolin and its analogues. Iso-gladiolin 28 and linear-gladiolin 29 derive 
from rearrangement and hydration of gladiolin respectively. 
To in-frame delete gbnD1 ER1 following the strategy described above, the deletion construct 
pGPI-gbnD1_ER1 was generated and mobilized into B. gladioli BCC1622 (detailed in 6.3.1). The 
gbnD1 ER1 deletion mutant B. gladioli BCC1622_ΔgbnD1_ER1 was successfully obtained and 
confirmed by PCR. (Figure 2.5).  
Having generated the B. gladioli BCC1622_ΔgbnD1_ER1 mutant, the effect of the mutation on 
gladiolin production could then be examined. Comparative metabolite profiling of B. gladioli 
BCC1622_ΔgbnD1_ER1 and WT B. gladioli BCC1622 was conducted by LC-MS (detailed in 6.4). 
The B. gladioli BCC1622_ΔgbnD1_ER1 mutant base peak chromatogram (BPS) showed the three 
gladiolin related peaks were absent, with no obvious new peak being formed (Figure 2.6 A). 
Furthermore, the extracted ion chromatogram (EIC) confirmed the production of gladiolin was 
abolished in BCC1622_ΔgbnD1_ER1 (Figure2.6 B). 
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Figure 2.5 Schematic representation of generation and PCR confirmation of B. gladioli BCC1622_ΔgbnD1_ER1. 
(A) Targeted in-frame deletion of the gbnD1 ER1 region of wild type chromosome is highlighted in green. Loss of 
the green region on the mutant chromosome after double crossover denotes successful deletion. Checking PCR 
primers are indicated by orange arrows and their binding sites on the mutant and WT chromosome and deletion 
plasmid DNA are indicated, respectively. The length of corresponding predicted PCR products is shown. (B) DNA 
electrophoresis gel of the PCR products confirms the genome type of the deletion mutant, resulting in a 449 bp 
product as observed in the positive control (deletion plasmid), and the negative control (WT allele) resulted in a 
1361 bp product. ‘CL’ refers to control, ‘WT’ refers to B. gladioli BCC1622 wild type. 
 
Figure 2.6 LC-MS analysis of metabolite extracts from BCC1622 wild type and BCC1622_ΔgbnD1_ER1. All 
chromatograms follow the layout of; WT B. gladioli BCC1622 indicated in black and B. gladioli 
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BCC1622_ΔgbnD1_ER1 mutant indicated in red. (A) Base peak chromatograms of metabolite extracts. (B) EICs at 
m/z=779.5309 ± 0.02 Da and 801.5129 ± 0.02 Da, corresponding to the [M+H]+ and [M+Na]+ ions of gladiolin 7 
and iso-gladiolin 28, (C) EICs at m/z= 777.5153 ± 0.02 Da and 799.4972 ± 0.02 Da corresponding to [M+H]+ and 
[M+Na]+ ions of unsaturated gladiolin 32. See appendix for mass spectra of the EICs. 
The possible products produced by the GbnD1 ER1 domain inactivated mutant are expected as 
shown in Figure 2.7, based on three scenarios: 1) The GbnD1 ER1 domain is of dual function, 
performing enoyl reduction in both module 1 and module 5, and the activity of GbnD1 ER1 in 
module 5 halts the inherent iterative nature of module 5, thus inactivation of GbnD1 ER1 would 
resulted in generation of structure 30; 2) The GbnD1 ER1 domain is of dual function but GbnD2 
Module 5 has no underlying ability to perform iteration, thus inactivation of GbnD1 ER1 would 
generate structure 31; 3) The GbnD1 ER1 domain only reduces the α, β-unsaturated intermediate 
arising from module 1 and has no effect on module 5, thus inactivation of GbnD1 ER1 would 
generate structure 32.  
 
Figure 2.7 Structural comparison of gladiolin and proposed derivatives arising from inactivation of GbnD1 ER1 
in vivo. Structural differences from gladiolin are highlighted in red, and m/z values for [M+H]+ and [M+Na]+ are 
shown. The proposed derivatives are comprised of the structural differences resulting from a combination of 
possible consequences of GbnD1 ER1 inactivation. The desaturation of C34-C35 (in all three derivatives) 
originates from elimination of GbnD1 ER1 activity in module 1. The desaturation of C26-C27 (in 30 and 31) 
originates from elimination of the proposed GbnD1 ER1 additional activity in module 5. The installation of a 
polyene region at C26-C31 (in 30) is the predicted result of restoring the iteration of module 5 by removing GbnD1 
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ER1 function towards this module. 
To probe whether gladiolin derivatives 30-32 (Figure 2.7) were produced after deletion of gbnD1 
ER1, the corresponding [M+H]+ and [M+Na]+ ions were searched in both mutant and WT 
metabolite extracts. The ions with molecular weight corresponding 30 and 31 were not detected 
in both the WT and mutant extract (data not shown). This result indicates the GbnD1 ER1 domain 
does not catalyse the inter-modular enoyl reduction in module 5. Interestingly, multiple peaks 
with m/z value corresponding to 32 were observed in the WT, whilst a new single peak with a 
different retention time (16.9 min) appeared in the mutant (Figure 2.6 C). Due to the very low 
intensities of all the peaks being noted, it was not possible to purify them for structural 
elucidation. However, none of these peaks could be observed in metabolite extraction from the 
single crossover mutant (data not shown), which strongly suggested they were all related to 
gladiolin biosynthesis.  
The new peak (16.9 min) in the mutant likely corresponds to 32 as this would be consistent with 
the predicted GbnD1 ER1 domain’s cis-acting enoyl reduction activity in module 1. The multiple 
peaks in the WT EIC at m/z= 777.5153 ± 0.02 Da and 799.4972 ± 0.02 Da (the same of the one of 
32) are predicted to be 33 and 34 (Figure 2.8), as well as their iso-gladiolin analogous. They would 
be formed by the trans-acting enoyl reduction events in module 5 or module 10 not being fully 
efficient during polyketide assembly. The low yield of 32 from the mutant strain could be the 
result of the excision of the GbnD1 ER1 domain from GbnD1 affecting the overall folding of GbnD1 
which slowed down the polyketide assembly. This could also be an alternative explanation for 
inability to detect the derivative 30 and 31. 
 
Figure 2.8 Proposed structure of unreduced gladiolin derivatives. Structures were proposed based on the 
hypothesis of trans-acting enoyl reduction events in module 5 (generates 33) or module 10 (generates 34) not 
being fully efficient during the polyketide assembly. 
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2.1.1.2 Site-directed mutagenesis of GbnD1 ER1 domain in the gladiolin PKS 
In order to avoid the disturbance to the overall structure of GbnD1, inactivation of the GbnD1 
ER1 domain was alternatively pursued via site-directed mutagenesis. This strategy aims complete 
domain inactivation without significantly affecting the conformation or folding of the GbnD1 
protein. 
The cis-acting ER domains of modular PKSs belong to the NAD(P)H-dependent medium-chain 
dehydrogenase/reductase (MDR) superfamily of enzymes, which typically comprise of two 
subunits: a N-terminal catalytic subdomain and a C-terminal Rossman-fold NADPH bind 
subdomain 81. Unfortunately, unlike other domains from modular PKSs, there is very limited 
structural and catalytical information on ER domains. Previous mutagenesis studies of the 
proposed catalytically important residues in the ER domain from rapamycin PKS (RapER13) and 
spinosyn PKS (SpnER2) all resulted in only lowering but not abolishing the activity (as introduced 
in section 1.2.1.5 ‘cis-acting Enoyl reductases’)82,80. However, site-directed mutagenesis of the 
NADPH binding motif of ER domains from nystatin (NysER5) 145 and erythromycin (EryER3)146 PKS 
have been reported to successfully inactivate their enoyl reduction activity. Changing the two 
adjacent glycine residues in the conserved NADPH binding motif HAAAGGVGMA of NysER5 and 
EryER3 to a serine and a proline resulted in non-production of parental products and relatively 
high production of unreduced analogous145,146, suggesting an completely inactive ER domain and 
a fully functioning assembly line in each instance. 
Further inspection of the NADPH binding pocket in SpnER2, the only reported crystal structure of 
ER domain from modular PKSs, suggested the two adjacent glycine residues (G138 and G139) 
located at the active site and involved in the binding of the NADPH (Figure 2.9). Replacing G138 
with serine and G139 with proline would disturb conformation of the α-helix thus impede 
accommodation of NADPH. This observation further supported the logic of mutagenesis study in 
NysER5 and EryER3. Thus, one possible strategy to inactivate the GbnD1 ER1 domain via 
mutagenesis, in the absence of structural information, would be following the mutagenesis 
approach outlined above. 
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Figure 2.9 Structure of NADPH binding site in SpnER2 domain from spinosyn PKS. Cofactor binding site of 
SpnER2 shows G138 and G139 (shown as sticks) involved in the binding of NADPH. Structure created in Pymol 
from PDB: 3SLK80. 
The cofactor binding motif of the GbnD1 ER1 domain was identified by sequence alignment with 
other ER domains from modular PKSs (Figure 2.10, see appendix for full result). The two adjacent 
glycines embedded in the NADPH binding motif of the GbnD1 ER1 domain were located at 
positions 388 and 389. The subsequent double mutation (G388S/G389P) was achieved by in vitro 
site-directed mutagenesis of the gbnD1 ER1 DNA encoding region and then an in-frame ‘knock-
in’ of the mutated gbnD1 ER1(G388S/G389P) segment back into B. gladioli 
BCC1622_∆gbnD1_ER1 by double crossover homologous recombination (detailed in 6.3.2) 
(Figure 2.11 A). This was achieved based on the same yeast homing endonuclease I-SceI144 system 
used for in frame deletion as previous described (Figure2.3). Both PCR analysis (Figure 2.11 B) 
and sequencing of the designed mutation region confirmed the successful mutagenesis.  
 
Figure 2.10 Partial result of multiple sequence alignment between GbnD1 ER1 domain and reported ER 
domains from type I modular PKSs. The conserved NADPH binding motif is indicated as an orange bar and the 
conserved two adjacent glycine residues are indicated by a red star. The numbers after ER domains refer to the 
module number within the respective PKS. Ery, erythromycin; Spn, spinosyn; Rap, rapamycin; Lkm, lankamycin; 
Cur, curacin. 
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Figure 2.11 Schematic representation of generation and PCR confirmation of B. gladioli BCC1622_ gbnD1_ER1 
(G388S/G389P). (A) Wild type gbnD1 ER1 cloned with flanking arms is denoted in green. Mutated gbnD1 ER1* 
fragments on pGPI plasmid and the in-frame knock-in mutant chromosome are highlighted by a purple. Insertion 
of the purple region on the mutant chromosome after double crossover denotes as a successful knock-in. 
Checking PCR primers are indicated by orange arrows and their binding sites on the mutant chromosome, 
parental allele BCC1622_ΔgbnD1_ER1 chromosome and knock-in plasmid pGPI-gbnD1_ER1* are indicated 
together with the length of corresponding predicted PCR products. (B) DNA electrophoresis gel of the PCR 
products confirmed the genotype of mutants, resulting in a 1136 bp product as observed in positive controls (WT 
and knock-in plasmid), while negative control (parental allele) resulted in 449 bp product. ‘CL’ refers to control, 
‘*’ refers to G388S/G389P mutation. 
Comparative metabolite profiling of the mutants and wild type was then conducted by LC-MS 
analysis. Again, gladiolin production was abolished in BCC1622_gbnD1_ER1*(G388S/G389SP) as 
shown in BPCs with no obvious new peak observed (Figure2.12 A). The abolished production of 
gladiolin was confirmed by EIC (Figure2.12 B). All predicted derivatives (Figure 2.7) were searched 
in the mutant and wild type metabolite extracts. A similar gladiolin derivatives production pheno 
type was observed in BCC1622_gbnD1_ER1*(G388S/G389P) mutant with the gbnD1 ER1 in-
frame deletion mutant (Figure 2.12 C). Only ions with molecular weight corresponding to 
unreduced gladiolin 32 could be detected (16.9 min) and the yield did not significantly increase 
compared to in the gbnD1 ER1 deletion mutant. This suggested that the low production of 
gladiolin derivatives in both gbnD1 ER1 deleted and mutated mutants was the result of a 
restricted substrate preference of the downstream assembly line.  
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Figure 2.12 LC-MS analysis of metabolite extract from BCC1622 wild type and BCC1622_gbnD1_ER1*(GG388-
399SP). All chromatograms follow the layout of: wild type indicated in black and BCC1622_gbnD1_ER1*(G388S-
G389P) indicated in red. (A) Base peak chromatograms. (B) Extracted ion chromatograms at m/z=779.5309±0.02 
Da and 801.5129±0.02 Da corresponding to the [M+H]+ and [M+Na]+ ion of gladiolin 7 and iso-gladiolin 28, C) 
Extracted ion chromatogram at m/z= 777.5153±0.02 Da and 799.4972±0.02 Da corresponding to [M+H]+ and 
[M+Na]+ ions of unsaturated gladiolin 33 and 34 in WT and 32 in BCC1622_gbnD1_ER1*mutant. See appendix for 
mass spectra of the EICs. 
Although no structural elucidation of the new metabolite (16.9 min) was possible, its presence in 
both the gbnD1 ER1 deletion and site-directed mutation mutants but not in WT and single 
crossover indicated the structure of this new metabolite as 32. It thus suggested the GbnD1 ER1 
domain has cis-acting enoyl reduction activity in module 1.   
2.1.2 In vitro characterization of the GbnD1 ER1 domain 
In an effort to complement the genetic data shown previously, detailed in vitro biochemical 
assays were also employed to provide additional information regarding the ability of the GbnD1 
ER1 domain to conduct both intra- and inter-modular enoyl reductions. This hypothesis requires 
that the GbnD1 ER domain must interact with ACP domains from module 1 and module 5, 
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catalyzing reduction of the α, β-unsaturated intermediate in each instance.  
In order to investigate this, the following protein constructs were designed: GbnD1 ACP1-ER1 
didomain, isolated GbnD1 ER1 domain and isolated GbnD2 ACP5 domain. pET-151-GbnD1_ACP1-
ER1, pET-151-GbnD1_ER1 and pET-151-GbnD2_ACP5 were created as N-terminal pHis6 
constructs, which were overexpressed in E. coli BL21 (DE3) and the corresponding N-pHis6 
recombinant proteins were purified as described in 6.5. The mass and purity of the purified 
recombinant protein were confirmed by SDS-PAGE and LC-MS analysis (Figure 2.13). 
 
Figure 2.13 SDS-PAGE and LC-MS analysis of purified N-His6-GbnD1 ACP1-ER1, N-His6-GbnD1 ER1, N-His6-GbnD2 
ACP5. 10% SDS-PAGE gel showed the size and purity of N-His6-GbnD1 ACP1-ER1 and N-His6-GbnD1 ER1 (A), 15% 
SDS-PAGE gel showed the size and purity of N-His6-GbnD2 ACP5 (B). Deconvoluted mass spectra of N-His6-GbnD1 
ACP1-ER1 (C), N-His6-GbnD1 ER1 (D) and N-His6-GbnD2 ACP5 (E). Peaks labeled as ‘*’ refer to the known 
gluconoylation of His-tag fusion proteins with +178 Da being observed147. The second ‘●’ peak in N-His6-GbnD1 
ER1 deconvoluted spectrum referred to phosphogluconoylation modification of His-tag with mass addition of 258 
Da147. For See appendix for raw mass spectra. 
2.1.2.1 Characterization of GbnD1 ER1 intra-modular enoyl reduction activity in module 1  
Firstly, the ability of the GbnD1 ER1 domain to catalyse enoyl reduction of a 2-butenoyl substrate 
attached to the GbnD1 ACP1 domain was examined. An in vitro enoyl reduction assay (outlined 
in Scheme2.1) was designed, using the commercially available 2-butenoyl-CoA ester as a 
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substrate mimic of the intermediate in module 1. The 2-butenoyl-phosphopantethienyl (Pant) 
chain from the CoA ester was first loaded onto the ACP domain using the reported PPtase 
catalyzed loading reaction (described in 6.6.6.1). The successful attachment of the 2-butenoyl-
PPant chain was monitored by LC-MS analysis of intact GbnD1 ACP1-ER1 before and after the 
loading reaction, which showed the expected 409 Da mass shift (Figure 2.14 A). The following 
reduction of the loaded 2-butenoyl unit by the GbnD1 ER1 domain was conducted by adding 
either NADH/NADPH as cofactor to the reaction. A control reaction was conducted with the same 
condition, without adding any cofactor.  
 
Scheme 2.1 Design of in vitro assay for investigating the GbnD1 ER1 domain’s intra-modular enoyl reduction 
activity. GbnD1 ACP1-ER1 didomain was first loaded with 2- butenoyl-PPant unit from substrate mimic crotonyl-
CoA via PPtase, Svp catalyzed loading reaction, followed by addition of cofactor NADPH/NADH 
 
Figure 2.14 LC-MS analysis of in vitro GbnD1 ER1 domain intra-module enoyl reduction activity. (A) 
Deconvoluted mass spectra of apo-GbnD1 ACP1-ER1 (top) and following incubation with 2-butenoyl-CoA Svp and 
MgCl2 (bottom). (B) Mass spectra of PPant ejected ions activated from 2-butenoyl-GbnD1 ACP1-ER1 following 
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incubating with NADPH (top), NADH (middle) or with no co-factor (bottom). 
As the mass shift from the reduced product to the substrate was only 2 Da, and therefore difficult 
to detect by intact protein MS, the enoyl reduction activity was instead monitored using the 
PPant ejection procedure148. This involves collision-induced activation of the 
phosphopantetheinylated proteins within the mass spectrometer to liberate the pantetheine 
(Pant) moiety from the ACP as a small molecule, allowing small mass shifts resulting from acyl 
chain modifications to be examined (Figure 2.14 B). Interestingly, the control reaction (lacking 
the required NADPH/NADH cofactor) resulted in the presence of both 2-butenoyl-PPant and 
butyryl-PPant ions at a ratio of around 1:1. This was probably due to GbnD1 ACP1-ER1 co-
purifying with the cofactor bound. However, complete conversion from 2-butenoyl-GbnD1 ACP1-
ER1 to butyryl-GbnD1 ACP1-ER1 was only observed following incubation with additional NADPH 
(Figure 2.14 B). There was only 5-10% conversion with NADH addition compared to the control 
reaction, indicating NADPH is the true cofactor of this ER domain. This result confirmed the 
GbnD1 ER1 domain’s intra-modular enoyl reduction activity in module 1. 
2.1.2.2 Probing the GbnD1 ER1 inter-modular enoyl reduction activity in module 5 
To investigate the proposed inter-modular activity of the GbnD1 ER1 domain with the ACP 
domain of module 5, a 2,4-hexadienoyl pantetheine (Pant) (synthesized by PhD student Christian 
Hobson), was used as a closer substrate mimic of the intermediate generated by module 5 to 
perform the designed in vitro assay shown in Scheme 2.2. 
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Scheme 2.2 Design of in vitro assay for investigating the putative inter-modular enoyl reduction activity of the 
GbnD1 ER1 domain. The GbnD2 ACP5 domain was first loaded with 2,4-hexadienoyl-PPant unit using the 
corresponding pantetheine form substrate mimic and the phosphopantetheinylation enzyme cassette catalyzed 
loading reaction followed by addition of GbnD1 ER and cofactor NADPH. 
Loading of the 2,4-hexadienoyl PPant unit onto the GbnD2 ACP5 domain was achieved using the 
phosphopantetheinylation enzyme cassette (detailed in 6.6.1.2). The resulting 2,4-hexadienoyl-
GbnD2 ACP5 was confirmed by a +435 Da mass shift on from the apo-GbnD2 ACP5 when 
monitored by LC-MS (Figure 2.15 A). The 2,4-hexadienoyl-GbnD2 ACP5 was then incubated with 
the GbnD1 ER1 domain and additional NADPH using the same conditions used in 2.1.2.1 (detailed 
in 6.2.2.2). A control reaction was conducted using the same conditions, but lacking GbnD1 ER1. 
Only 2,4-hexadienoyl-PPant ion could be detected in both of the control and experimental 
reaction (Figure 2.15 B) showing there was no ER-catalyzed reduction. This suggested that GbnD1 
ER1 does not interact with GbnD2 ACP5 in an inter-modular fashion.  
 
Figure 2.15 LC-MS analysis of in vitro GbnD1 ER1 domain inter-modular enoyl reduction activity in module 5. 
(A) Deconvoluted mass spectra of apo-GbnD2 ACP5 (top) and following incubation with 2,4-hexadienoyl-Pant and 
loading enzymes cassette in the presence of MgCl2 and ATP (bottom). (B) Mass spectra of PPant ejected ion 
activated from 2,4-hexadienoyl-GbnD2 ACP5 incubated with GbnD1 ER1 and NADPH (bottom) or only with 
NADPH (top). 
However, this negative result could also be caused by the isolated GbnD1 ER1 being purified in 
an inactive form. Therefore, in order to test this possibility, another in vitro assay (Scheme 2.3) 
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was conducted, in which the GbnD1 ER domain was incubated with 3-methyl-butenoyl-Pant 
(synthesized by Dr. Douglas Roberts) and monitored for reduction of the enoyl functionality 
(detailed in 6.2.2.2). LC-MS analysis of extracted reaction mixture showed 60-70% substrate was 
converted to 3-methyl-butyryl-Pant while there was no conversion observed in the control 
reaction when using denatured GbnD1 ER1 domain (Figure 2.16). This result confirmed the 
isolated GbnD1 ER1 domain was purified in active form.  
 
Scheme 2.3 Design of in vitro assay for monitoring activity of isolated GbnD1 ER1 domain. The isolated GbnD1 
ER1 domain was incubated with 3-methyl-butenoyl-Pant and cofactor NADPH. 
 
Figure 2.16 LC-MS analysis of in vitro assay demonstrating enoyl reduction activity of the isolated GbnD1 ER1 
domain. Base peak chromatogram from LC-MS analysis of extracted reaction mixture of the GbnD1 ER1 domain 
incubated with 3-methyl-butenoyl-Pant and NADPH (bottom) and control group using denatured GbnD1 ER1 
(top). 
All the above results in this section provided key evidence to support the idea that GbnD1 ER1 
domain is unable to engage in productive interactions with the ACP domain from module 5, 
suggesting that the GbnD1 ER1 domain is not able to catalyze the proposed ‘inter-module’ 
reduction in module 5. 
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2.2 Characterization of GbnE 
The findings detailed in Section 2.1 essentially ruled out the ability of the GbnD1 ER1 domain to 
catalyse enoyl reduction activity on a module 5 intermediate in an inter-modular manner. This 
suggested that the putative trans-acting enoyl reductase, GbnE, is a more likely candidate to 
perform enoyl reduction in both module 10 and module 5. To probe this dual functional activity 
of GbnE as well as the potential effect of GbnE to the non-iterative usage of module 5, GbnE was 
first characterized via in vivo approach.  
2.2.1 In vivo characterization of GbnE 
2.2.1.1 In-frame deletion of gbnE 
Since GbnE is encoded by a stand along gene, in-frame deletion was still considered as useful 
approach to investigate its function in the biosynthesis of gladiolin. Utilizing the same 
methodology as employed for deletion of gbnD1_ER1, a deletion construct, pGPI-gbnE, was first 
generated and mobilized into B. gladioli BCC1622 to obtain B. gladioli BCC1622_ΔgbnE (Figure 
2.17 A). Successful deletion of gbnE was confirmed by PCR and sequencing (Figure 2.17 B).  
 
Figure 2.17 Schematic representation of generation and PCR confirmation of B. gladioli BCC1622_ΔgbnE. (A) 
Targeted in-frame deletion region on WT B. gladioli BCC1622 chromosome is highlighted as a blue. Loss of the 
blue region on the mutant chromosome after double crossover denotes successful deletion. Checking PCR 
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primers are indicated by orange arrows and their binding sites on the mutant chromosome, WT chromosome and 
deletion plasmid are indicated together with the length of corresponding predicted PCR products. (B) DNA 
electrophoresis gel of the PCR products confirmed the genome type of the gbnE deletion mutant, resulting in a 
457 bp product as observed in the positive control (deletion plasmid), and the negative control (WT allele) 
resulted in a 1756 bp product. ‘CL’ refers to control, ‘WT’ refers to B. gladioli BCC1622 wild type. 
Comparative metabolite profiling of B. gladioli BCC1622_Δ gbnE and WT B. gladioli BCC1622 was 
conducted by LC-MS analysis. Interestingly, the B. gladioli BCC1622_Δ gbnE metabolite extract 
(Figure 2.18 A and B) showed that although the gladiolin production significantly reduced, it was 
maintained at low level, around 5-10% of wild type production. This seemed to suggest GbnE is 
intimately involved in gladiolin biosynthesis, and could be partially complemented by 
homologous enzyme(s) in the cell.  
 
Figure 2.18 LC-MS analysis of metabolite extracts from B. gladioli BCC1622 wild type and BCC1622_ΔgbnE. All 
chromatograms follow the layout of: WT B. gladioli BCC1622 indicated in black and B. gladioli BCC1622_ΔgbnE 
indicated in red. (A) Base peak chromatograms. (B) Extracted ion chromatograms at m/z=779.5309 ± 0.02 Da and 
801.5129 ± 0.02 Da corresponding to the [M+H]+ and [M+Na]+ ions of gladiolin 7 and iso-gladiolin 28. C) Extracted 
ion chromatogram at m/z = 777.5153 ± 0.02 Da and 799.4972 ± 0.02 Da corresponding to [M+H]+ and [M+Na]+ 
ions of unsaturated gladiolin 33 and 34. See appendix for mass spectra of the EICs. 
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Possible derivatives produced by gbnE deletion mutant were proposed (Figure 2.15) based on 
three possible scenarios:1) GbnE domain is of dual function, performing enoyl reduction in both 
module 5 and module 10, and the activity of GbnE in module 5 halts the inherent iterative nature 
of this module, thus inactivation of GbnE would resulted in generation of structure 35; 2) GbnE 
is of dual function but GbnD2 Module 5 has no underlying ability to perform iteration, thus 
inactivation of GbnE would generate structure 36; 3) Like its counterpart EntL in etnangien 
biosynthesis, GbnE only reduces the α, β-unsaturated intermediate arising from GbnD4 module 
10 and has no effect on module 5, thus inactivation of GbnE would generate structure 34.   
 
Figure 2.19 Structural comparison of gladiolin and proposed derivatives produced by the gbnE deletion mutant. 
Structural differences from gladiolin are highlighted in red, and m/z values for [M+H]+ and [M+Na]+ are shown. 
The proposed derivatives are comprised of the structural differences resulting from a combination of possible 
consequences of gbnE deletion. The desaturation of C16-C17 (in all three derivatives) originate from elimination 
of GbnE activity in module 10. The desaturation of C26-C27 (in 35 and 36) originate from elimination of GbnE 
activity in module 5. The installation of a polyene region at C26-C31 (in 35) is the result of restoring the iteration 
of module 5 by removing GbnE function towards this module.  
To probe whether derivatives 34-36 (Figure 2.19) were produced after deletion of gbnE, the ions 
corresponding to their molecular weight were searched for in metabolite extracts of B. gladioli 
BCC1622_ ΔgbnE. Neither 35 or 36 was observed (data not shown) and 34 (and 33) was detected 
at significantly lower level than in the wild type (Figure 2.18 C).  
The decreased production of gladiolin and related derivatives in the B. gladioli BCC162_ΔgbnE 
mutant strain suggested a general slowing down of the PKS assembly line in the absence of GbnE, 
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which further indicated the crucial role of the enoyl reduction events performed by GbnE to the 
assembly line. This could be because the reduced intermediates are preferred by the downstream 
assembly line or the assembly line requires the trans-acting protein-protein interaction from 
GbnE for efficient processing.  
It is, however, possible that the polar effect introduced by deletion of gbnE was responsible for 
the overall low production of gladiolin related products. In order to rule out this possibility and 
to thus validate the crucial function of GbnE to the assembly line, gbnE complementation to B. 
gladioli BCC1622_ΔgbnE was performed. 
2.2.1.2 Complementation of gbnE 
Firstly, gbnE was cloned onto an expression vector pMLBAD (detailed in 6.3.3), which was 
reported to be used for performing successful regulated gene expression under the control of an 
arabinose-inducible PBAD promoter in Burkholderia cepacian species149. The confirmed construct 
pMLBAD-gbnE was then mobilized into BCC1622_ΔgbnE by tri-parental mating (detailed in 6.3.4). 
Mutant BCC1622_ΔgbnE::gbnE was screened by antibiotic selection and confirmed by PCR 
(detailed in 6.3.3) (Figure 2.20). 
 
Figure 2.20 PCR confirmation of B. gladioli BCC1622_ΔgbnE::gbnE. DNA electrophoresis gel of the PCR products 
confirmed the genome type of gbnE complemented mutant, resulting in a 1398 bp product like the positive 
control wild type ‘CL’ refers to control. 
0.2%-2% of L-arabinose was reported to be the optimal final concentration used for the induction 
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of gene expression in Burkholderia species149. For comparison, 0.2% or 2% of L-arabinose was 
added to the medium for mutant metabolite production (detailed in 6.4.1). Comparative 
metabolite profiling between BCC1622 wild type, BCC1622_ΔgbnE, BCC1622_ΔgbnE::gbnE and 
empty vector control BCC1622_ΔgbnE::pMLBAD induced at different concentration of L-
arabinose were performed by LC-MS analysis (Figure 2.21). Gladiolin EICs showed that the 
complemented mutant BCC1622_ΔgbnE::gbnE induced at 0.2% L-arabinose restored 90% 
gladiolin production. The empty vector control group BCC1622_ΔgbnE::pMLBAD induced at the 
same concentration of L-arabinose seemed to maintain the similar level of the gladiolin 
production as BCC1622_ΔgbnE. This confirms the successful complementation. Nevertheless, 2% 
L-arabinose was found to abolish gladiolin production in both the complemented mutant 
BCC1622_ΔgbnE::gbnE and control BCC1622_ΔgbnE::pMLBAD. Since the mutant with 2% L-
arabinose added in production medium showed no growth defect, this was predicted to result 
from other competitive pathway(s) being switched on or greatly up regulated by high 
concentration of L-arabinose.  
This result provided evidence that no polar effect was brought into the gbnE deletion mutant, 
and the decreased gladiolin production in gbnE deletion mutant related to the loss of GbnE’s 
function in the assembly line. 
 
Figure 2.21 LC-MS analysis of gladiolin production in B. gladioli BCC1622 wild type, BCC1622_ΔgbnE, 
BCC1622_ΔgbnE::gbnE and BCC1622_ΔgbnE::pMLBAD. Extracted ion chromatograms at m/z=799,5309±0.02 Da, 
801.5129±0.02 Da corresponding to [M+H]+ and [M+Na]+ ion of gladiolin (17.4 min) and iso-gladiolin (17.8 min). 
Percentage refers to the concentration of L-arabinose in media. 
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2.2.1.3 In-frame deletion of putative complementary trans-acting ER  
In order to probe whether GbnE’s function in the gladiolin biosynthesis could be complemented 
by homologous enzyme(s) in B. gladioli BCC1622, the genome of B. gladioli BCC1622 was 
searched for gbnE homologue(s). A standalone AT-AT-ER tri-domain, GdsB is located in a trans-AT 
PKS gene cluster and GdsB ER domain was found to have 57.7 % sequence identity to GbnE. The 
metabolic product of this products was revealed by the Challis group to be gladiosatin, a novel 
secondary metabolite. From the structure and the associated gene cluster, a biosynthetic 
pathway was proposed, in which several trans-acting enoyl reduction events are predicted to be 
required (data not published). It was thus considered as a very good candidate for 
complementing the function of GbnE in the gladiolin biosynthesis. 
In an attempt to investigate the putative complementary function of the GdsB ER domain, as well 
as to probe whether iteration of module 5 could be restored when the enoyl reduction event in 
module 5 is completely removed, in-frame deletion of GdsB ER domain encoded DNA region was 
then performed in both B. gladioli BCC1622 WT and BCC1622_ΔgbnE. Deletion of gdsB_ER 
followed the same methodology used for deletion of gbnD1 ER1 and gbnE. Single knock-out 
mutant B. gladioli BCC1622_ΔgdsB_ER and double knock-out mutant B. gladioli 
BCC1622_ΔgbnEΔgdsB_ER were successfully obtained and confirmed by PCR (Figure 2.22 B). A 
weak band of size close to 1851 bp was noted in the double knockout mutant PCR products, 
which seemed to suggest a single crossover genotype as a PCR product of 606 bp was also 
observed. Attempts to amplify the SceI recognition region from the BCC1622_ΔgbnEΔgdsB_ER 
genome, which could verify whether the genome has the pGPI-gdsB_ER integrated, resulted in 
no PCR products while the control group using pGPI-gdsB_ER as a template resulted in positive 
PCR products (data not shown). This confirmed the loss of pGPI-gdsB_ER and thus validated it 
was double crossover mutant. 
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Figure 2.22 Schematic representation of generation and PCR confirmation of B. gladioli BCC1622_ΔgdsB_ER 
and BCC1622_ΔgbnEΔgdsB_ER. (A) Targeted in-frame deletion region on wild type chromosome and 
BCC1622_ΔgbnE is highlighted in orange. Loss of the orange region on the mutant chromosome after double 
crossover denotes successful deletion. Checking PCR primers are indicated by orange arrows and their binding 
sites on the mutant chromosome, parental chromosome and deletion plasmid respectively are indicated together 
with the length of corresponding predicted PCR products. (B) DNA electrophoresis gel of the PCR products 
confirmed the genotype of gdsB_ER deletion mutants, resulting in a 606 bp product as observed in the positive 
control (deletion plasmid), and the negative control (WT and BCC1622_ΔgbnE allele) resulted in a 1851 bp 
product. ‘CL’ refers to control, ‘WT’ refers to B. gladioli BCC1622 wild type. 
LC-MS analysis of the metabolites produced by both the single and double knock-out mutants 
showed that knocking out gdsB ER did not affect the production of gladiolin. Knocking out both 
gdsB_ER and gbnE seemed to promote gladiolin production compared to B. gladioli 
BCC1622_ΔgbnE (Figure 2.23). This indicated the GdsB ER domain was not the (only) homologue 
that could complement GbnE’s function. The increased production of gladiolin could because it 
shares common precursors with gladiostatin, so obstruction of gladiostatin biosynthesis by 
deletion of GdsB ER domain shifts metabolite flux towards gladiolin production. These results 
suggested other enzymes must be encoded by the genome that can complement GbnE. 
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Figure 2.23 LC-MS analysis of gladiolin production in B. gladioli BCC1622 wild type, BCC1622_ΔgbnE, 
BCC1622_ΔGdsB_ER and BCC1622_ΔgbnEΔGdsB_ER. Extracted ion chromatograms at m/z=799.5309±0.02 Da, 
801.5129±0.02 Da corresponding to [M+H]+ and [M+Na]+ ion of gladiolin (17.4 min) and iso-gladiolin (17.8 min). 
2.2.2 In vitro characterization of GbnE 
To complement the in vivo data, the proposed activity of GbnE in module 5 and module 10 was 
further characterized via in vitro biochemical assays.  
2.2.2.1 Enoyl reduction activity of GbnE 
To demonstrate the FMN-dependent enoyl reduction activity of GbnE, pET151-based constructs 
for recombinant N-His6-GbnE expression were first generated (described in 6.5.1). Unfortunately, 
overproduction and purification trials resulted in only trace amounts of recombinant N-His6-GbnE; 
whilst most of the material remained in the insoluble fraction. Optimization of overproduction 
conditions, including lowering IPTG concentration, changing expression cell lines (such as E. coli 
C43 (DE3) for avoiding possible toxicity, E. coli Rosetta (DE3) for possible rare codon usage), did 
not significantly increase the soluble N-His6-GbnE yield.  
Glutathione S-transferase (GST) and small ubiquitin-related modifier (SUMO) tags are known to 
successfully promote the solubility of many fusion proteins. Therefore, constructs of pGEX-4T1-
GbnE and pET-SUMO-GbnE were generated for to obtain N-GST-GbnE and N-His6-SUMO-GbnE 
constructs (described in 6.5.1). Overproduction and purification trials showed that, although the 
N-GST tag did not significantly promote the solubility of GbnE, a dramatic increase in the amout 
of GbnE was purified for the N-His6-SUMO-GbnE fusion protein (detailed in 6.5.3 and 6.5.4). It is 
was noted that the purified GbnE exhibited a strong yellow coloration, indicating GbnE was 
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purified with the flavin co-factor bound, consistent with its predicted FMN-dependent enoyl 
reduction activity. The purity and mass of the purified N-His6-SUMO-GbnE were confirmed by 
SDS-PAGE analysis and LC-MS analysis (Figure 2.24). 
 
Figure 2.24 SDS-PAGE and LC-MS analysis of purified N-His6-SUMO-GbnE. (A) 10% SDS-PAGE gel showing size 
and purity of N-His6-SUMO-GbnE, the yellow color of the protein indicated incorporation of a flavin cofactor. (B) 
Deconvoluted mass spectrum confirming the exact mass of N-His6-SUMO-GbnE (-N-Met).  Peaks labeled as ‘*’ 
refer to the spontaneous gluconoylation of His-tag on corresponding fusion proteins with additional 178 Da being 
observed147. See appendix for raw mass spectra. 
To characterize the enoyl reduction capability of GbnE, an in vitro assay was designed as shown 
in Scheme 2.4, using the GbnD2 ACP5 domain loaded with 2,4-hexadienoyl PPant as the substrate 
mimic of intermediate in module 5. Similar to the assays for testing the GbnD1 ER1 domain 
activity (section 2.1.2.2), the GbnD2 ACP5 domain was first loaded with the 2,4-hexadienoyl 
PPant unit using the phosphopantetheinylation enzyme cassette. The enoyl reduction was then 
initiated by addition of GbnE and cofactor. Both NADPH and NADH were tested as the hydride 
donating cofactor for FMN. As GbnE was purified with flavin co-factor bound no additional 
FMNH2 or FMN was added into the reaction. A negative control reaction was conducted using 
the same conditions, but lacking GbnE. The enoyl reduction activity was monitored by LC-MS 
analysis of the intact GbnD2 ACP5 domain.  
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Scheme 2.4 Design of in vitro assay for examination of enoyl reduction activity of GbnE. The GbnD2 ACP5 
domain was first loaded with 2,4-hexadienoyl PPant unit using the corresponding pantetheine form substrate 
mimic and phosphopantetheinylation enzymes cassette, followed by addition of GbnE and cofactor NAD(P)H. 
By comparison of the ejected PPant ions activated from GbnD2 ACP5-bound species (Figure 2.25), 
a ratio of 95:5 of the 4-hexenoyl-PPant ion: 2,4-hexadienoyl-PPant ion was observed in both 
reaction groups with NADPH or NADH added. In contrast, only the 2,4-hexadienoyl-PPant ion 
could be detected in the control reaction. This result showed the FMN-NAD(P)H-dependent enoyl 
reduction activity of GbnE and also provided evidence of trans-acting activity towards the ACP 
domain of module 5.  
 
Figure 2.25 LC-MS analysis of in vitro enoyl reduction activity of GbnE. Mass spectra of PPant ejected ion 
activated from 2,4-hexadienoyl-ACP5 incubated with (from top to bottom) GbnE and NADPH, GbnE and NADH, 
only NADPH.  
2.2.2.2 GbnE exhibits specific interactions with the gladiolin PKS 
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Having established the trans-acting activity of GbnE towards the ACP domain in module 5, the 
specific interaction between GbnE and the assembly line was then interrogated. In addition to 
GbnD2 ACP5 domain, GbnE is hypothesized to interact with ACP domain in module 10 (Figure 
2.2). As α, β-double bonds of the intermediate formed in module 3, 4 and 12 are retain in the 
final product, the ACP domains from these modules should not interact with GbnE. To examine 
these specific interactions, module 3, 4,10 and 12 ACP domains, were selected to be 
overproduced as recombinant proteins for enoyl reduction assays with GbnE. The corresponding 
pET28a (+) based constructs for all ACPs were generated and overexpressed in E. coli BL21 (DE3). 
All ACP domains, except for the GbnD1 ACP4 domain with no overproduction being observed, 
were purified as N-His6 fusion protein successfully (procedures detailed in 6.5.3 and 6.5.4, 
plasmid construction and purification of the GbnD5 ACP12 domain were conducted by Dr. 
Matthew Jenner). The purity and mass of the purified ACP domains was confirmed by SDS-PAGE 
and LC-MS analysis (Figure 2.26).  
 
Figure 2.26 SDS-PAGE and LC-MS analysis of N-His6-GbnD1 ACP3, N-His6-GbnD4 ACP10 and N-His6-GbnD5 
ACP12. (A) 15% SDS-PAGE gel showing the size and purity of N-His6-GbnD1 ACP3, N-His6-GbnD4 ACP10 and N-
His6-GbnD5 ACP12. Deconvoluted mass spectra confirming the exact mass of (B) N-His6-GbnD1 ACP3(-N-Met), (C) 
N-His6-GbnD4 ACP10 (-N-Met) and (D) N-His6-GbnD5 ACP12(-N-Met). Peaks labeled as ‘*’ refer to the 
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spontaneous gluconoylation of His-tag on corresponding fusion proteins with additional 178 Da being observed147. 
See appendix for raw Mass spectra. 
All ACPs were then subjected for the same in vitro enoyl reduction assays with GbnE (detailed in 
6.6.3) (scheme 2.4). Successful loading of 2,4-hexadienoyl-PPant unit onto all ACP domains were 
first confirmed by LC-MS analysis (Figure 2.27). The enoyl reduction assays were initiated by 
addition of GbnE and NADPH. GbnE was omitted from all control reactions. The reduced product, 
4-hexenoyl-PPant ion, could only be detected when the substrate was loaded on the GbnD2 ACP5 
and GbnD4 ACP10 domain, with only 2-5% 2,4-hexadienoyl PPant ion observed (Figure 2.28 left). 
Meanwhile no 4-hexenoyl-PPant ion was found in all control groups (Figure 2.28 right). These 
data provided evidence that only the GbnD2 ACP5 and GbnD4 ACP10 domain can effectively 
deliver the enoyl substrate to GbnE for reduction, whereas the GbnD1 ACP3 and GbnD5 ACP12 
domain cannot. It thus confirmed the specific interactions between GbnE and ACP domains from 
module 5 and 10 as proposed. 
 
Figure 2.27 LC-MS analysis of 2,4-hexadienoyl-PPant loading onto the GbnD1 ACP3 (A), GbnD2 ACP5 (B), GbnD4 
ACP10 (C) and GbnD5 ACP12 domain(D). Deconvoluted mass spectra of apo-ACP (top) and following incubation 
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with 2,4-hexadienoyl-Pant and loading enzymes cassette in the presence of MgCl2 and ATP (bottom). 
 
Figure 2.28 LC-MS analysis of GbnE in vitro enoyl reduction with GbnD2 ACP5, GbnD4 ACP10, GbnD1 ACP3, and 
GbnD5 ACP12 domain. Mass spectra of PPant ejected ion activated from 2,4-hexadienoyl-ACPs incubated with 
both GbnE and NADPH (left), or with only NADPH (right). Spectra from top to bottom of both groups were from 
assays conducted with the GbnD2 ACP5, GbnD4 ACP10, GbnD1 ACP3 and GbnD5 ACP12 domain respectively. 
2.2.2.3 Probing catalytic mechanism of GbnE 
As discussed in section 1.2.2.5 ’trans-acting enoyl reductases’, the catalytic mechanism of trans-
acting ERs from trans-AT PKS remains unclear and requires further investigation. However, the 
structure and catalytic mechanism of their phylogenetically and structurally-related homologue 
FabK, the FMN-dependent enoyl-ACP reductase involved in the bacterial fatty acid biosynthesis, 
has been well studied150,151,152. The enoyl reduction catalyzed by FabK proceeds via a Bi-Bi double 
displacement mechanism, with the active site first bond with NAD(P)H cofactor to reduce the 
FMN group, followed by the resulting NAD(P)+ being displaced by the enoyl substrate, which is 
then reduced by the FMNH2 group, thereby returning the enzyme to its original state151,152. The 
X-crystal strucutre of FabK from Streptococcus pneumoniae suggested that a histidine residue 
(His144) (Figure 2.29), which is located in the active site and also near the FMN cofactor, is the 
key catalytic residue150. This was also supported by the observation that the side chain of His144 
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was found to be involved in a conformational change with and without substrate bound, which 
is consistent with the Bi-Bi double displacement mechanism. 
 
Figure 2.29 Structure of active site in FabK from Streptococcus pneumoniae. The X-crystal structure of FabK 
shows His144 located in the active site to the FMN cofactor. Generated using Pymol from PDB: 2Z6I150. 
In order to probe the catalytic mechanism of GbnE, a site-directed mutagenesis study for 
identification of the key catalytic residue(s) of GbnE was also pursued. Multiple sequence 
alignment between GbnE, other homologous trans-acting ERs from trans-AT PKSs, the PUFA 
biosynthesis ER PfaD and enoyl-ACP reductase FabK were performed (see appendix for full 
sequence alignment results). The proposed catalytic histidine residue (His144 in the FabK) was 
found to be conserved in the GGHTD motif in most of the sequences, and was located at position 
His198 in GbnE (Figure 2.30).  
 
Figure 2.30 Partial result of multiple sequences alignment between GbnE and homologous enzymes. The 
conserved Histidine in the GGHTD motif is highlighted with a red star. Full sequence alignment result is shown in 
the appendix. 
A mutant construct pETSUMO-GbnE(H198V) was generated by site-directed mutagenesis 
(detailed in 6.5.2), and GbnE(H198V) was successfully overproduced and purified as a soluble N-
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His6-SUMO fusion protein through the same process as for the wild type GbnE (detailed in 6.5.3 
and 6.5.4). Notably, the solubility and yellow color of the mutant GbnE suggested it was correctly 
folded, and structurally unaffected by the H198V mutation. The purity and mass of the N-His6-
SOMO-GbnE-H198V were then confirmed by SDS-PAGE analysis and LC-MS analysis (Figure 2.31). 
 
Figure 2.31 LC-MS analysis of purified N-His6-SUMO-GbnE, N-His6-SUMO-GbnE(H198V). Deconvoluted 
spectrum confirming the exact mass of (A) N-His6-SUMO-GbnE (-N-Met), and (B) N-His6-SUMO-GbnE(H198V) (-
methionine). Peaks labeled as ‘*’ refer to the spontaneous gluconoylation of His-tag on corresponding fusion 
proteins with additional 178 Da being observed147. See appendix for raw Mass spectra. 
To evaluate the enoyl reduction activity of GbnE(198V), the same in vitro assay (Scheme 2.4) was 
performed with GbnE(H198V), together with WT protein as control. The LC-MS analysis of the 
GbnD2 ACP5 domain with 2,4-hexadinoyl PPant bound following incubation of GbnE(H198V) and 
cofactor showed (Figure 2.32) the enoyl reduction activity of GbnE was completely abolished in 
the mutant protein. This confirmed the critical catalytic role of His198 in GbnE catalysing enoyl 
reduction. 
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Figure 2.32 LC-MS analysis of in vitro enoyl reduction activity of GbnE (H198V). Mass spectra of PPant ejected 
ions activated from 2,4-hexadienoyl-ACP5 incubated with (from top to bottom) GbnE and NADPH, GbnE and 
NADH, GbnE(H198V) and NADPH, GbnE(H198V) and NADH, only NADPH.  
2.3 Conclusions and future work 
In this chapter, for identification of the ER required for module 5 of the gladiolin PKS, as well as 
to probe the potential impact of this enoyl reduction event to the non-iterative usage of this 
module, in vivo and in vitro approaches were combined to characterize the candidate ERs, cis-
acting enoyl reductase GbnD1 ER1 domain and trans-acting enoyl reductase GbnE,  
In-frame deletion and site-directed mutagenesis to inactivate the GbnD1 ER1 domain in the 
gladiolin PKS, followed by the metabolite profiling of the mutants, identified a new derivative to 
be the proposed unreduced gladiolin 32. This suggests the GbnD1 ER1 domain has intra-modular 
enoyl reduction activity in module 1. This was further confirmed in vitro by incubating the 
purified recombinant GbnD1 ACP1-ER1 di-domain, loaded with a 2,4-hexadienoyl unit, with 
NADPH which resulted in successful reduction of the substrate. No in vivo data supported the 
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inter-modular enoyl reduction activity in module 5 of the GbnD1 ER1 domain, which was also 
confirmed by the in vitro assay that isolated GbnD1 ER1 domain was not capable of reducing the 
2,4-hexadienoyl unit tethered on GbnD2 ACP5 domain. 
In-frame deletion of gbnE and metabolite profiling indicated GbnE plays an important role in 
supporting efficient processing of the gladiolin assembly line as a decreased yield of gladiolin and 
related derivatives was observed when gbnE was absent. The FMN-dependent trans-acting enoyl 
reduction activity of GbnE was biochemically characterized. Incubation of GbnE with NADPH and 
four different ACP domains (GbnD1 ACP3, GbnD2 ACP5, GbnD4 ACP 10 and GbnD5 ACP12) 
showed GbnE is capable of catalysing reduction of substrates tethered on ACP domains from 
module 5 and 10 but not from module 3 and 12. This suggested the gladiolin assembly line 
recruits the trans-acting GbnE specifically in module 5 and module 10. Besides, the catalytic 
mechanism of trans-acting ERs was probed by site-directed mutagenesis and biochemical assays, 
which identified a conserved catalytic essential histidine residue (H198).  
As trans-acting enoyl reduction is a widely employed strategy to install the saturated C-C bond in 
trans-AT polyketide biosynthesis, the molecular mechanism underlying the specific interaction 
between the ERs and the ACP domains is of great interest and could guide future engineering 
efforts. Bioinformatic and biophysical studies need to be employed to better understand the 
nature of this specific protein-protein interaction. 
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Chapter 3 
Probing the molecular mechanism of chain 
length control in gladiolin biosynthesis 
The work described in chapter 2 identifies a trans-acting ER, GbnE, as the catalytic entity 
responsible for installing a saturated center at C26-C27 in gladiolin biosynthesis (Figure 3.1), and 
accounts for one of the principle structural differences between etnangien and gladiolin. In place 
of a saturated C-C bond, etnangien possesses three double bonds, which are hypothesized to 
originate from iterative use of EtnE Module 5. Although the etnangien biosynthetic gene cluster 
also harbors a trans-acting ER, EtnL, it is possible that it does not engage in a productive 
interaction with the ACP domain of EtnE Module 5, and thus the module undergoes three rounds 
of chain extension, keto-reduction and dehydration to generate the triene moiety. However, 
given the high degree of similarity between the gladiolin and etnangien PKSs, it is possible that 
the equivalent module, GbnD2 Module 5, can also catalyse iterative chain elongation, 
ketoreduction and dehydration, which is prevented by the action of GbnE (Figure 3.1). 
This details efforts to examine the iterative nature of GbnD2 Module 5, and the effect of GbnE on 
this process using in vitro biochemical methods. 
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Figure 3.1 Comparison of partial biosynthetic pathways of gladiolin (A) and etnangien (B). Schematic view 
shows the iterative use of EntE Module 5 and non-iterative use of GbnD2 Module 5, and the proposed roles of 
the trans-acting ERs in controlling these behavious. 
3.1 Iterative nature of GbnD2 Module 5 
3.1.1 Production of recombinant GbnD2 Module 5 
To examine whether GbnD2 Module 5 exhibits iterative activity, an in vitro biochemistry approach 
was employed. Using standard cloning procedures, pET28a-GbnD2_Module 5 (KS-DH-KR-ACP) 
was generated for overproduction and purification as an N-His6 construct (detailed in 6.5.1). 
Large scale overproduction followed by nickel affinity chromatography and size exclusion 
purification (detailed in 6.5.3 and 6.5.4), afforded the purified GbnD2 Module 5 tetra-domain 
protein, with the size and purity of the construct confirmed by SDS-PAGE and LC-MS analysis 
(Figure 3.2). 
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Figure 3.2 SDS-PAGE and LC-MS analysis of purified N-His6-GbnD2 Module 5. (A) 6% SDS-PAGE gel showing the 
size and purity of N-His6-GbnD2 Module 5. (B) Deconvoluted mass spectrum confirming the mass of N-His6-
GbnD2 Module 5 (-N-Met). Peak labeled ‘*’ corresponds to the spontaneous gluconoylation of His-tag on fusion 
proteins with additional 178 Da being observed147. See appendix for raw Mass spectra. 
3.1.2 Investigating the activity of GbnD2 Module 5 in vitro 
Initial attempts to probe chain elongation in GbnD2 Module 5 centered on monitoring the 
covalently tethered growing acyl chain, using intact protein mass spectrometry. However, due to 
the large size of GbnD2 Module 5, the acquired mass spectra of the intact module resulted in a 
broad peak (Figure 3.2 B), which made resolution of small mass increments due to elongation 
extremely difficult. Therefore, an alternative strategy based on monitoring the isolated GbnD2 
ACP5 domain, which is significantly smaller in size and thus allowing discrimination of small mass 
shifts on the acyl chain, was devised (Scheme 3.1 A). In this assay, instead of loading malonyl-
PPant onto the integral ACP domain, the preacylated-KS domain of GbnD2 Module 5 was supplied 
with the malonylated GbnD2 ACP5 domain as a stand-alone protein. Upon interaction of 
malonylated ACP5 domain with the acylated-module 5, chain elongation, ketoreduction and 
dehydration can then occur, with the extended acyl chain attached to the isolated GbnD2 ACP5 
domain (Scheme 3.1 B). If GbnD2 Module 5 is capable of catalyzing multiple rounds of chain 
extension, then the isolated ACP5 domain can transfer the attached extended acyl chain back to 
the KS domain and itself become holo form, priming GbnD2 Module 5 for a second round of 
elongation (Scheme 3.1 B). This process can occur multiple times resulting in iterative activity. In 
this way, the isolated malonyl-GbnD2 ACP5 domain would be continually consumed to form 
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species of the GbnD2 ACP5 domain with iteratively extended products tethered, and the holo-
GbnD2 ACP5 species would be accumulated accordingly as every back transfer occurs. 
 
Scheme 3.1 Design of in vitro assay (A) and proposed mechanism (B) for examining the iterative nature of 
GbnD2 Module 5. (A) The GbnD2 ACP5 domain is loaded with a malonyl unit by Svp catalyzed malonyl-CoA 
loading reaction, followed by incubation with GbnD2 Module 5 pre-acylated using 2,4-hexadienoyl-SNAC. (B) The 
pre-acylated GbnD2 Module 5 is supplied with the isolated manoyl-GbnD2 ACP5 domain. The chain extension 
reaction yields a product tethered to the isolated GbnD2 ACP5 domain which is transferred back to the KS domain 
and the holo-GbnD2 ACP5 domain is formed. The second round of chain extension proceeds via condensation 
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with another molecule of the malonylated GbnD2 ACP5 domain and further rounds of these process to produce 
the iteratively-extended product. 
The in vitro assay was conducted as described, and was allowed to proceed for up to 20 hours to 
allow maximum possible conversion to product (detailed in 6.6.4.1). Intact protein mass spectra 
of the GbnD2 ACP5 domain were collected at three time points, 2, 5 and 20 hours. The 
deconvoluted mass spectra of the intact GbnD2 ACP5 domain at these time points displayed 
multiple additional peaks when compared to the malonyl-ACP5 starting material (Figure 3.3 A). 
Calculation of the mass shifts for the newly formed peaks in the 2 and 5 hours reactions revealed 
three new species, corresponding to one to three rounds of chain elongation, reduction and 
dehydration, ultimately generating a pentaene acyl chain (Figure 3.3 A). Allowing the reaction to 
proceed for 20 hours resulted in a fourth chain extension and reduction, yielding a hexaene as 
well as a small amount of β-keto unmodified species (Figure 3.3 A). The formation of all iteratively 
extended products increased with time. Moreover, an increasing formation of the holo GbnD2 
ACP5 domain and consumption of malonylated GbnD2 ACP5 domain over time was observed as 
expected. Peaks corresponding to the acetylated GbnD2 ACP5 domain were also observed, which 
are likely the result of decarboxylation of the malonyl unit (either in the MS, spontaneous or KS-
catalysed). As an additional observation, during the course of these reactions, the solution turned 
yellow indicating polyene formation in the test tube (Figure 3.3 B). 
These observations strongly suggest that GbnD2 Module 5 is able to catalyze iterative chain 
elongation using the isolated GbnD2 ACP5 domain. The ability of the GbnD2 ACP5 domain to re-
acylate the KS domain of module 5, and therefore re-prime the module for elongation, is an 
interesting observation. However, whether this activity is an artifact of the in vitro set-up of the 
reaction, or indeed a feature exclusive to iterative modules requires further study, as detailed in 
section 3.1.3.  
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Figure 3.3 LC-MS analysis of in vitro reconstitution of iterative activity of GbnD2 Module 5. (A) Deconvoluted 
mass spectra of the isolated malonyl-GbnD2 ACP5 domain, following incubation with 2,4-hexadienoyl-acylated-
GbnD2 Module 5 and NADPH for 2 hours (top), 5 hours (middle) and 20 hours (bottom). The peaks labelled with 
a black dot were found to be the sodium adduct of the corresponding protonated ion as their intensities showed 
the same peak intensity pattern. (B) Yellow colour of the reaction solution indicates polyene formation. 
3.1.3 Probing the ACP-selectivity of GbnD2 Module 5 iteration 
The results described in 3.1.2 demonstrate the ability of GbnD2 Module 5 to catalyse iterative 
chain elongation using a stand-alone GbnD2 ACP5 domain. The key step which promotes iterative 
activity is the reacylation of the KS domain by the chain-extended ACP5 domain. In these 
experiments, the GbnD2 ACP5 domain is supplied as an isolated entity, which is different to the 
integrated situation of the ‘native’ module, and therefore the reacylation activity may be an 
artifact of ‘dissected’ nature of the assay. However, equally, the ability of GbnD2 ACP5 domain to 
reacylate the KS domain could be a result of specific protein-protein interaction that facilitates 
the chain translocation between the GbnD2 ACP5 domain and the KS domain of module 5 (as 
introduced in section 1.2.2.5 ‘Acyl carrier protein domains and their interactions with other 
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domains’). This would mean that other ACP domains may not possess this ability. To test this 
hypothesis, ACP domains from the gladiolin PKS modules containing the same set of reductive 
domains (i.e. KS-DH-KR) were selected, cloned, overexpressed and purified. The GbnD1 ACP3 and 
the GbnD4 ACP10 domains, used in the Chapter 2, were selected as candidates to test this theory.  
It was noted that the purified recombinant N-His6-GbnD1 ACP3 and N-His6-GbnD4 ACP10 
domains underwent considerable gluconoylation (Figure 2.26). The mass addition of the 
gluconoylated species (+ 178 Da) is similar to an ACP species with two rounds of iteratively 
extended product tethered (+ 172 Da). In addition to this, another set of peaks corresponding to 
the gluconoylated species would also be formed during the reaction, which would bring 
complexity to the data analysis. Thus, the His-tag cleavage of both N-His6-GbnD1 ACP3 and N-
His6-GbnD4 ACP10 domains was cleaved using thrombin. The cleavage was confirmed by SDS-
PAGE analysis and LC-MS (Figure 3.4).  
 
Figure 3.4 SDS-PAGE analysis and LC-MS analysis of N-His6-tag cleaved GbnD1 ACP3 and GbnD4 ACP10 domains. 
15% SDS-PAGE gel (top) and deconvoluted mass spectra (bottom) confirming the identity of His-tag cleaved 
GbnD1-ACP3 (A) and GbnD4 ACP10 domains (B). See appendix for raw mass spectra. 
The in vitro assay in Scheme 3.1 A was then repeated using the purified GbnD1 ACP3 (-His-tag) 
and GbnD4 ACP10 (-His-tag) respectively under the same conditions (detailed in 6.4.4.1). The 
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deconvoluted mass spectra of the intact ACP species from the corresponding reactions showed 
that, unlike in the reaction using the GbnD2 ACP5 domain (Figure 3.5 a), no chain extension 
products were observed for the GbnD1 ACP3 domain (Figure 3.5 b). Intrestingly, additional to first 
round chain extension, the GbnD2 ACP10 domain was able to undergo the second and third chain 
extension reaction. (Figure 3.5 c). However, the obvious difference in intensity of the iteratively 
extended products between reactions using the GbnD2 ACP5 and GbnD4 ACP 10 domains could 
still supports the conlcusion that there is a specific interaction between the GbnD2 ACP5 domain 
and the GbnD2 KS5 domain during the intermediate back-transfer, or reacylation process for 
iteration.  
 
Figure 3.5 LC-MS analysis of in vitro iteration control assays for GbnD2 Module 5. Deconvoluted mass spectra 
of the isolated malonyl-GbnD2 ACP5 (a), malonyl-GbnD1 ACP3 (b) and malonyl-GbnD4 ACP10 (c) following 
respective incubation with 2,4-hexadienoyl-acylated-GbnD2 Module 5 and NADPH. 
The minor interaction between the GbnD4 ACP10 domain and the GbnD2 KS5 domain was 
tentatively attributed to the structural similarity between the GbnD2 ACP5 and the GbnD4 ACP10 
domain, as this was consistent with the findings that they are the only ACP domains from the 
gladiolin assembly line that are capable of interacting with GbnE. It was therefore plausible to 
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speculate that the GbnD2 ACP5 domain interacts with the GbnD2 KS5 domain for intra-modular 
translocation in a similar way that it interacts with GbnE for enoyl reduction. Thus, in a 
competitive situation, GbnE could prevent the GbnD2 ACP5 domain from transfering the one-
round extended product back to the GbnD2 KS5 domain. 
3.2 The effect of GbnE on GbnD2 Module 5 iteration 
Having established the iterative nature of GbnD2 Module 5, and that a specific interaction exists 
with its cognate ACP domain, the next step was to examine the effect of the trans-acting ER 
domain upon the iterative activity. The hypothesis outlined in Figure 3.1 A dictates that, following 
enoyl reduction of the α,β-unsaturated intermediate, iterative chain elongation is halted. 
3.2.1 GbnE abolishes iteration of GbnD2 Module 5 
To probe whether the GbnE has an impact on the iterative activity of this module5, the in vitro 
iteration assay was repeated in the presence of GbnE. In the same manner as in section 3.1.2, 
the GbnD2 KS5 domain was pre-acylated with a 2,4-hexadienoyl unit, followed by incubation with 
isolated malonylated GbnD2 ACP5, NADPH and GbnE (Scheme 3.2). The ratio of pre-acylated 
GbnD2 Module 5: malonyl-GbnD2 ACP5: GbnE was set as 1:2:1.  
 
Scheme 3.2 Design of in vitro iteration assays for monitoring GbnD2 Module 5 iteration in the presence of 
GbnE .  
PhD Thesis: Xinyun Jian  Chapter 3 
76 
The reaction in the presence of GbnE appeared to abolish the production of any iteratively-
extended products (Figure 3.6 b). The formation of the holo-GbnD2 ACP5 domain, resulting from 
the back transfer process (Figure3.6 b) was consistently found to be much lower compared to the 
reaction without GbnE (Figure 3.6 a), indicating no back transfer occurred.  
Interestingly, although the one-round elongated product was observed (Figure3.6 b), it was found 
to be the un-reduced species. This indicated that, with GbnE present, the isolated malonyl-GbnD2 
ACP5 domain could still interact with the GbnD2 KS5 domain for the chain elongation, but the 
interaction of the resulting the elongated β-keto-GbnD2 ACP5 with the KR and DH domains for 
the chain modification was blocked in the in vitro reconstituted condition. This could be due to 
the high affinity between GbnE and the discrete GbnD2 ACP5 domain.  
 
Figure 3.6 LC-MS analysis of in vitro GbnD2 Module 5 iteration assays with and without addition of GbnE. 
Deconvoluted mass spectra of isolated malonyl-GbnD2 ACP5 domain following incubation with 2,4-hexadienoyl-
acylated-GbnD2 Module 5 and NADPH without (a) and with (b)addition of GbnE.  
These data strongly support that GbnE is able to prevent the iterative activity of GbnD2 Module 
5 during the gladiolin biosynthesis. However, the mechanism by which this occurs requires 
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further investigation. In principle, two routes for this phenomenon exist: a) GbnE engages in 
protein-protein interactions with the GbnD2 ACP5 domain preventing intermediate back. b) The 
catalytic activity of GbnE results in a saturated intermediate, which prevents the back-transfer 
process due to a substrate specificity of the GbnD2 KS5 domain or the kinetic difference in 
acylation of the upstream KS5 domain and the downstream GbnD2 KS6 domain.  
3.2.2 Protein-protein interactions between GbnE and the GbnD2 ACP5 domain 
prevent re-acylation of the GbnD2 KS5 domain  
In order to investigate whether protein-protein interactions between GbnE and GbnD2 ACP5 
domain have an effect on the iteration, the catalytically inactivated GbnE mutant, GbnE(H198V), 
was employed. It was previously shown to be well folded in Chapter 2, and therefore can still 
engage in protein-protein interactions with the GbnD2 ACP5 domain.  
The assay outlined in Scheme 3.2 was repeated, but this time in the presence of GbnE(H198V). 
Interestingly, the subsequent LC-MS analysis of the GbnD2 ACP5 domain revealed that iteration 
of GbnD2 Module 5 was inhibited by the presence of GbnE(H198V), yielding an almost identical 
spectrum to WT GbnE (Figure 3.7). These observations strongly suggest that merely the presence 
of GbnE, and the protein-protein interactions between itself and GbnD2 ACP5 domain, are 
sufficient to halt iterative activity. 
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Figure 3.7 LC-MS analysis of in vitro GbnD2 Module 5 iteration assays with and without addition of GbnE 
(H198V). Deconvoluted mass spectrum of the isolated malonyl-GbnD2 ACP5 domain following incubation with 
2,4-hexadienoyl-acylated-GbnD2 Module 5 and NADPH without (a) and with (b)addition of GbnE (H198V).  
3.2.3 The ‘gate-keeping’ role of the GbnD2 KS6 domain 
The data presented in 3.2.2 convincingly shows how the mere presence of GbnE, and not 
necessarily its catalytic activity, is all that is required to abolish iteration in GbnD2 module 5. 
However, whether formation of a saturated acyl intermediate, resulting from the GbnE catalysis, 
contributes to the directionality or flux of the assembly line at this biosynthetic stage also 
required investigation. Genetic data from chapter 2 showed that deletion of GbnE in the gladiolin 
producing strain resulted in a general ‘slowing down’ of the assembly line (section 2.1.1.1) This 
suggested that the fidelity of the assembly line is preserved by the downstream KS domains in a 
‘gate-keeping’ fashion to preferentially accept the GbnE processed α,β-saturated intermediate.  
A KS domain conducts two catalytic processes during the chain elongation cycle: chain 
translocation and Claisen-like chain elongation. Substrate specificity of KSs from modular PKS, 
especially from trans-AT PKS, have been revealed in both processes.62,153 Thus, to fully examine 
the proposed ‘gate-keeping’ function of the GbnD2 KS6 domain, the substrate specificity of it in 
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both processes was inspected. 
3.2.3.1 Construct design and protein overproduction  
GbnD2 Module 6 consists of a KS domain and two tandem ACP domains (Figure 2.2). This type of 
enzymatic domain architecture is typically associated with β-branching, with the latter ACP 
domain aiding in the interaction with the trans-acting β-branching enzymes.154 Therefore, the 
GbnD2 ACP6b domain was considered not needed for both the chain translocation and 
elongation process. Unfortunately, initial construct of GbnD2 KS6-ACP6a yielded insoluble 
protein. In an effort to obtain a soluble construct, instead of further isolation of GbnD2 KS6 and 
GbnD2 ACP6a as individual domains, the entire module 6 with the second ACP domain 
inactivated was explored as an alternative.  
Expression construct pET28a-GbnD2 Module 6 was initially generated, followed by mutation of 
the conserved serine residue (S941) for phosphopantetheinylation of the second ACP domain, to 
alanine via site-directed mutagenesis, to achieve the final construct pET28-GbnD2 Module 6 
(S941A). N-His6-GbnD2 Module6 (S941A) was then overproduced and purified as described in 
6.5.3 and 6.5.4. The identity of the purified N-His6-GbnD2 Module6 (S941A) was confirmed by 
SDS-PAGE and LC-MS analysis (Figure 3.8). 
 
Figure 3.8 SDS-PAGE and LC-MS analysis of purified N-His6-GbnD2 Module 6(S941A). (A) 6% SDS-PAGE gel of N-
His6-GbnD2 Module 6 (S941A). (B) Deconvoluted mass spectrum confirming the exact mass of N-His6-GbnD2 
Module 6 (S941A). The Peak labeled ‘*’ corresponds to the spontaneous gluconoylation of His-tag on 
corresponding fusion proteins with additional 178 Da being observed147. See appendix for raw mass spectra. 
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3.2.3.2 Substrate specificity of the GbnD2 KS6 domain in chain translocation 
In order to examine the substrate specificity of the GbnD2 KS6 domain towards α,β-saturated 
and α,β-unsaturated substrates in the chain translocation step, a comparative in vitro assay was 
conducted (Scheme 3.3). Utilizing GbnD2 Module 6 and the upstream GbnD2 ACP5 domain 
loaded with either a 4-hexenoyl or a 2,4-hexadienoyl acyl chain, the ability of the GbnD2 ACP5 
domain to transfer these intermediates to the GbnD2 KS6 domain could be measured. This could 
be achieved by monitoring the ratio of acyl-GbnD2 ACP5 to the newly formed holo-GbnD2 ACP5 
species.  
Both 2,4-hexadienoyl-GbnD2 ACP5 and 4-hexenoyl-GbnD2 ACP5 were first synthesized via 
phosphopantetheinylation enzymes cassette catalyzed acyl-PPant loading assays, using the 
corresponding pantetheine form substrates synthesized by PhD student Christian Hobson. The 
full conversion from apo form to respective acyl-PPant-loaded form were first confirmed (Figure 
3.9), to ensure the GbnD2 KS6 domain is provided with equal concentration of the acyl transfer 
partner. 
 
Scheme 3.3 Design of in vitro assays for monitoring substrate specificity of GbnD2 KS6 domain in the 
translocation process. The GbnD2 ACP5 domain is respectively loaded with 4-hexenoyl-Pant (top) and 2,4-
hexadienoyl-Pant (bottom) via phosphopantetheinylation enzymes cassette, followed by incubation with GbnD2 
Module 6(S941A) for inter-modular chain translocation. 
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Figure 3.9 LC-MS analysis of in vitro PPtase catalyzed 2,4-hexadienoyl-PPant and 4,-hexenoyl-PPant loading of 
GbnD2 ACP5 domain. Deconvoluted mass spectrum of apo-GbnD2 ACP5 (bottom), following incubation with 
phosphopantetheinylation catalytic enzymes cassette, Svp, MgCl2, and 4-hexenoyl-Pant (bottom), or 2,4-
hexadienoyl-Pant (top). Successful loading results in mass shift of 435 Da for 2,4-hexadienoyl-PPant unit and 437 
Da for 4-hexenoyl unit-PPant. 
The acyl transfer reaction was initiated by incubating the saturated and unsaturated acyl-GbnD2 
ACP5 domain with GbnD2 Module 6(S941A) in a ratio of 1:3 (as detailed in 6.6.5.1). Control 
reactions were conducted lacking the GbnD2 Module 6(S941A). The assays were allowed to 
proceed for up to 8 hours and data were collected at 4 time points. The deconvoluted mass 
spectrum of the GbnD2 ACP5 domain from each assay was compared. This showed the increasing 
formation of the holo-GbnD2 ACP5 domain from the 4-hexenoyl-GbnD2 ACP5 was incubated with 
GbnD2 Module 6 (Figure 3.10 A). However, very little holo-GbnD2 ACP5 when the 2,4-
hexadienoyl-GbnD2 ACP5 was used compared to the control reaction (Figure 3.10 B). These 
observations clearly demonstrated the preference of the GbnD2 KS6 domain for α, β-saturated 
acyl units over α, β-saturated acyl units in the chain translocation step.  
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Figure 3.10 LC-MS analysis of in vitro chain translocation between the GbnD2 ACP5 domain and GbnD2 KS6 
domain. (A) Deconvoluted mass spectra of 4-hexenoyl-GbnD2 ACP5 (top) following incubation with GbnD2 
Module 6(S941A) for 2 hours, 4 hours, 6 hours, 8 hours. (B) Deconvoluted mass spectra of 2,4-hexadienoyl-GbnD2 
ACP5 (top) following incubation with GbnD2 Module 6(S941A) for 2 hours, 4 hours, 6 hours, 8 hours. ‘CL’ refers 
to control reaction lacking GbnD2 Module 6(S941A) after 8 hours incubation.  
3.2.3.3 Substrate specificity of the GbnD2 KS6 domain in chain elongation 
In addition to the chain translocation step, the GbnD2 KS6 domain was also tested for substrate 
preference at the chain elongation stage, utilizing the in vitro assays outlined in scheme 3.4. In 
the first instance, acylation of GbnD2 KS6 domain active site with a α, β-saturated or a α,β-
unsaturated acyl units was required, in order to provide the same starting point for the 
comparison of the elongation reactions. Although substrate preference can be observed for the 
ACP-bound acyl chains, it is possible to obtain reasonable levels of KS acylation using acyl-SNAC 
substrates. Therefore, in an attempt to equally supply GbnD2 KS6 domain with saturated and 
unsaturated acyl substrates, GbnD2 Module 6 (S941A) was incubated with the same 
concentration of 2,4-hexadienoyl-SNAC and 4-hexenoyl-SNAC (detailed in 6.6.5.2). The acylation 
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reactions were analysed by intact protein mass spectrometry, showing a expected similar 
acylation percentage (around 30%) (Figure 3.11).  
 
Scheme 3.4 Design of in vitro assays for monitoring substrate specificity of GbnD2 KS6 domain during chain 
elongation. The KS domain of GbnD2 Module 6(S941A) is respectively acylated by 2,4-hexadienoyl-SNAC (top 
route) and 4-hexenoyl-SNAC (bottom route) to reach a similar acylation level, followed by supply with extender 
unit via Svp catalyzed malonyl-CoA loading reaction for the KS domain catalyzed chain elongation reaction.  
 
Figure 3.11 LC-MS analysis of acylation of the KS domain in GbnD2 Module 6(S941A). Deconvoluted mass 
spectra of apo-GbnD2 Module 6(S941A) (bottom) following incubation with 2,4-hexadienoyl-SNAC (middle) and 
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4-hexenoyl-SNAC (top) respectively. Acylation by 2,4-hexadienoyl and 4-hexenoyl unit was observed as 95 Da and 
97 Da mass shift respectively.  
With acylated GbnD2 Module 6 (S941A) in hand, the elongation assays were initiated by providing 
the GbnD2 ACP6a domain with a malonyl extender unit via the PPtase catalyzed malonyl-PPant 
loading reaction (detailed in 6.6.5.2). The deconvoluted mass spectra of intact GbnD2 Module 6 
(S941A) species from both assays showed that both 4-hexenoyl- and 2,4-hexadienoyl-elongated 
products are observed with similar turnover ratio (Figure 3.12). This indicated that the GbnD2 
KS6 domain does not have strict substrate specificity in the chain elongation process.   
 
Figure 3.12 LC-MS analysis of GbnD2 Module6 (S941A) in vitro chain elongation assays. Deconvoluted mass 
spectra of 4-hexenoyl-acylated-GbnD2 Module 6(S941A) (top) and 2,4-hexadienoyl-GbnD2 Module 6 (S941A) 
(bottom) respectively following loading with malonyl-PPant by PPtase. 
3.3 Conclusions and future work. 
In this chapter, insights into the key structural difference between the construction of etnangien 
and gladiolin were obtained via investigation of the molecular mechanism underlying the non-
iterative usage of module 5 in the gladiolin PKS. Firstly, an optimized in vitro iterative chain 
extension assay was developed for examining the ability of GbnD2 Module 5 to act iteratively in 
which the pre-acylated GbnD2 Module 5 was supplied with isolated malonyl-ACP5 ‘in trans’. This 
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allowed multiple turnovers to be achieved in addition to facilitating convenient reaction 
monitoring. With this strategy, GbnD2 Module 5 was successfully demonstrated to be capable of 
catalyzing up to 4 cycles of chain elongation and modification in vitro.  
Furthermore, the addition of the trans-acting ER, GbnE abolished the iterative activity of GbnD2 
Module 5. Utilizing the catalytically inactivated GbnE, it was possible to show that interactions 
between GbnE and the GbnD2 ACP5 domain are all that is required to shut-down iteration. This 
could be due to a multitude of complex factors, likely centered around protein-protein 
interactions preventing intermediate back transfer and higher order protein structural 
rearrangements, and requires further investigation. In addition, GbnD2 KS6 domain appeared to 
show a preference towards α,β-saturated acyl chains over an α,β-unsaturated ones. This suggests 
that although GbnE can abolish the module iteration process, the gatekeeping activity of GbnD2 
KS6 domain also prevents chain translocation before enoyl reduction has occurred.  
Using the aforementioned data, a molecular mechanism for chain length control in gladiolin 
biosynthesis can be proposed, and is outlined in (Figure 3.12). Following GbnD2 Module 5-
catalysed chain elongation and subsequent ketoreduction and dehydration; the α,β-unsaturated 
intermediate is rejected by the downstream ‘gate-keeping’ GbnD2 KS6 domain for chain 
translocation (route b). However, the back-transfer of this α,β-unsaturated intermediate from the 
GbnD2 ACP5 domain to the GbnD2 KS5 domain (route c) is blocked by the efficient protein-
protein interaction between GbnE and the GbnD2 ACP5 domain during the enoyl reduction event 
(route a). The GbnE-catalysed enoyl reduction event generates the α, β-saturated intermediate 
which is then preferentially accepted by the downstream GbnD2 KS6 domain (route d). Therefore, 
the single chain extended, α, β-unsaturated intermediate, is provided with a ‘fast-track’ to enoyl 
reduction and subsequent passage to the downstream GbnD2 KS6 domain, thereby maintaining 
the fidelity of gladiolin biosynthesis.  
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Figure 3.12 Schematic diagram of the proposed mechanism of the chain length control in the gladiolin 
biosynthesis. The iteration of module 5 is shut down via the recruitment of the trans-acting GbnE to this module. 
The direction and fidelity of chain assembly at this biosynthetic stage is preserved by the protein-protein 
interaction between GbnE and the GbnD2 ACP5 and ‘gate-keeping’ GbnD2 KS6 domains. The routes labeled by 
green are denoted as the free routes, the routes labeled by red are denoted as obstructed routes.   
It is possible to extend this hypothesis to the etnangien system. Here, logic would dictate that the 
equivalent trans-acting ER domain (EtnL), located within the etnangien BGC, is unable to interact 
with the EntE ACP5 domain. Assuming an analogous sequence of events, the α, β-unsaturated 
intermediate formed by one cycle of chain extension and modification is not accepted by the 
downstream EtnE KS6 domain. Therefore, the chain is back-transferred onto the EntE KS5 domain 
to undergo another cycle of chain extension and reduction. This sequence would have to happen 
once more before being passed onto the EtnE KS6 domain. Whether the three cycles of chain 
extension and reduction is programmed, or merely an artifact of kinetics remains to be elucidated. 
For future work, efforts could be made to further pin down the mechanism that GbnE uses to 
shut down the iteration of gladiolin module 5. This could include kinetic analysis of the GbnE 
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catalyzed enoyl-GbnD2 ACP5 enoyl reduction, and the GbnD2 KS6 domain catalyzed intermodular 
transfer and the GbnD2 KS5 domain catalyzed intramodular transfer. In order to obtain a 
complete picture, initially the analogous set of biochemical assays should be conducted using the 
etnangien EtnE Module 5 and the corresponding EtnL ER domain. In addition, a ‘cross-talk’ 
approach to in vivo engineering of both biosynthetic pathways could be a investigated, e.g. either 
swapping the GbnD2 ACP5 domain with the EntE ACP5 domain or GbnE with EntL in attempts to 
elicit iteration in gladiolin biosynthesis, or shut down the iteration in etnangien biosynthesis.
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Chapter 4 
Investigation of a double chain initiation 
mechanism in icosalides biosynthesis 
As discussed in section 1.3.3, IcoA, responsible for the biosynthesis of icosalides, contains an 
unusual domain architecture due to the presence of an internal starter C domain (IcoA C4 domain) 
in module 3, which is directly adjacent to an LCL domain (IcoA C3 domain). The domain 
architecture suggests the IcoA C3 domain and the IcoA C4 domain are required to co-operate for 
accomplishing a second round of chain initiation and an elongation event (Scheme 4.1). Firstly, 
the IcoA A3 domain is proposed to load the IcoA PCP3 domain with an L-serine residue. This 
would be followed by the IcoA C4 domain initiating a second round of chain assembly via 
condensation of the serine residue with a 3-hydroxyacyl unit, presumably hijacked from 3-
hydroxyacyl-ACP in fatty acid biosynthesis126,127. Lastly, the IcoA C3 domain is proposed to 
catalyse a second condensation event, forming an ester bond between the β-hydroxyl acyl unit 
and the intermediate tethered to upstream IcoA PCP2 domain. If so, the IcoA C4 domain is 
believed to be the first example of an embedded starter C domain (Scheme 4.1). 
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Scheme 4.1 Proposed biosynthetic events in IcoA Module 3. Green arrows indicate which domains are proposed 
to catalyse each reaction. The black dots in the fatty acid biosynthesis represent ACP domains. IcoA A3 domain 
first load the downstream PCP3 domain with L-serine followed by C4 domain initiate a second round of chain 
assembly by incorporation of a 3-hydroxycayl unit hijacked from fatty acid biosynthesis, the C3 domain finally 
accomplish the biosynthesis in this module to link the newly formed Ser-hydroxydectonyl unit with the upstream 
assembled peptide chain by forming an ester bond.  
4.1 Characterization of the IcoA C4 domain  
The catalytic ability of the IcoA C4 domain to acylate the serine residue tethered onto the IcoA 
PCP3 domain with a 3-hydroxyacyl chain was first examined in vitro. 
4.1.1 Production of recombinant IcoA C4 domain 
The constructs pET151-IcoA_PCP3 and pET28a-IcoA_C4 were generated for the corresponding N-
His6-tag recombinant protein over production and purification (detailed in 6.5.1). The N-His6-IcoA 
PCP3 domain and N-His6-IcoA C4 domain were overproduced and purified as described in 6.5.3 
and 6.5.4 The mass and purity of purified recombinant protein was confirmed by SDS-PAGE and 
LC-MS analysis (Figure 4.1)  
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Figure 4.1 SDS-PAGE and LC-MS analysis of purified N-His6-IcoA PCP3 and N-His6-IcoA C4. (A) 12% SDS-PAGE gel 
and 10%SDS-PAGE gel showing the size and purity of N-His6-IcoA PCP3(left) and N-His6-IcoA C4(right) respectively, 
(B) Deconvoluted mass spectra confirming the exact mass of N-His6-IcoA PCP3 (-N-Met) (left) and N-His6-IcoA C4 
(-N-Met) (right) respectively. Peak labeled as ‘*’ corresponds to the spontaneous gluconoylation of the His-tag on 
fusion proteins, with an additional 178 Da observed.147 See appendix for raw mass spectra. 
4.1.2 Characterization of the N-acylation activity of the IcoA C4 domain 
An in vitro assay outlined in Scheme 4.2 was utilized to characterize the N-acylation activity of 
the IcoA C4 domain. Due to the intrinsic instability of L-serine-Pant (found by Dr. Douglas Roberts 
during the synthesis trials), L-alanine-Pant (synthesised by Dr. Douglas Roberts) was alternatively 
used as a substrate mimic to first generate L-Ala-PPant-PCP3 as a substrate for the IcoA C4 domain. 
Loading of the L-Ala-PPant unit onto the IcoA PCP3 domain was achieved using the 
phosphopantetheinylation enzymes cassette as detailed in 6.6.1.2. The successful attachment of 
the L-alanine-PPant unit was confirmed by LC-MS analysis of the intact IcoA PCP3 domain 
following the loading reaction, with the expected 412 Da mass addition being observed (Figure 
4.2 A).  
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Scheme 4.2 Design of in vitro assays for testing the N-acylation activity of the IcoA C4 domain. IcoA PCP3 
domain. IcoA PCP3 domain is first loaded with L-Ala by phosphopantetheinylation enzyme cassette, followed by 
incubation with the IcoA C4 domain and 3R or 3S-hydroxybutyryl-Pant 
 
Figure 4.2 LC-MS analysis of the N-acylation activity of the IcoA C4 domain. (A) Deconvoluted mass spectra of 
the apo IcoA PCP3 domain (top) and following incubation with Svp, CoA, MgCl2, ATP and L-Ala (bottom). L-Ala-
PPant loading was observed as a 412 Da mass shift from apo protein. (B) deconvoluted mass spectra of the L-Ala-
PPant-IcoA PCP3 species (top) and following incubation with the IcoA C4 domain and 3-hydroxylacyl-Pant with 3R 
configuration (middle) or 3S configuration (bottom).   
The subsequent condensation reaction was then conducted by incubation of L-Ala-PPant-IcoA 
PCP3 with the IcoA C4 domain and 3-hydroxybutyryl-pantetheine, which mimics the predicted 
natural substrate 3-hydroxyoctanoyl-ACP (see 6.6.6). The 3-hydroxyacyl-ACPs are produced 
exclusively in the 3R-configuration during fatty acid biosynthesis. To examine whether the IcoA 
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C4 domain has this proposed stereo specificity towards the fatty acid substrate, both R and S 
configured 3-hydroxybutyryl-pantetheine (synthesised by Dr. Matias Rey) were tested in the assay. 
LC-MS analysis of the intact L-Ala-PPant-IcoA PCP3 following condensation reactions revealed a 
peak corresponding to the condensed L-Ala-hydroxybutyryl product in both reactions, while no 
equivalent peak was detected in the control reaction lacking the IcoA C4 domain (Figure 4.2 B).  
This result demonstrated the catalytic ability of the IcoA C4 domain to utilise a 3-hydroxyacyl 
moiety to re-prime the NRPS chain assembly but without any of the predicted stereospecificity. 
It is possible the promiscuous stereo specificity of the IcoA C4 domain was due to the substrate 
mimics not being close enough to the natural substrate.  
4.2 Characterization of the IcoA C4-A3-PCP3 tri-domain 
To probe whether using more accurate substrate mimics would increase the specificity of the 
IcoA C4 domain, an L-serine and a fatty acid substrate with a longer alkyl chain were required. 
Due to the instability of L-serine-pantetheine noted in the previous study, direct loading of L-
serine by the IcoA A3 adenylation activity was attempted. Instead of separately including the 
isolated IcoA A3 domain into the assay, the IcoA C4-A3-PCP3 tri-domain was used. 
4.2.1 Production of recombinant IcoA C4-A3-PCP3 tri-domain 
Construct pET28-IcoA_C4-A3-PCP3 was generated for producing the N-His6 recombinant IcoA C4-
A3-PCP3 tri-domain. As the activity of the IcoA C4 domain within the tri-domain construct was 
also planned to be monitored via intact protein mass spectrometry, an appropriate negative 
control was also designed. As introduced in section1.3.2.2, C domains from modular NRPSs 
contain a conserved catalytic core motif HHxxxDG, and the catalytic role of the second histidine 
residue as a general base in several systems has been confirmed by mutagenesis studies.119,118,129 
This putative catalytic histidine was therefore located within the conserved HHxxxDG motif of the 
C4 domain and was mutated to an alanine on the pET28-IcoA_C4-A3-PCP3 construct, via site-
directed mutagenesis as detailed in 6.5.2. The N-His6 recombinant IcoA C4-A3-PCP3 and IcoA C4*-
A3-PCP3 (H143A) tri-domains were overproduced and purified as detailed in 6.5.3 and 6.5.4. The 
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mass and purity of the purified recombinant proteins were confirmed by SDS-PAGE and LC-MS 
analysis (Figure 4.3). Surprisingly, a certain percentage of the holo form of both constructs was 
detected, suggested the PPase from primary metabolism in E. coli BL21(DE3) could recognize and 
modify the IcoA PCP3 domain. Although this is unusual it was also observed following 
reconstitution of the valinomycin NRPS in E. coli.155  
 
Figure 4.3 SDS-PAGE and LC-MS analysis of purified N-His6-IcoA C4-A3-PCP3 and N-His6-IcoA C4*-A3-
PCP3(H143A). (A) 6% SDS-PAGE gel showing the size and purity of N-His6-IcoA_C4-A3-PCP3 (left) and N-His6-IcoA 
C4*-A3-PCP3(H143A) (right). Deconvoluted mass spectra confirming the exact mass of N-His6-IcoA_C4-A3-PCP3 
(-N-Met) (B) and N-His6-IcoA_C4*-A3-PCP3(H143A) (-N-Met) (C). Peak labeled as ‘*’ corresponds to spontaneous 
gluconoylation of the His-tag on fusion proteins with additional 178 Da observed.147 The peak labeled as ‘●’ refers 
to the holo species with mass addition of 341 Da. For raw mass spectra see appendix. 
4.2.2 Characterization of the chain initiation activity of the IcoA C4-A3-PCP3 tri-
domain  
An in vitro assay outlined in Scheme 4.3 using 3R or 3S-hydroxyoctanoyl-pantetheine was planned 
to reconstitute the chain initiating activity of the IcoA C4-A3-PCP3 tri-domain. Both wild type and 
mutant apo-C4-A3-PCP3 tri-domain were converted to their holo form by treatment with the 
PPant transferase, Svp, and coenzyme A, and subsequently incubated with ATP and L-Ser for the 
adenylation reaction. Intact protein mass spectrometry showed the expected mass shift of 428 
Da from the apo form to the L-Ser loaded form (Figure 4.4). This demonstrated the proposed 
serine adenylation activity of the IcoA A3 domain, however a significant amount of the holo 
species was also detected in each instance. This could be the result of the hydroxy group in the 
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serine residue, without following condensed to fatty acid chain, attacking the thioester bond and 
thus causing the hydrolysis of serine residue from the IcoA PCP3 domain. 
 
Scheme 4.3 Design of in vitro assay for examination of the chain priming activity of IcoA C4-A3-PCP3. The tri- 
domain is converted to holo form by Svp catalyzed PPant unit loading, followed by incubation with L-Ser, MgCl2 
and ATP for the A domain catalyzed L-Ser loading reaction and subsequently incubated with 3R or 3S-
hydroxyoctanoyl-Pant for the C domain catalyzed condensation reaction. 
 
Figure 4.4 LC-MS analysis of the L-serine adenylation activity of A domain in IcoA C4-A3-PCP3 and IcoA C4*-A3-
PCP3 (H143A). Deconvoluted mass spectra of the apo (top) IcoA C4-A-PCP tri-domain (A) and the IcoA C4-A-
PCP(H143A) tri-domain (B) following incubation with Svp, CoA, MgCl2, ATP and L-Ser(bottom). Holo modification 
and Ser-PPant loading were observed as 341 Da and 428 Da mass shift from apo protein respectively 
To avoid hydrolysis of the serine residue from the IcoA PCP3 domain to allow for maximum 
turnover for the following condensation reaction, the activity of the IcoA C4-A3-PCP3 tri-domain 
was monitored using a one-pot adenylation and condensation reaction outlined in Scheme 4.4. 
In this assay the apo-IcoA C4-A3-PCP3 tri-domain was first converted to its holo form, and 
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subsequently incubated with L-Ser, ATP and either 3R- or 3S-hydroxyoctanoyl-pantetheine (see 
6.6.7). The control reaction was conducted under the same conditions using the IcoA C4*-A3-
PCP3 (H143A) tri-domain. 
 
Scheme 4.4. Optimized in vitro one-pot assay for reconstitution of the chain initiating activity of IcoA C4-A3-
PCP3. The tri-domain is first converted to holo form by Svp catalyzed PPant unit loading, followed by incubation 
with L-Ser and MgCl2 and ATP 3R or 3S-hydroxyoctanoyl-Pant for the one-pot L-Ser adenylation and subsequent 
condensation reaction. 
LC-MS analysis of the intact IcoA C4-A3-PCP3 tri-domain following incubation with 3R-
hydroxyoctanoyl-Pant resulted in a peak corresponding to condensation of L-Ser with 3-
hydroxyoctanoyl, with peaks for the holo- and L-Ser-loaded forms also observed (Figure 4.5 A). 
However, no equivalent peak was observed when 3S-hydroxyoctanoyl-Pant was used as a 
substrate or in the control reactions using the IcoA C4-A3-PCP3(H143A) tri-domain mutant using 
either 3R or 3S configured substrates (Figure 4.5 B). These results suggested the IcoA C4 domain 
is responsible for the embedded hydroxyacyl initiating activity and it does harbor the proposed 
stereospecificity for the 3R-configured hydroxyoctonyl group.  
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Figure 4.5 LC-MS analysis of in vitro reconstitution of chain initiating activity of IcoA C4-A3-PCP3. Deconvoluted 
mass spectra of (A) IcoA C4-A-PCP tri-domain and (B) IcoA C4-A-PCP(H143A) tri-domain following incubation with 
ATP, L-Ser and 3R-hydroxyoctanoyl-Pant (top) or 3S-hydroxyoctanoyl-Pant (bottom). L-Ser-PPant loading and 
subsequent condensation with 3-hydroxyoctanoyl unit were observed as an 87 Da and further 142Da mass shift 
from the holo proteins respectively.  
4.3 Characterization of IcoA Module 3 
The second condensation event in IcoA Module 3 is proposed to be the IcoA C3 domain catalyzed 
ester bond formation between the free hydroxyl group of the β-hydroxyl acyl unit and the 
intermediate tethered to the upstream IcoA PCP2 domain. An in vitro one-pot assay (Scheme 4.6.) 
using the full length IcoA Module 3 and a substrate mimic of the upstream assembled peptide 
chain, Ser-(D)-Leu-butyryl-SNAC was designed to reconstitute the activity of the whole module in 
vitro. 
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Scheme 4.5 Design of on-pot in vitro assay for reconstitution of the activity of IcoA Module 3. The IcoA Module 
3 is first converted to holo form by Svp catalyzed PPant unit loading, followed by the one-pot incubation with L-
Ser, MgCl2, ATP, 3R or 3S-hydroxyoctanoyl-Pant and Ser-(D)-Leu-butyryl-SNAC. 
The construct pET28-IcoA_module 3 was generated and the corresponding N-His6 fusion protein 
was overproduced and purified as detailed in 6.5.1, 6.5.3 and 6.5.4. SDS-PAGE analysis of the 
purified N-His6-IcoA Module 3 showed good purity (Figure 4.6 A) however intact protein mass 
spectrometry analysis identified 3 peaks in the deconvoluted chromatogram (Figure 4.6 B). The 
peak with m/z of 169,584 Da, corresponding to the expected N-His6-IcoA Module 3 (calculated 
m/z=169,584 Da), was the lowest intensity species, with the major species containing an increase 
in mass of 594 Da. A further peak was also observed with an additional 178 Da mass compared 
to the major species, which corresponds to the spontaneous gluconoylation of a His-tag fusion 
protein. This suggested the major species was also an overproduced N-His6 fusion protein and 
was therefore a derivative of N-His6-IcoA Module 3. 
 
Figure 4.6 SDS-PAGE and LC-MS analysis of purified N-His6-IcoA Module 3. (A) 6% SDS-PAGE gel showing the size 
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and purity of N-His6-IcoA Module 3. (B) Deconvoluted mass spectra confirming the existence and the exact mass 
of N-His6-IcoA Module 3 (-N-Met) as well as displayed another two peaks. The peak labeled as ‘?’ refers to 
dominated species with observed m/z=170.178 Da (with additional 594 Da than expected mass of IcoA Module 
3). The peak labeled ‘*’ corresponds to the spontaneous gluconoylation of His-tag on the ‘major species’ with 
additional 178 Da observed.147 Row MS spectrum see appendix. 
To further characterize the identity of the purified IcoA Module 3 derivative, one-pot 
phosphopantetheinylation and L-serine adenylation of all three species was attempted using 
conditions previously described (see 6.6.8). Intact protein mass spectrometry analysis of the 
reaction showed the expected mass shift could only be observed on the authentic apo-IcoA 
Module 3 species but not the major species (Figure 4.7). This strongly indicated that for the major 
species, the serine residue of the PCP3 domain which undergoes phosphopantetheinylation was 
occupied. Given that the IcoA C4-A3-PCP3 tri-domain purified largely in its holo form, the 
detection of this major species (+594 Da) was tentatively explained as follows; the PCP domain 
of IcoA module 3 was converted to its holo form by the PPtase from the E. coli primary 
metabolism and the IcoA A3 domain and IcoA C4 domain subsequently performed their functions 
utilizing the available intracellular substrate. Addition of the proposed natural substrates of 
module 3, a serine residue and 3-hydroxydectonoyl unit, would account for a mass shift of 598 
Da. It is unclear why this reaction did not occur during overproduction of the IcoA C4-A3-PCP3 
tri-domain. 
To probe this possibility, an analogue of the proposed substrate of the IcoA C3 domain, Ser-(D)-
Leu-butyryl-SNAC, was directly incubated with the purified module 3 to see if a mass shift 
corresponding to fully assembled product of module 3 could be observed (6.6.8). Unfortunately, 
a dramatically decreased intensity and resolution of peaks corresponding to module 3 and its 
derivatives was observed by intact mass spectrometry, likely due to the high concentration of the 
small molecule SNAC substrate greatly depressing the signal of the  1̴70 kDa IcoA Module 3.  
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Figure 4.7 LC-MS analysis following apo to holo modification and L-Serine loading of IcoA module 3 and 
proposed identity of the unknown derivative of IcoA module 3. Deconvoluted mass spectra of IcoA Module 3 
(bottom) following incubation with Svp, CoA, MgCl2, (middle) and additional L-Ser, ATP (Top). Apo to holo 
conversion and subsequent loading of L-Ser were observed as a 341 Da and 428 Da mass shift from apo IcoA 
Module 3 respectively. The peak labelled as ‘?’ denotes the ‘major species discussed above and was predicted to 
be IcoA Module 3 with an analogue of the 3-hydroxyldectonyl-serinyl-PPant unit attached on the PCP domain. 
4.4 Trials for in vitro reconstitution of icosalides derivatives 
biosynthesis 
Since the IcoA C4 domain showed some substrate promiscuity with respect to the chain length 
of the fatty acid substrate, biosynthesis of novel icosalides derivatives via incorporation of new 
fatty acid moieties was attempted.  
As icosalides are assembled from simple acyl chain and amino acid building blocks, and by a 
relatively small assembly line, in vitro reconstitution of the entire NRPS with unnatural substrate 
is an attractive approach for the production of novel icosalides derivatives (Figure 4.8). This 
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approach would also avoid any interference from the cellular natural fatty acid substrates. To first 
reconstitute the functional icosalide NRPS two strategies have been attempted.  
 
Figure 4.8 Schematic view of in vitro reconstituted biosynthesis of novel icosalides derivatives. The required 
components for in vitro biosynthesis of novel icosalides derivatives are shown. The naturally incorporated fatty 
acid moieties in Icosalide A1 and proposed substrate analogues are highlighted in orange. 
4.4.1 Strategy 1: two-piece reconstitution 
Successful in vitro reconstitution of small or partial assembly lines have been reported,155,156,157 
with a maximal protein molecular weight of   ̴350 kDa. The icosalide NRPS is a single protein 
with a molecular weight of  5̴50 kDa, so two constructs were planned to reconstitute the entire 
NRPS with the excision site between the IcoA C3 domain and the IcoA C4 domain (Figure 4.9 A). 
This cut site was chosen because both domains have previously been successfully isolated in 
soluble form (data for the IcoA C3 domain not shown). 
The DNA encoding for IcoA-Part I and IcoA-part II was separately cloned into pET28a (+) via 
Gibson assembly (Figure 4.9 A) and the corresponding recombinant N-His6 fusion proteins were 
overproduced and purified (detailed in 6.5.1, 6.5.3 and 6.5.4). The purified proteins were 
analysed by SDS-PAGE, showing bands of approximately the correct molecular weight, although 
a protein standard of sufficiently large molecular weight to confirm this was not available (Figure 
4.9 B). 
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Figure 4.9 In vitro reconstitution of IcoA by a two-part strategy. (A) Schematic diagram of the DNA cloning 
strategy used to create icoA expression constructs (B) 6% SDS-PAGE gel analysis of purified recombinant N-His6-
IcoA-Part I and N-His6-IcoA-Part II. 
The two purified proteins were incubated with L-serine, L-leucine, 3R-hydroxyoctanoyl-PPant, ATP, 
MgCl2, CoA and SvP (detailed in 6.6.9.). The reaction was then extracted and the extracts we 
analysed by LC-MS analysis. Unfortunately, the expected enzymatic product was not observed.  
4.4.2 Strategy 2: one-piece reconstitution 
The failure of the first strategy was very likely due to the linker region between the IcoA C3 and 
IcoA C4 domains being important for the function of the entire NRPS. Therefore, cloning and 
expression of the entire IcoA NRPS as a single protein was attempted. Due to the challenges 
associated with purification of a protein of   ̴550 kDa molecular weight, the novel icosalides 
derivatives production was then planned to be attempted by cell free assays following confirming 
the functionality of the IcoA NRPS. 
First, icoA ( 1̴5 kb) was captured from the genomic DNA by transformation associated 
recombination (TAR) cloning (detailed in 6.8). The icoA fragment was then cloned into pET28a(+) 
to generate pET28a(+)-icoA and the sequence was confirmed by restriction digestion (Figure 4.10) 
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Figure 4.10 Restriction digestion map of the pET28a(+)-icoA. Expected restriction map for pET28a(+)-icoA 
digested with BamHI (A) or ScaI (B). (C) DNA electrophoresis gel of the restriction digestion results confirming the 
pET28a(+)-icoA construct.  
To first confirm the overproduction and functionality of IcoA, pET28a(+)-icoA was expressed in E. 
coli BAP1, an engineered E. coli strain with NRPS and PKS specific PPtase encoded gene integrated 
into the genome158, for monitoring the icosalides production (detailed in 6.9). After 20 hours 
induction the cells were extracted and LC-MS analysis was used to search for icosalides 
production. Unfortunately, no icosalides were detected in the extracts.  
4.5 Conclusions and future work 
In this chapter, in vitro biochemical assays were employed to elucidate the biosynthetic reactions 
catalyzed by module 3 of the icosalide NRPS. The N-acylation activity of the IcoA C4 domain was 
first demonstrated by incubating the IcoA C4 domain with the PCP3 domain loaded with L-Ala 
and 3-hydroxybutyryl-pantetheine, which resulted in production of a 3-hydroxybutyryl-alaninyl-
IcoA PCP3 species. This represents the first example of an embeded chain initiating C domain. 
The adenylation and stereospecific chain initiating activity of the IcoA A3-C4-PCP3 tri-domain was 
reconstituted in vitro using natural substrate L-serine and closer substrate mimic 3-
hydroxyoctonyl-pantetheine. The observed 3R- stereoselectivity of IcoA C4 domain towards the 
3-hydroxyacyl moiety suggested the proposed origin of this moiety from fatty acid biosynthesis.  
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The full length IcoA Module 3 was overproduced and purified to investigate the ability of the IcoA 
C3 domain to catalyse the second condensation reaction of this module. Intact protein mass 
spectrometry analysis of the recombinant module 3, showed IcoA Module 3 had a higher than 
expected molecular weight that was close to the additional mass, which would be expected if a 
serine and a 3-hydroxydectonyl moiety were assembled on the holo PCP domain by the activity 
of the C and A domain. The PCP domain must be loaded since IcoA Module 3 could not be 
converted to holo form or loaded with serine by A domain. Since minor holo modification was 
also observed in the purified IcoA C4-A3-PCP3 tri-domain, this indicated the promiscuity of the 
PPtase from E. coli primary metabolism towards the icosalide NRPS. 
In vitro reconstitution of the entire icosalide NRPS was also attempted in order to develop a 
system that could produce novel icosalides derivatives. A two-piece reconstitution strategy was 
firstly employed, in which IcoA was purified as two separate recombinant proteins which were 
then incubated with the required amino acid and fatty acid building blocks and cofactors. 
However, none of the expected final product was detected. The IcoA encoding gene was then 
captured by TAR cloning and the entire NRPS was overproduced in E. coli. This also did not result 
in success as no icosalide production was observed in the IcoA overproducing cells. 
In the future, the mechanism for the stereoselectivity of the IcoA C4 domain towards the 3R-
hydroxyacyl unit could be probed via a structural study. The substrate scope of the IcoA C4 
domain could also be investigated to allow for rational engineering of icosalides derivative. As 
the proposed promiscuity of PPtase from E. coli primary metabolism towards IcoA is quite 
intriguing, proteomics should be used to confirm the identity of the purified IcoA Module 3 
derivative. Optimization of IcoA overproduction conditions and confirmation of the 
corresponding gene expression should also be performed to complete the in vitro reconstitution 
of icosalides production experiments. Successful generation of such a system would lead to the 
ability to access novel icosalides derivatives through feeding precursor analogues.
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 Chapter 5 
Conclusions and future perspectives 
Antimicrobial activity-guided and genomics-driven natural product discovery in Burkholderia 
gladioli BCC0238 has resulted in the identification of a polyketide macrolide antibiotic, gladiolin, 
that exhibits potent activity against Mycobacterium tuberculosis, and a set of cyclic 
lipopeptodilide compounds, icosalides, originally believed to be fungal metabolites. The 
biosynthetic pathways for both of these metabolites have interesting features that have been 
explored using various in vivo and in vitro methodologies in this thesis. 
Gladiolin is structurally related to etnangien, isolated from the myxobacterium Sorangium 
cellulosum. However, etnangien suffers from significant instability due to the presence of a 
conjugated polyene in the side chain, originating from programmed iteration of EtnE Module 5. 
In comparison, though it has the same domain organization, GbnD2 Module 5 does not iterate, 
instead recruiting a trans-acting enoyl reductase to reduce the double bond generated from a 
single cycle of chain elongation. Despite their critical structural differences, the trans-AT 
polyketide synthases (PKSs) responsible for the biosynthesis of these compounds are remarkably 
similar, with 70 out of 71 enzymatic domains identical in the assembly line. This study aimed to 
identify the ER activity required by GbnD2 Module 5 and to probe the chain length control 
mechanism in gladiolin biosynthesis. 
The presence of an ER domain in module 1 of the gladiolin PKS (the GbnD1 ER1 domain) in place 
of an ACP domain at the corresponding position in the etnangien PKS, represents the sole 
difference between the architecture of gladiolin and etnangien PKSs. The GbnD1 ER1 domain was 
therefore assigned as the first candidate to provide the required enoyl reduction activity in 
GbnD2 Module 5, in an inter-modular manner. Using a combination of in vivo in-frame deletion, 
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point-mutations and in vitro biochemical assays, the GbnD1 ER1 domain was shown to only 
perform enoyl reduction in module 1 but not module 5. An alternative candidate was a trans-
acting ER, GbnE which is present in gladiolin biosynthetic cluster with its counterpart EntL 
presenting in the one of etnangien, was originally proposed to provide a trans-acting enoyl 
reduction in module 10 of each assembly line. By applying similar approaches, GbnE was shown 
to catalyse enoyl reduction specifically in both module 5 and module 10 of the gladiolin assembly 
line. Furthermore, biochemical evidence was provided for the inherent iterative nature of 
module 5 of the gladiolin PKS and the ability of GbnE to abolish the iteration of this module. The 
results also suggested the abolishment of the iteration is facilitated by the protein-protein 
interaction between GbnE and the ACP domain in this module. In addition, the ‘gate-keeping’ 
role of the downstream GbnD2 KS6 domain by preferentially accepting the GbnE processed α,β-
saturated intermediate was also biochemically characterized. The results suggest GbnE and the 
GbnD2 KS6 domain play an important role in conserving the biosynthetic fidelity of the gladiolin 
biosynthesis, however, the kinetics that facilitate this process require further investigations (as 
detailed in 3.3). 
In order to obtain a complete picture, initially the analogous set of biochemical assays should be 
conducted using the etnangien EtnE module 5 and the corresponding trans-acting ER EtnL. If our 
hypothesis is correct, the presence of EtnL should have no effect on the ability of EtnE module 5 
to iterate (Figure 5.1 A). An even more intriguing study would be to examine whether there is 
‘cross-talk’ between the trans-acting ERs (EtnL/GbnE) and the ACP domain in module 5 in 
etnangien and gladiolin pathways, for example as shown in Figure 5.1 B. This has the potential to 
shed light on the evolutionary origin of the intricate differences between these two PKS pathways. 
This work also forms the basis for further studies to uncover the molecular mechanism underlying 
the specific recruitment of trans-acting ERs in trans-AT PKS assembly lines, which could ultimately 
guide future bioengineering efforts. GbnE can be used as a model system to better understand 
the nature of the specific protein-protein interactions between trans-acting ERs and the 
corresponding ACP domains. This could be achieved using a suite of biochemical and biophysical 
techniques (Figure 5.1 C), including: 1) bio-layer interferometry analysis of the binding affinity 
between interacting ACPs and GbnE to provide further kinetic information of this specific 
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interaction. 2) sequence alignment and phylogenetic analysis of interacting ACP domains and 
trans-acting ERs, coupled with saturation mutagenesis to identify the conserved residue(s) that 
important for this specific interaction. 3) structural studies of GbnE and interacting ACP domains 
by crystallography, NMR or carbene footprinting to identify the structural features required for 
this specific interaction. 
 
Figure 5.1 Future perspectives of different chain length control mechanisms employed by the gladiolin and 
etnangien assembly lines. (A) In vitro reconstitution of the trans-acting ER activity of EntL and iterative activity 
of module 5 of the etnangien PKS, showing non-interaction between EntL and the EntE ACP5 domain allows the 
iteration. (B) In vivo ‘cross-talk’ engineering of etnangien biosynthetic pathway using the chain length control 
logic from gladiolin assembly line. (C) Bioinformatics and biophysics studies of the nature of the specific 
interaction between GbnE and GbnD2 ACP5 domain.  
The NRPS responsible for the biosynthesis of icosalides exhibits an unprecedented domain 
architecture revealing a starter C domain (IcoA C4 domain) situated directly adjacent to a LCL 
domain (IcoA C3 domain) suggesting an unusual double chain initiation mechanism for icosalides 
assembly. The ability of the isolated IcoA C4 domain to load a 3-hydroxyacyl unit by N-acylation 
activity to re-prime the peptide chain assembly was biochemically characterized. The 
stereoselectivity of the IcoA C4 domain towards the 3R-configured hydroxyl-acyl moiety was also 
demonstrated using the IcoA C4-A3-PCP3 tri-domain, confirming the proposed origin of this 
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moiety as being from primary fatty acid biosynthesis. This represents the first example of an 
experimentally examined internal starter C domain. Given the relatively modest size of the NRPS 
icoA gene (15 kb), cloning of this gene into a heterologous expression vector was also achieved, 
with the aim to reconstitute the entire icosalide NRPS in vitro which could be used to produce 
novel icosalides derivatives by feeding unnatural fatty acid substrates. IcoA overproduction in E. 
coli requires further optimization of the expression conditions to confirm the functionality of the 
reconstituted NRPS as well as for the production of novel derivatives. 
Recent studies have shown that it is possible to create ‘hybrid’ NRPSs via assembly of exchange 
units (XUs).159 The XU region of an NRPS is comprised of an A-PCP-C mobile unit, which can be 
swapped in and out of NRPS pathways. Using this approach in conjunction with a functional in 
vitro IcoA NRPS, in theory every position of the icosalides structure could be altered using this 
combinatorial biosynthesis approach (Figure 5.2). 
 
Figure 5.2 Schematic view of rational engineering of novel icosalides derivatives via a combinatorial 
biosynthesis strategy. Structurally diverse novel icosalides derivatives could be achieved by swapping the 
‘exchangeable unit’ (A-PCP-C tri-domain) to incorporate different amino acid building blocks (X-aa) and feeding 
novel fatty acid moieties to the starter C domains (number highlighted in red). 
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Chapter 6 
Materials and methods 
6.1 Materials 
6.1.1 Growth Media 
Luria-Bertani (LB) medium was purchased from Sigma Aldrich. In 1 L H2O, 25 g LB powder was 
added. For agar plate 15 g bacto agar (Sigma Aldrich) was added. 
Tryptic Soy Broth (TSB) was purchased from Sigma Aldrich. In 1 L H2O, 12 g TSB powder was 
added. For agar plate 15 g bacto agar (Sigma Aldrich) was added. 
Basal salts medium (BSM): In 1 L H2O, 4.25 g K2HPO4·3H2O, 1 g NaH2PO4·H2O, 2 g NH4Cl, 0.2 g 
MgSO4·7H2O, 0.012 g FeSO4·7H2O, 0.003 g MnSO4·H2O, 0.003 g ZnSO4·7H2O, 0.003g CoSO4·7H2O, 
0.10 g nitrilotriacetic acid, 0.2 g yeast extract and 4 g glycerol were added. pH was adjusted to 
7.2. For agar plate 15 g bacto agar (Sigma Aldrich) was added. 
M9 minimal medium: In 1 L H2O, 6 g Na2HPO4, 3 g KH2PO4, 0.5 g NaCl, 1 g NH4Cl and 10 g sucrose, 
1mL 1M MgSO4 and 100ul 1M CaCl2 were added and pH was adjusted to 7.4. For agar plate 15 g 
bacto agar (Sigma Aldrich) was added. 
6.1.2 Buffers 
10X Tris/Borate/EDTA (TBE) buffer: 890 mM Tris, 890 mM boric acid, 20 mM pH 8.0 EDTA. Stored 
at room temperature and diluted to 1X before use. 
Loading buffer：20 mM Tris-HCl, 300 mM NaCl, 20 mM Imidazole, pH 8.0. Sterile filtered and 
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stored at 4 °C. 
Imidazole elution buffer：20 mM Tris-HCl, 300 mM NaCl, with serial imidazole concentration (50 
mM, 100 mM, 200 mM, 300 mM, 500 mM) pH 8.0. Sterile filtered and stored at 4 °C 
Storage buffer: 20 mM Tris-HCl, 300 mM NaCl, pH 8.0. Sterile filtered and stored at 4 °C. 
5X SDS-PAGE sample buffer: 10% w/v SDS, 10 mM 2-mercaptoethanol, 20% w/v glycerol, 0.2 M 
Tris-HCl (pH 6.8), 0.05 % w/v bromophenol blue. Stored at -20 °C and diluted to 1X with protein 
sample when used. 
10X SDS-PAGE running buffer: 25 mM Tris, 192 mM glycine, 0.1% w/v SDS. Stored at room 
temperature and diluted to 1X before use. 
Chemically competent cell preparation buffer I (CCC I): 30 mM CH3CO2K, 80 mM CaCl2, pH 5.8. 
Autoclaved and stored at 4 °C. 
Chemically competent cell preparation buffer II (CCC II): 30 mM CH3CO2K, 80 mM CaCl2, 15% 
w/v glycerol, pH 5.8. Autoclaved and stored at 4 °C. 
Yeast plasmid isolation solution 1: 10% w/v sucrose, 50 mM pH 8.0 Tris-HCl, 10 mM EDTA 
Yeast plasmid isolation solution 2: 0.2 M NaOH, 1% w/v SDS 
Yeast plasmid isolation solution 3: 3 M CH3CO2K, pH 8.0 
6.1.3 Reagents and Kits 
Antibiotics: 
Table 6.1 List of antibiotics  
Antibiotic* Working Conc. Strain to be applied 
Ampicillin 100 μg/mL E. coli carrying recombinant pET151 
Kanamycin 50 μg/mL E. coli carrying recombinant pET28a(+) or pRK2013 
Trimethoprim 50 μg/mL E. coli carrying recombinant pGPI-SceI 
150 μg/mL Burkholderia carrying recombinant pGPI-SceI 
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Tetracycline 50 μg/mL E. coli carrying pDAI-SceI 
200 ug/mL Burkholderia carrying pDAI-SceI 
Polymyxins 600 U/mL For triparental mating selection 
* All antibiotics were purchased from Sigma Aldrich 
Restriction enzymes and T4 DNA ligase were purchased from New England Biolabs. 
MagJET Genomic DNA Kit was purchased from Thermo Fisher Scientific. 
GeneJET Gel Extraction Kit was purchased from Thermo Fisher Scientific.  
GeneJET Plasmid Miniprep Kit was purchased from Thermo Fisher Scientific. 
Champion™ pET151 Directional TOPO® Expression Kit was purchased from Thermo Fisher 
Scientific. 
Champion™ pET SUMO Protein Expression System Kit was purchased from Thermo Fisher 
Scientific.  
Gibson Assembly® Master Mix was purchased from New England Biolabs. 
GeneArt™ Seamless Cloning and Assembly Kit was purchased from Thermo Fisher Scientific. 
Q5® Site-Directed Mutagenesis Kit was purchased from New England Biolabs. 
6.1.4 Bacterial strains 
Table 6.2 List of bacterial strains 
Name Description Source or ref.  
Escherichia coli 
E. coli TOP10 mcrA, Δ(mrr-hsdRMS-mcrBC), Phi80lacZ(del)M15, 
ΔlacX74, deoR, recA1, araD139, Δ(ara-leu) 
7697, galU, galK, rpsL(SmR), endA1, nupG, host for 
general cloning 
Invitrogen 
PhD Thesis: Xinyun Jian  Chapter 6 
111 
E. coli BL21 (DE3) E. coli B dcm ompT hsdS(rB-mB-) gal, host for 
recombinant protein expression 
Invitrogen 
E. coli BAP1 E. coli BL21 (DE3) ΔprpRBCD (sfp), host for 
recombinant protein expression 
reference158 
E. coli SY327 araD, Δ(lac pro) argE(Am) recA56 rifR nalA  λpir , 
donor strain for conjugation between E. coli and 
Burkholderia 
reference160 
E. coli HB101/ 
pRK2013 
F- Lambda- araC14 leuB6(Am) DE(gpt-proA)62 
lacY1 glnX44(AS) galK2(Oc) recA13 rpsL20(strR) 
xylA5 mtl-1 thiE1 hsdS20(rB-, mB-), carries pRK2013, 




B. gladioli BCC1622 Wild type, gladiolin and icosalides producing strain Mahenthirali
ngam/Challis 
labs 




S. cerevisiae VL6-48N MATα trp1-Δ1 ura3-Δ1 ade2-101 his3-Δ200 lys2 
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Table 6.3 List vectors 
Name Description Source or ref. 
pGPI-SceI oriR6K TpR mob+ carries I-SceI cut site, for gene deletion in 
Burkholderia 
reference144 
pDAI-SceI oripBBR1 TetR mob+ Pdhfr FLAG epitope, carries the I-SceI, reference144 
pMLBAD pBBR1 ori araC-PBAD TpR mob+, for gene expression in 
Burkholderia 
reference149 
pET28a(+)  pBR322 ori KanR T7lac f1 N-His6 C-His6, for recombinant 
protein expression in E. coli  
Novagen 
pET151-TOPO® pBR322 ori AmpR T7lac N-His6-V5, carries TOPO-cloning 





pET-SUMO pBR322 ori KanR T7lac N-His6-SUMO, carries TA-cloning 





pCAP1000 pUC ori ARSH4/CEN6 Kan/NeoR TRP1 φC31int-attP oriT 
(RP4) pAHD-URA3, for gene cluster capturing 
Challis lab 
 
6.2 General DNA manipulation 
6.2.1 Genomic DNA isolation 
Preparation of genomic DNA for PCR was achieved using MagJET Genomic DNA Kit. 
Preparation of genomic DNA for TAR cloning was achieved on a large scale using the following 
method. Cells were harvested from a 5 mL Burkholderia overnight culture by centrifugation (4000 
xg, 10 mins) and the pellet was washed with 5 mL SET buffer. The cell pellet was then re-
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suspended in 500 μL SET buffer and 60 μL 10% w/v SDS and 14 µL proteinase K (20 mg/mL) was 
added. The cell resuspension was incubated at 55 °C for 1 h followed by addition of 200 μL NaCl 
(5 M) and thorough mixing of the solution. The mixture was then supplemented with 500 μL PCI 
(Phenol/chloroform/isoamylol=25:24:1) solution, mixed thoroughly and centrifuged at 12,000 
rpm for 10 min. The supernatant was transferred to a fresh Eppendorf tube and 500 μL 
chloroform was added, mixed thoroughly and centrifuged at 12,000 rpm for 10 min. The 
supernatant was transferred to a fresh Eppendorf tube and 0.6 CV isopropanol was added to 
allow the genomic DNA precipitation. The precipitate DNA was centrifuged at 12,000 rpm for 10 
min and washed with 70 % v/v ethanol. The pellet was dry in air and finally dissolved in 100 μL 
sterile water.     
6.2.2 Polymerase chain reaction (PCR) 
Q5® Hot Start High-Fidelity DNA polymerase was used for DNA fragment PCR and OneTaq® Hot 
Start DNA polymerase was used for colony PCR screening and TA cloning PCR. A typical reaction 
was set up is detailed in Table 6.4. 
Table 6.4 Components of typical PCR reactions 
Component Volume 
Q5® Hot Start High-Fidelity 2X Master Mix/ 
OneTaq® Hot Start Quick-Load 2X Master Mix 
12.5 μL 
10 μM Forward primer 1.25 μL 
10 μM Reverse primer 1.25 μL 
DNA template variable 
DMSO 1-2μL* 
Nuclease-Free Water To 25μL  
*4% or 8% DMSO was added depending on the GC content of target region of DNA template. 
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Thermocycling conditions was set up as in Table 6.5 using Master Cycler nexus GX2 (Eppendorf): 
Table 6.5 Thermocycling conditions for a routine PCR 
Step Temperature Time 
Initial denaturation 98/95 °C* 3 min 
 
30 cycles 
Denaturation 98/95 °C* 30 s 
annealing 58-70 °C 30 s 
Extension 72 °C 30 s/kb or 1 
min/kb** 
Final extension 72 °C 10 min 
Hold  4 °C - 
* 98 °C or 95 °C was applied at denaturation step when using Q5® Hot Start High-Fidelity DNA 
polymerase or OneTaq® Hot Start DNA polymerase respectively.  
** 30 s/Kb or 1 min/Kb speed was applied at extension step when using Q5® Hot Start High-
Fidelity DNA polymerase or OneTaq® Hot Start DNA polymerase respectively. 
6.2.3 Fragment DNA purification 
DNA products from PCR reaction or plasmid DNA digestion were separated on 0.7% agarose gel 
electrophoresis in TBE buffer and gel slices containing desired DNA fragments were excised and 
purified using GeneJET Gel Extraction Kit. Purified DNA fragments were dissolved in 30-100 μL 
sterile deionized water and the resulting concentration was measured on a NanoDrop™ Lite 
Spectrophotometer.  
6.2.4 DNA restriction digestion and ligation 
Typical DNA restriction enzyme digestions were set up as detailed in Table 6.6. 
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Table 6.6 Components of DNA restriction digestion reactions 
Component Volume/Amount 
DNA 1 μg 
10X CutSmart buffer 5 μL 
Restriction enzyme(s)* 1μL (10 units)  
Sterile water To 50 μL 
* 1μL for each enzyme was added when double digestion applied. 
The reaction was mixed gently and incubated at 37 °C for 1.5 - 3 h followed by incubation at 65 °C 
for 5 min to inactivate the enzymes. 
Purified digested DNA fragments and linearized vector plasmid DNA were ligated using T4 DNA 
ligase. A typical DNA ligation was set up as Table 6.7. 
Table 6.7 Components of typical DNA ligation reactions 
Component Volume/Amount 
Linearized vector DNA 50 ng 
Fragment DNA 3 x of linearized vector molar concentration 
10X T4 DNA ligae buffer 2 μL 
T4 DNA ligase 1μL 
Sterile water To 50 μL 
The reaction was mixed gently and incubated at room temperature for overnight and stored at -
20 °C before transformation or electroporation. 
6.2.5 TOPO® cloning 
TOPO cloning within this work was achieved using Champion™ pET151 Directional TOPO® 
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Expression Kits. A 4 nucleotide CACC- overhang was added to the 5’ of forward primer for primer 
design to allow directional cloning into pET151. Insert fragment DNA was amplified using Q5® 
Hot Start High-Fidelity DNA polymerase and purified by gel extraction before the cloning. A 
typical TOPO cloning reaction is detailed in Table 6.8. 
Table 6.8 Components of TOPO® cloning reactions 
Component Volume/Amount 
Purified fragment DNA 0.5-4 μL* 
Salt solution 1 μL 
TOPO® vector 1 μL 
Sterile water To 6 μL 
* Variable volume of fragment DNA was added to reach the fragment DNA: TOPO® vector molar 
ratio as 0.5:1 to 2:1. 
The reaction was mixed gently and incubate for 1 h at room temperature and then transformed 
into E. coli TOP10 chemical competent cells. 
6.2.6 TA® cloning 
TA cloning within this work was achieved using Champion™ pET SUMO Protein Expression System 
Kit. No special primer design was required for TA cloning. Insert fragment DNA was amplified 
using OneTaq® Hot Start DNA polymerase to give the both 5’ and 3’ A overhang and purified by 
gel extraction before the cloning. The typical TA cloning reaction was set as in Table 6.9. 
Table 6.9 Components of typical TA® cloning reactions 
Component Volume/Amount 
Purified fragment DNA 1-7 μL * 
10X Ligation buffer 1 μL 
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pET-SUMO vector 1 μL (25 ng) 
T4 DNA ligase 1μL 
Sterile water To 10 μL 
* Variable volume of fragment DNA was added to reach the fragment DNA: TOPO® vector molar 
ratio as 1:1. 
The reaction was mixed gently and incubate for 1 h at room temperature and then transformed 
into E. coli TOP10 chemical competent cells. 
6.2.7 Gibson assembly and GeneArt assembly 
Multiple DNA fragment assembly into a vector within this study were achieved using Gibson 
Assembly® Master Mix or GeneArt™ Seamless Cloning and Assembly Kit. For primers design, 20 
bp was set as length of overlapping region. Before assembly reaction, the insert fragment DNA 
was amplified using Q5® Hot Start High-Fidelity DNA polymerase and purified by gel extraction 
and vector was linearized by restriction digestion and purified by PCR purification. The typical 
assembly cloning reaction was set as in Table 6.10 and Table 6.11. 
Table 6.10 Components of typical Gibson assembly reactions 
Component Volume/Amount 
Linearized vector (10 μL in 
total) 
100 ng 
Purified Fragments Variable* 
2X Gibson Assembly Master Mix  10 μL 
Sterile water To 20 μL 
*Variable amount of each fragment was added to reach each fragment: vector molar ratio as 3:1, 
and total amount of fragments and vector are need to be between 0.03-0.2 pmol to give the best 
cloning efficiency.  
The reaction was mixed gently and incubate for 2 h at 50 °C and stored at -20 °C before 
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transformed into E. coli TOP10 chemical competent cells. 
Table 6.11 Components of typical GeneArt assembly reactions 
Component Volume/Amount 
Linearized vector 100 ng 
Purified Fragments Variable* 
5X Reaction buffer 4  
Sterile water to 18 μL 
10X enzyme mix  2 μL** 
*Variable amount of each fragment was added to reach each fragment: vector molar ratio as 2:1. 
**10X enzyme mix must be added at last step and needed be returned back to -80 °C immediately.  
The reaction was mix gently and incubate for 30 min at temperature and placed on ice less than 
5 min and immediately proceed to the transformation step. 
6.2.8 DNA purification for electroporation  
All the above cloning reactions (described in 6.2.4 - 6.2.7) were purified by ethanol precipitation 
before electroporation. The ethanol precipitation was as follows; 1/10 reaction volume of 3 M 
pH 5.2 sodium acetate was added to the reaction mixture followed by addition of 2.5X reaction 
volume of ethanol and mixed thorough. The mixture was frozen at -20 °C for 20 min, and was 
centrifuged at 13,000 rpm, 4 °C for 30 min. The supernatant was decanted carefully and the pellet 
was washed with 70% ethanol and dried. 15 μL of water was added to dissolved the purified DNA.     
6.2.9 Transformation and electroporation 
Preparation of competent cells 
For chemical transformation of E. coli TOP10 or BL21(DE2), chemically competent cells were first 
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made. A single colony of E. coli TOP10 or BL21(DE2) was inoculated in 5 mL LB and grown at 37 °C, 
180 rpm overnight. Subculture the overnight culture 0.5 mL/50 mL LB in 250 mL flask at 37 °C, 
180 rpm shaker for around 3.5 h to reach the OD600 value of 0.4-0.6. The culture was then cooled 
on ice for 30 min to stop cells growing and cells were harvested by centrifuging for 10 min at 3000 
rpm and 4°C. The supernatant was removed and the cell pellet was resuspended in 30 mL CCC I 
buffer and kept on ice for 1 h. Cells were then harvested by centrifuging for 10 min at 3000 rpm 
and 4°C and supernatant was removed. The cell pellet was washed with 30 mL CCC I buffer again 
and resuspended in 1.5 mL CCC II buffer and aliquoted into 80 μL. Aliquots were flash froze and 
stored at -80 °C. 
Similar cell growing and harvest process were applied when preparing the electrocompetent cells 
except the cell pellet was washed and resuspended in 15% glycerol, and aliquoted into 80 μL. 
Chemical transformation 
Frozen chemical competent cells were thawed on ice, and 50-100 ng of plasmid DNA or 8 μL of 
cloning reaction mixture was added and gently mixed. Mixture was left on ice for 30 min and heat 
shocked at 42 °C for 60 s and cooled on ice for 2 min. 500 μL was added and the cell resuspension 
was incubated at 37 °C for 1 h. 100 μL culture was spread on appropriate selective LB agar plate 
and incubated at 37 °C for overnight. 
Electroporation 
Frozen electrocompetent cells were thawed on ice, and 50-100 ng of plasmid DNA or 10 μL of 
purified cloning reaction (described in 6.2.8) was added and gently mixed. The mixture was left 
on ice for 5 min before transferred to a pre-cooled 1 mm gap electroporation cuvette (Bio-Rad). 
The electroporation was performed with the Gene Pulser II (Bio-Rad) set at 2.5 kV, 25 μF and 200 
Ω. Immediately after electroporation 500 μL LB was added to the cuvette and cell resuspension 
was incubated at 37 °C for 1 h. 100 μL culture was spread on appropriate selective LB agar plate 
and incubated at 37 °C for overnight. 
6.2.10 Plasmid DNA mini-prep 
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5 mL E. coli overnight culture was used for a typical plasmid DNA mini-prep using GeneJET 
Plasmid Miniprep Kit. Purified plasmid DNA was dissolved in 50 μL sterile deionized water and 
concentration was measured by NanoDrop™ Lite Spectrophotometer. 
6.3 Genetic manipulation of Burkholderia 
6.3.1 Targeted in-frame gene deletion in Burkholderia  
The in-frame deletion of genes from Burkholderia gladioli BCC1622 was conducted using the 
following methodology.144 First, the deletion construct was generated. Here, ~1 kb homologous 
region that sit upstream and downstream of the gene of interest were amplified, purified and 
cloned into pGPI-SceI vector (using the DNA restriction digest and ligation or Gibson Assembly 
method (see 6.2.4 and 6.2.7)) and transferred into E. coli SY327 by electroporation. The resulting 
plasmid was isolated from candidate E. coli SY327 colonies and confirmed by restriction digestion 
and sequencing. The plasmid was mobilized into Burkholderia gladioli BCC1622 via tri-parental 
mating (described in 6.3.3). Single trimethoprim resistance colonies were selected as candidates 
of the single cross-over mutant followed by colony PCR screening. pDAI-SceI was introduced into 
the single crossover mutant strain by tri-parental conjugation and exconjugants were selected for 
with tetracycline resistance (to select for pDAI-SceI) and trimethoprim sensitive (indicating the 
loss of the integrated plasmid). Candidates with TcRTpS phenotype were either wild-type or 
double crossover mutants which can be discriminated by PCR screening. The in-frame deletion 
was confirmed by sequencing. The mutant was grown on minimal medium M9 to remove pDAI-
SceI and confirmed by the loss of tetracycline resistance. Related primers and expected PCR 
products size for the deletion mutants: B. gladioli BCC1622_ΔgbnD1_ER1, B. gladioli 
BCC1622_ΔgbnE, B. gladioli BCC1622_ΔgdsB_ER, B. gladioli BCC1622_ΔgbnEΔgdsB_ER are listed 
in Table 6.12. 
6.3.2 Site-directed mutagenesis in Burkholderia 
Site-directed mutagenesis of gbnD1_ER1 on Burkholderia genomic DNA was achieved via the in-
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frame knocking in of the mutated gbnD1_ER1 encoded segment into BCC1622_ΔgbnD1_ER1. The 
gbnD1_ER1 fragment, flanked by the same homologous arms used for gbnD1_ER1 in-frame 
deletion, was first subcloned onto pCR-Blunt vector to generate pCR-Blunt-gbnD1_ER1. 
Mutagenesis of G388S/G399P was then conducted using the Q5 site directed mutagenesis kit 
following the protocol in section 6.5.2. to generate pCR-Blunt-gbnD1_ER1*. The mutated 
gbnD1_ER1 segment with flanking arms were then cloned into pGPI-SceI vector using restriction 
site of XbaI and EcoRI to generate pGPI-gbnD1_ER1*and transferred into E. coli SY327 by 
electroporation. In-frame knocking-in gbnD1_ER1* followed the same procedure as in-frame 
deletion in section 6.3.1.1, via mobilizing pGPI-gbnD1_ER1* into BCC1622_ΔgbnD1_ER1 and 
selection for double crossover mutants. Related primers for pCR-Blunt-gbnD1_ER1* construction, 
double crossover mutant PCR screening and expecting PCR products size are listed in Table 6.12. 
6.3.3 Gene complementation in Burkholderia  
For gbnE complementation in Burkholderia, the arabinose-inducible PBAD promoter carrying 
expression vector pMLBAD149 was used to construct pMLBAD-gbnE. GbnE was amplified with the 
primers listed in Table 6.12 below, purified and cloned into pMLBAD via Gibson assembly 
(described in 6.2.7). The confirmed pMLBAD-gbnE was electroporated into E. coli SY327 
(described in 6.2.9) and mobilized into B. gladioli BCC1622_ΔgbnE via tri-parental mating 
(described in 6.3.3). Exconjugants with TpR phenotype were picked as B. gladioli 
BCC1622_ΔgbnE::gbnE candidates and were confirmed by PCR with primers listed in Table 6.12. 
Table 6.12 Overview of constructs used in gene in-frame deletion, site-directed mutagenesis and 
complementation in Burkholderia 
Construct 
(use) 




5’-For: CTGTCTAGATTGTCGTCCTCGTCGC (XbaI) 
5’-Rev: CAGAAGCTTGAGCGCGTGCACGGTA (HindIII) 
1008 bp 
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in-frame deletion) 3’-For: GCAAAGCTTGTGGTGATCCGCCATCG (HindIII) 




MT: 449 bp  




5’-For: ATATCTAGAAGCAAGCGGTCCGACAGG (XbaI) 
5’-Rev: ATAAAGCTTATCGGCGTTGCCAAGCGA (HindIII) 
928 bp 
3’-For: TATAAGCTTTCGATGGCCGATTCGGGC (HindIII) 




MT: 457 bp  












MT: 606 bp  





For: CTGTCTAGATTGTCGTCCTCGTCGC (XbaI) 






pGPI-gbnD1_ER1* Screening-For: CTGTTGCAAGCGCACGATTAGC WT: 449 bp   










Screening primers are the same as For and Rev primers 
1398 bp 
*MT denotes mutant, WT denotes wild type. Italic letters denote the overlapping regions used 
for Gibson assembly. Underlying letters denote the restriction sites. Italic and underlying letters 
denote region for site-directed mutagenesis. 
6.3.4 General tri-parental mating procedures 
Transferring plasmids into Burkholderia strain from E. coli was achieved via the tri-parental 
mating process. Donor strains were E. coli SY327 carrying recombinant pGPI-SceI or pMLBAD or 
pDAI-SceI and helper strain was E. coli HB101 carrying pRK2013. In each tri-parental mating 
experiment, both donor strain and helper strain were inoculated into 5 mL LB medium containing 
appropriate antibiotics respectively and incubated overnight in a 37 °C shaking incubator. The 
host Burkholderia strain was grown in 5 mL TSB medium overnight in a 30 °C shaking incubator. 
Cells from the above cultures were harvested and resuspended in 5 mL LB medium containing 10 
mM MgCl2 and this procedure was repeated. 100 μL of each culture was mixed, resulting in a 300 
μL mixture, and 100 μL of the mixture was plated onto sterile nitrocellulose disks which were 
placed onto LB agar containing 10 mM MgCl2. The plate was allowed to dry and incubated 
overnight at 30 °C in duplicate. The cells were then removed from the disc and resuspended in 
0.9% NaCl. A serial dilution from 0 to -5x was carried out and 100 μL from each dilution were 
plated onto selective agar plate, TSA (Tp 150 μg/mL, PMX 600 U/mL) was applied when donor 
strain was E. coli SY327 carrying recombinant pGPI-SceI or pMLBAD, TSA (Tc200 μg/mL, PMX 600 
U/mL) was applied when donor strain was E. coli SY327 carrying pDAI-SceI. This selects against E. 
coli and wild type Burkholderia cells. The plates were incubated for 48-72 h at 30 °C to allow the 
exconjugants to grow. 100 μL of helper strain, donor strain and Burkholderia culture were plated 
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onto corresponding selective plate respectively as negative controls and these should remain 
clear with no growth. 
6.4 Burkholderia metabolite extraction and LC-MS analysis 
6.4.1 Metabolite production and extraction 
Production of gladiolin, icosalides and their respective derivatives was achieved by growth of B. 
gladioli BCC1622 wild type or related gene deletion and mutagenesis mutants at 30 °C on solid 
minimal medium containing glycerol as a sole carbon source (BSM). For restoring gladiolin 
production in the gene complementation mutant, L-arabinose with final concentration of 0.2% 
or 2% was used as inducer and added to the BSM medium. Following incubation for 3 days the 
growth was removed by scraping with a spatula from the agar plate, any remaining bacteria were 
killed with chloroform vapor, and the agar was cut into ~0.5 cm cubes. Approximately 4 mL of 
acetonitrile was added per 1 plate of agar and the resulting mixture was left for 1 h. The extract 
was filtered and 100 μL of the resulting supernatant was then subjected for LC-MS analysis. 
6.4.2 Metabolite LC-MS analysis 
LC-MS analysis of Burkholderia metabolite was performed using a Dionex UltiMate 3000 UHPLC 
connected to a Zorbax Eclipse Plus column (C18, 100 × 2.1 mm, 1.8 μm) coupled to a Bruker MaXis 
IMPACT ESI-QTOF mass spectrometer. The UHPLC elution profile is detailed in Table 6.13. The 
mass spectrometer was operated in positive ion mode with a scan range of 50-3000 m/z. Source 
conditions were: end plate offset at −500 V; capillary at −4500 V; nebulizer gas (N2) at 1.6 bar; dry 
gas (N2) at 8 L min−1; dry temperature at 180 °C. Ion transfer conditions were: ion funnel RF at 
200 Vpp; multiple RF at 200 Vpp; quadrupole low mass at 55 m/z; collision energy at 5.0 eV; 
collision RF at 600 Vpp; ion cooler RF at 50–350 Vpp; transfer time at 121 s; pre-pulse storage 
time at 1 s. Calibration was performed with 1 mM sodium formate through a loop injection of 20 
µL at the start of each run. 
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Table 6.13 UHPLC elution profile metabolite LC-MS analysis 
Time (min) Water / 0.1% FA (%) MeCN / 0.1% FA (%) Flow Rate (mL/min) 
0.0 80 20 0.2 
5.0 80 20 0.2 
35.0 0 100 0.2 
40.0 0 100 0.2 
45.0 80 20 0.2 
6.5 Recombinant protein overproduction and purification 
6.5.1 Cloning of recombinant protein expression constructs: 
The constructs used for recombinant protein expression in E. coli are cloned via different methods, 
and are listed in Table 6.14. All insert DNA fragments were amplified from B. gladioli BCC0238 
gDNA and purified as described in 6.2.2 and 6.2.3. The detailed cloning procedures are described 
in 6.2.4 -6.2.7. 



























































































































*upper italic denotes un-annealing region, lower italic denotes overlapping regions used in 
Gibson assembly, underlined denotes restriction sites. 
6.5.2 Site-directed mutagenesis 
Mutant constructs listed in Table 6.16 were generated using Q5 Site-directed Mutagenesis Kit. 
Firstly, the linear mutant plasmids were amplified using corresponding primers, noting the 
amount of DNA template was limited to 1-25 ng/μL. The PCR products were analyzed by taking 5 
μL of crude PCR product to DNA electrophoresis for confirming product yield and purity. 
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Table 6.15 Components of Q5® Site-Directed Mutagenesis reactions 
Component volume 
PCR product 1 μL 
2X KLD reaction buffer 5 μL 
10X KLD Enzymes Mix 1 μL 
Nuclease free water 3μL 
The reaction was left at room temperature for 5 min and immediately transformed to E. coli 
TOP10 chemically competent cells.  
Table 6.16 Overview of the primers and mutations for mutant constructs 



















* The lower case and italic letters indicate un-annealing nucleotide(s).  
6.5.3 Recombinant protein overproduction 
For general recombinant protein overproduction procedures, single transformants of E. coli 
BL21(DE3) carrying the recombinant plasmid were inoculated in 10 mL LB with the appropriate 
antibiotic and grown at 37 °C in a 180 rpm shaker for overnight as seed culture. A 1L scale LB flask 
with appropriate antibiotic was sub-cultured from overnight seed cultures at 37 °C in a 180 rpm 
shaker for ~3.5 h to reach an approximate OD600 value of 0.6-0.8, and then induced with 0.5 mM 
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IPTG, and was left shaking at 15°C for 16 - 20 h. For large scale protein production, followed by 
FPLC purification and size exclusion purification, the expression volume was scaled up to 3 - 5 L. 
For large size proteins (≥100 kDa, e.g. N-His6-IcoA_C4-A3-PCP3 and N-His6-IcoA Module 3) or 
proteins with solubility issues (e.g N-His6-SUMO-GbnE), or proteins with both features (e.g. N-
His6-GbnD2 Module 5), the culture was induced with 0.1-0.25 mM IPTG to slow the 
overproduction process. Following expression, the cells were harvested by centrifuging 5000 rpm, 
4 °C for 15 min and resuspended in 10 mL of loading buffer per litre of culture. 
6.5.4 Recombinant protein purification 
The harvested cell was lysed using a Constant Systems Cell disruptor. The lysate was clarified by 
centrifugation at 17,000 rpm, 4 °C for 30 min and the supernatant was filtered with 0.22 μM 
syringe filter. The resulting supernatant was subjected to different purification procedures (as 
listed in Table 6.17) depending on the soluble recombinant protein yield and purity. The following 
purification procedures are described in 6.5.4.1-6.5.4.3.   
Table 6.17 Overview of tag type, size and purification method for recombinant protein 
Recombinant protein Fusion tag Size (kDa) Purification method* 
GbnD1 ER1-ACP1 N-His6-V5  61.3 Bench-top IMAC 
GbnD1 ER1 N-His6-V5  44.9 Bench-top IMAC 
GbnD2 ACP5 N-His6-V5 16.8 Bench-top IMAC 
GbnD1 ACP3 N-His6 16.6 Bench-top IMAC 
GbnD2 ACP4 N-His6 21.2 Bench-top IMAC 
GbnD4 ACP10 N-His6 17.5 Bench-top IMAC 
GbnE N-His6-V5  54.8 FPLC IMAC followed by size exclusion 
N-His6-SUMO 64.4 FPLC IMAC followed by size exclusion 
GbnE(H198V) N-His6-SUMO 64.3 FPLC IMAC followed by size exclusion 
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GbnD2 Module 5 N-His6 161.7 FPLC IMAC followed by size exclusion 
GbnD2 KS6-ACP6a N-His6 95 Bench-top IMAC 
GbnD2 Module 6 (S941A) N-His6 111.6 FPLC IMAC followed by size exclusion 
IcoA C4 N-His6-V5 57.4 Bench-top IMAC 
IcoA PCP3 N-His6-V5  12.7 Bench-top IMAC 
IcoA C4-A3-PCP3 N-His6 119.4 Bench-top IMAC 
IcoA C4-A3-PCP3 (H143A) N-His6 119.3 Bench-top IMAC 
IcoA Module3 N-His6 169.7 Bench-top IMAC 
IcoA_PartI N-His6 288.2 Bench-top IMAC 
IcoA_PartII N-His6 266.0 Bench-top IMAC 
* IMAC referred to immobilized metal-ion affinity chromatography  
6.5.4.1 Bench-top immobilized metal-ion affinity chromatography  
The filtered supernatant was loaded on a 1 mL HiTrap® HP Chelating Column (GE Healthcare), 
pre-charged with 100 mM NiSO4 and equilibrated with loading buffer. The loaded column was 
washed with 15 mL loading buffer to remove any non-specifically binding protein impurities, 
followed by serial elution with 5 mL 50 mM, 3mL 100 mM, 3 mL 200 mM, 3 mL 300 mM imidazole 
elution buffer. Fractions were analyzed by SDS-PAGE (described in 7.5.5) and target protein 
containing fractions were collected and concentrated by Viva-spin concentrator (GE Healthcare) 
with an appropriate MWCO according to the recombinant protein size (listed in Table 6.17). The 
concentrated fractions were washed with 10 CV storage buffer and aliquoted and stored at -80 °C. 
6.5.4.2 Fast protein liquid chromatography (FPLC) 
FPLC purification was performed with ÄKTA pure (GE Healthcare) connected with 5mL HiTrap® 
HP pre-charged column and Fraction Collector (GE Healthcare) F9-C. After loading with filtered 
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lysate, the column was washed with loading buffer until the UV280 absorption trace was flat 
followed by elution over a gradient of 0 - 100% 500 mM imidazole elution buffer in 100 mL. 2mL 
fractions were collected and analyzed by SDS-PAGE. Target protein-containing fractions were 
collected and concentrated to 2 mL by Viva-spin concentrator (GE Healthcare) with an 
appropriate MWCO according to the recombinant protein size (listed in Table 6.17) and subjected 
to the following size exclusion purification. 
6.5.4.3 Size exclusion chromatography 
Size exclusion purification was performed on ÄKTA pure (GE Healthcare) connected with 
HiLoad 16/600 Superdex 200 pg column (GE Healthcare) and Fraction Collector (GE Healthcare) 
F9-C. 2 mL nickel affinity chromatography purified protein was loaded on pre-equilibrated column 
with storage buffer. The column was then eluted over 1.2 CV with storage buffer and 2 mL 
fractions were collected and analyzed by SDS-PAGE. Pure target protein containing fractions were 
collected and concentrated by Viva-spin concentrator (GE Healthcare) with an appropriate 
MWCO according to the recombinant protein size (listed in Table 6.17) and aliquoted and stored 
at -80 °C.  
6.5.5 SDS-PAGE analysis of protein 
SDS-PAGE was used to analyse the size of recombinant protein overproduction, yield and purity 
of purification fractions. Protein samples were mixed with 5X SDS-PAGE loading buffer and loaded 
onto different percentage Tris-glycine SDS-polyacrylamide gels (recipe in Table 6.18) depending 
on the size of protein, 15% for ≤20 kDa, 10% for 20-80 kDa, 6% for ≥ 80 kDa. The gel was run in 
SDS-PAGE running buffer using Bio-Rad mini gel electrophoresis system. PageRuler Prestained 
Protein Ladder (Thermo Sientific) was used as reference to estimate the size of protein. Gel was 
stained in InstantBlue™ Protein Stain (Expedeon). 
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Table 6.18 Recipe of Tris-glycine SDS-polyacrylamide gels 
 
Component 
Volume of component (mL) 
5 mL Resolving gel  2 mL 
Stacking gel 6% gel 10% gel 15% gel 
H2O 2.6 1.9 1.1 1.4 
30% acrylamides mix 1.0 1.7 2.5 0.33 
1.5 M Tris* 1.3 1.3 1.3 0.25 
10% SDS 0.05 0.05 0.05 0.02 
10% ammonium persulfate 0.05 0.05 0.05 0.02 
TEMED 0.004 0.002 0.0002 0.002 
*pH 8.8, 1.5 M Tris was used for resolving gel and pH 6.8, 1.5 M Tris was used for stacking gel. 
6.6 In vitro biochemical assays  
6.6.1 General PPTase-catalysed phosphopantetheinyl loading ACP assays 
6.6.1.1 CoA substrate loading assays162 
100 μM ACP was incubated with 2 μM Svp (PPtase from Streptomyces verticillus162), 10 mM MgCl2 
and 500 μM CoA or CoA thioester in storage buffer in a total volume of 50 μL. The reaction was 
allowed to proceeded at room temperature for 30 min. The completion of the loading reaction 
was monitored by LC-MS (section 6.7). 
6.6.1.2 Pantetheine substrate loading assays163 
100 μM ACP was incubated with 2 μM Svp, 2 μM pantethenate kinase (PanK), 2 μM 
phosphopantethein adenylytranferase (PPAT) and 2 μM dephosphocoenzyme A kinase (DPCK) in 
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the presence of 10 mM MgCl2, 5 mM ATP and 1 mM acyl-pantetheine substrate in storage buffer 
in total volume of 50 μL. The reaction was allowed to proceeded at room temperature for 1h. 
The completion of loading reaction was monitored by LC-MS (section 6.7). 
6.6.2 Characterization of GbnD1 ER1 domain 
6.6.2.1 GbnD1 ACP-ER1 di-domain enoyl reduction assay 
GbnD1 ACP-ER1 was first loaded with a 2-butenoyl-PPant unit using 2-butenoyl-CoA according to 
procedures described in 6.6.1.1. 50 μM crotonyl-GbnD1 ACP-ER1 was then incubated with 500 
μM NADPH/NADH in storage buffer in a final volume of 50 μL. The reaction was allowed to 
proceeded at room temperature for 5h. The control reaction was conducted under the same 
conditions without adding cofactor NADPH/NADH. The enoyl reaction was monitored LC-MS 
analysis (section 6.7). 
6.6.2.2 Stand-alone GbnD1 ER1 enoyl reduction assay 
From an ACP bound substrate 
GbnD1 ACP5 was loaded with 2,4-hexadienoyl-PPant unit using 2,4-hexadienoyl pantetheine as 
described in 6.6.1.2. Then, 50 μM 2,4-hexadienoyl-GbnD2 ACP5 was incubated with 50 μM 
GbnD1 ER1 and 500 μM NADPH or NADH in storage buffer in a final volume of 50 μL. The reaction 
was allowed to proceed at room temperature for 5 h. A control reaction was conducted under 
the same conditions without adding GbnD1 ER1. The enoyl reaction was monitored by injection 
ion generated from intact protein species in LC-MS analysis (section 6.7). 
From a pantetheine substrate 
50 μM GbnD1 ER1 was incubated with 1 mM 3-methyl-butenoyl-Pant in storage buffer in a final 
volume of 50 μL. The reaction was allowed to proceeded at room temperature for 5 h. Control 
reaction was conducted at same condition with boiled GbnD1 ER1. The completed reaction was 
extracted with (2x 100 μL) of acetonitrile and the extracted products was dissolved in 100 μL 
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methanol and subjected for LC-MS analysis (section 6.4.2). 
6.6.3 Characterization of GbnE  
GbnD2 ACP5 (or GbnD1 ACP3, GbnD4 ACP10 and GbnD5 ACP12 in corresponding assays) was first 
loaded with 2,4-hexadienoyl-PPant unit using 2,4-hexadienoyl pantetheine using procedures 
described in 6.6.1.2. 50 μM 2,4-hexadienoyl-ACP was than incubated with 50 μM GbnE or 
GbnE(H198V) and 500 μM NADPH or NADH in storage buffer in a final volume of 50 μL. The 
reaction was allowed to proceed at room temperature for 5 h. Control reaction was conducted 
under the same conditions but lacking GbnE. The enoyl reaction was monitored by injection ion 
generated from intact ACP species in LC-MS analysis (section 6.7).  
6.6.4 Characterization of GbnD2 Module5  
6.6.4.1 Characterization of the iterative nature of GbnD2 Module5  
50 μM GbnD2 Module 5 was incubated with 1 mM 2,4-hexadienoyl-NAC in storage buffer in a 
final volume of 50 μL at room temperature for 3h followed by concentration to 150 μM using a 
Viva-spin concentrator (GE Healthcare).  Meanwhile, GbnD2 ACP5 domain was loaded with a 
malonyl unit using malonyl-CoA following the procedures in 6.6.1.1. 50 μM acylated-GbnD2 
Module 5 was incubated with 100 μM malonyl-GbnD2 ACP5, and 800 μM of NADPH in storage 
buffer to a final volume of 50 μL. The reaction was allowed to proceed at room temperature for 
20h and monitored over time (2 h and 5 h and 20 h). Control reactions were conducted under 
the same conditions using GbnD1 ACP3 and GbnD4 ACP10 respectively instead of GbnD2 ACP5. 
For detection of iteration, intact ACP species were monitored by LC-MS analysis (section 6.7).  
6.6.4.2 Probing the ability of GbnE to stop the iteration of GbnD2 Module5  
The pre-acylation of GbnD2 Module 5 and malonylation of GbnD2 ACP5 followed the same 
conditions and procedures as in 7.6.4.1. 50 μM GbnE or GbnE(H198V) was then mixed with 50 
μM acylated-GbnD2 Module 5, 100 μM malonyl-GbnD2 ACP5 and 800 μM of NADPH in storage 
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buffer to a final volume of 50 μL. The reaction was allowed to proceeded at room temperature 
for 5 h and monitored by LC-MS analysis of intact GbnD2 ACP5 species (section 6.7).  
6.6.5 Characterization of GbnD2 Module 6 (S941A)  
6.6.5.1 GbnD2 Module 6 (S941A) and GbnD2 ACP5 domain acyl transferring assays 
GbnD2 ACP5 was first loaded with 4-hexenoyl-PPant or 2,4-hexadienoyl-PPant units using the 
corresponding pantetheine substrates using procedures described in 6.6.1.2. 100 μM GbnD2 
ACP5 with substrate loaded was then incubated with 300 μM GbnD2 Module 6(S941A) in storage 
buffer in a final volume of 50 μL. The reaction was allowed to proceed at room temperature for 
8h. To detect the acyl transferring from GbnD2 ACP5 to KS domain in GbnD2 Module 6(S941A), 
intact GbnD2 ACP5 species were monitored over time course (2 h ,4 h, 6 h and 8 h) by LC-MS 
analysis (section 6.7). 
6.6.5.2 GbnD2 Module6 (S941A) elongation assay  
50 μM GbnD2 Module 6(S941A) was first incubated with 1 mM 4-hexenoyl- or 2,4-hexadienoyl-
NAC respectively in a final volume of 50 μL. The reaction was allowed to proceed at room 
temperature for 3h. For confirmation of acylation, intact GbnD2 Module 6 (S941A) species was 
monitored by LC-MS analysis. 50 μM acylated GbnD2 Module 6 (S941A) was then incubated with 
1 μM Svp, 500 μM Malonyl-CoA, and 10 mM MgCl2 in storage buffer in a final volume of 50 μL. 
The reaction was allowed to proceeded at room temperature for 5h. To detect the elongation the 
intact GbnD2 Module 6 (S941A) species was monitored by LC-MS analysis (section 6.7). 
6.6.6 Characterization of IcoA C4 domain 
IcoA PCP3 was first loaded with L-Ala PPant unit using L-Ala pantetheine as described in 6.6.1.2. 
100 μM L-Ala-IcoA PCP3 was incubated with 100 μM IcoA C4 and 1 mM of 3R-hydroxyoctanoyl 
pantetheine or 3S-hydroxyoctanoyl pantetheine in storage buffer in a final volume of 50 μL. The 
reaction was allowed to proceed at room temperature overnight. For detection of condensation, 
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intact IcoA C4 species was monitored by LC-MS analysis (section 6.7).   
6.6.7 Characterization of IcoA C4-A3-PCP3 tri-domain 
IcoA C4-A3-PCP3 tri-domain was converted to its holo form as described in 6.6.1.1. 100 μM holo-
IcoA C4-A3-PCP3 was then incubated with 500 μM L-Ser, 500 μM ATP, 10 mM MgCl2, 1 mM of 
(3R)-hydroxyoctanoyl pantetheine or 3S-hydroxyoctanoyl pantetheine in storage buffer in a final 
volume of 50 μL and the reaction was allowed to proceed for 6h at room temperature. The control 
reaction was conducted using the same conditions while using IcoA C4-A3-PCP3(H143A) instead 
of IcoA_C4-A3-PCP3. For detection of condensation, intact wild type and mutant IcoA C4-A3-
PCP3 species was monitored by LC-MS analysis (section 6.7).  
6.6.8 Characterization of IcoA Module 3 
Holo modification of IcoA Module 3 was following the procedures decribed in 6.6.1.1. Serine 
adenylation of IcoA Module 3 was conducted by incubation of 100 μM holo IcoA Module 3 with 
500 μM L-Ser, 500 μM ATP, 10 mM MgCl2 in storage buffer in a final volume of 50 μL and the 
reaction was allowed to proceed for 3h at room temperature. For detection of holo modification 
and serine adenylation, intact IcoA Module 3 species was monitored by LC-MS analysis (section 
6.7). 
6.6.9 Two-piece In vitro reconstitution of icosalides biosynthesis  
IcoA_Part I and IcoA_Part II were first converted to holo form by incubation of 40 μM recombinant 
protein with 2 μM Svp, 200 μM CoA, 5 mM MgCl2 in the total volume of 50 μL at room 
temperature for 30 min. 20 μM of each holo form protein were than incubated with 5 mM L-
serine, 5 mL L-leucine, 1 mM 3R-hydroxyoctonyl-Pant and 1mM ATP in a total volume of 100 μL 
at room temperature for 5 h. The completed reaction was extracted with ethyl acetate (2 x 100 
μL) and the solvent was evaporated. The extracted product was dissolved in 100 μL acetonitrile 
and analysed by LC-MS analysis (section 6.4.2).   
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6.7 LC-MS analysis of proteins and in vitro intact protein assays 
All proteins and in vitro assays were analysed on a Bruker MaXis II electrospray ionisation time-
of-flight mass spectrometer (ESI-TOF-MS), connected to a Dionex 3000 RS UHPLC fitted with an 
ACE C4-300 RP column (100 x 2.1 mm, 5 μm, 30 °C). The UHPLC elution profile is detailed in Table 
6.19. 
The mass spectrometer was operated in positive ion mode with a scan range of 200–3000 m/z. 
Source conditions were: end plate offset at −500 V; capillary at −4500 V; nebulizer gas (N2) at 1.8 
bar; dry gas (N2) at 9.0 L min−1; dry temperature at 200 °C. Ion transfer conditions were: ion funnel 
RF at 400 Vpp; multiple RF at 200 Vpp; quadrupole low mass at 300 m/z; collision energy at 8.0 
eV; collision RF at 2000 Vpp; transfer time at 110.0 µs; pre-pulse storage time at 10.0 µs. 
Table 6.19 UHPLC elution profile for intact protein LC-MS analysis 
Time (min) Water / 0.1% FA (%) MeCN / 0.1% FA (%) Flow Rate (mL/min) 
0.0 95 5 0.2 
5.0 95 5 0.2 
35.0 0 100 0.2 
40.0 0 100 0.2 
45.0 95 5 0.2 
 
6.8 Full length icosalide NRPS encoded gene cloning 
6.8.1 Capturing plasmid construction 
The capturing plasmid pCAP1000-Icos was constructed from the optimized capturing vector 
pCAP1000 (generated by Dr. Chuang Huang) with the homologous flanking arms and counter 
selective marker pADH-URA3 encoded fragments assembled via GeneArt assembly as described 
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in 6.2.7 (primers listed in Table 6.20).   
Table 6.20 Overview of primers for construct pCAP1000-icoA 
















* Italic letters denote overlapping region used in GeneArt assembly. 
6.8.2 Yeast transformation 
Burkholderia gladioli BCC238 genomic DNA was isolated as described in 6.2.1. Purified genomic 
DNA was digested with ApaLI and capturing plasmid pCAP1000-Icos was digested with PmeI. Both 
the digestions were purified by ethanol precipitation method described in 7.2.8. 2 µg of digested 
genomic DNA and 50 ng of linearized pCAP1000-Icos were used for yeast spheroplast 
transformation. The yeast spheroplast preparation and transformation were conducted 
according to previously reported protocol.164 
6.8.3 Candidate yeast colonies screening 
To identify candidate yeast colonies harboring cluster captured pCAP1000 plasmid (pCAP1000-
icoA) colonies were picked and grown on a selective plate at 30 °C overnight and then screened 
by colony PCR. Specifically, the cells were scooped and resuspended in 200 µl yeast plasmid 
isolation 1 buffer containing 0.1% v/v 2-mercaptoethanol and 0.2 mg/mL zymolyase 20T. The 
suspension was incubated at 37 °C for 2 h and then mixed with 400 µl solution 2 by inversion. 
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300 µl solution 3 was added and the mixture was centrifuged for 10 min at 13000 rpm. The 
supernatant transferred was then mixed with equivalent volume isopropanol to allow the DNA 
precipitation. The precipitated DNA was collected by centrifuging for 10 min at 13000 rpm and 
the pellet was dried in air and dissolved in 100 µl water. 1 µl of the isolated DNA was used for 
PCR screening using IcoA_C4-For and IcoA_C4-Rev (listed in Table 6.14).  
6.8.4 IcoA containing plasmid DNA extraction and confirmation 
The PCR screened positive candidate colony was grown in 10 mL selective liquid medium at 30 °C 
shaker for 20-30 h. The cells were collected and plasmid DNA was isolated by similar procedures 
as described in section 6.8.3, except after addition of solution 3 and centrifuging the supernatant 
was transferred and extracted with 500 µL PCI(Phenol/chloroform/isoamylol=25:24:1) solution 
and centrifuged at 13000 rpm for 10 min. The resulting supernatant was then mixed with 500 µL 
isopropanol to allow the DNA precipitation and centrifuged at 13000 rpm for 10 min. The pellet 
was then washed with 70 % ethanol and dried in air and finally dissolved in 20 µl water. 10 µl of 
isolated plasmid DNA was transferred into E. coli TOP10 by electroporation for replication 
(described in 6.2.9). The transformants were grown in 5 mL LB and plasmid DNA was isolated by 
mini-prep kit. The cluster containing plasmid pCAP1000-Icos-cluster was finally confirmed by SacI 
and BamHI restriction enzyme digestion. Expecting fragments size were 4784, 4428, 3105, 2490, 
237, 162, 642, 8174 bp for SacI digestion and 1081, 1203, 210, 1837, 1442, 1196, 6361, 210, 
10464 bp for BamHI digestion. 
6.9 Icosalides full length NRPS heterologous expression in E. coli 
For heterologous expression in E. coli, icoA was first cloned onto pET28a (+) from pCAP1000-Icos-
cluster using NdeI and EcoRI site. The plasmid pET28a(+)-icoA was confirmed by restriction 
digestion and transformed to E. coli BAP1158 cells were transformed. A single colony was picked 
for over production of the recombinant IcoA. Specifically, the overnight culture was sub-cultured 
in 50 mL LB containing 50 µg/mL kanamycin and induced with 0.1 mM IPTG at 15 °C for 20 h after 
cell density reaching OD600 0.6-0.8. For confirmation of the functionality of the over produced 
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NRPS, 10 mL of the induced and non-induced culture was extracted with 20 mL ethyl estate. The 
extract was dried and dissolved in 500 µl acetonitrile for LC-MS analysis to monitor icosalides 
production.  
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MHHHHHHGKP IPNPLLGLDS TENLYFQGID PFT 
10         20         30         40         50         60  
AAPSPSGEAS TPLPAGDYGL VVRTVHALDE LSVEPWTPGE PGDDEVLIEV RASALNFPDV  
 
        70         80         90        100        110        120  
MCVQGLYPTQ PAYPFVPGFE VAGVVAAVGR AVVGIRVGEA VLALTGERMG GLASRVVVPA  
 
       130        140        150        160        170        180  
ANVLPKPSRL SFEEAASLPV AFLTAHHAFE TGRLAAGERV LIQTATGGCG LAAIQLARLR  
 
       190        200        210        220        230        240  
GARVYGTSSR AAKRALLERI GVEHVLDYRA AFDRELAGLT DGRGVDVVLN MLSGDAIQRG  
 
       250        260        270        280        290        300  
LDSLAPAGRY VEIAVHGLRT SGTLDLSRLV DNQSFHSIDL RRARARGLDW GETLAGLLPL  
 
       310        320        330        340        350        360  
FETGALVPIV SRVYPAEQLG EALRYVATGE HVGKVVIRHR GGALDDCVEA CVSRLVAQRE  
 
       370        380        390  
IAAREAARPA SLPVVPRRAS AAAQPASETH AP 
 
N-His6-GbnD1 ACP1-ER1 
MHHHHHHGKP IPNPLLGLDS TENLYFQGID PFT 
10         20         30         40         50         60  
PEPAEAGNVA VQATDADSFD LNISHDEIIE RSVAPDAATS RRRTIDSGPD LILERELAES  
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        70         80         90        100        110        120  
LGQSLYLPAD EIDPERPFVE LGLDSIVGVE WARAINKAYG IALPATRLYD HVTIRLLAAH  
 
       130        140        150        160        170        180  
LVEQWGVARR DSARPAEPPV GLVAPVTRAP IAAAPSPSGE ASTPLPAGDY GLVVRTVHAL  
 
       190        200        210        220        230        240  
DELSVEPWTP GEPGDDEVLI EVRASALNFP DVMCVQGLYP TQPAYPFVPG FEVAGVVAAV  
 
       250        260        270        280        290        300  
GRAVVGIRVG EAVLALTGER MGGLASRVVV PAANVLPKPS RLSFEEAASL PVAFLTAHHA  
 
       310        320        330        340        350        360  
FETGRLAAGE RVLIQTATGG CGLAAIQLAR LRGARVYGTS SRAAKRALLE RIGVEHVLDY  
 
       370        380        390        400        410        420  
RAAFDRELAG LTDGRGVDVV LNMLSGDAIQ RGLDSLAPAG RYVEIAVHGL RTSGTLDLSR  
 
       430        440        450        460        470        480  
LVDNQSFHSI DLRRARARGL DWGETLAGLL PLFETGALVP IVSRVYPAEQ LGEALRYVAT  
 
       490        500        510        520        530        540  






MGSSHHHHHH GSGLVPRGSA SMSDSEVNQE AKPEVKPEVK PETHINLKVS DGSSEIFFKI  
 
KKTTPLRRLM EAFAKRQGKE MDSLRFLYDG IRIQADQTPE DLDMEDNDII EAHREQIGG 
        10         20         30         40         50         60  
MAMITASSLG NADFRNDYRI KYAYLAGAMY RAIASKELVV ALGKAGLMGF LGTGGLRLDD  
 
        70         80         90        100        110        120  
IEAAILQIQA ELGVDGVYGM NLLADLERPE REEATVDLYL RHGVRHVEAA AYMRVTPALV  
 
       130        140        150        160        170        180  
RYRLRGASIG ADGRAVARHH VVAKVSRPEV ASQFMQPAPP ALVQQLVAAG RLDAREAELA  
 
       190        200        210        220        230        240  
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PQLPLAGDIC VEADSGGHTD RGVAYVLIPA MQSLRDELMT RHRYAKRIRI GAAGGIGTPQ  
 
       250        260        270        280        290        300  
AAAAAFVMGA DFIVTGSINQ CTREAGTSDV VKALLQELDV QDTAYAPAGD MFELGAKVQV  
 
       310        320        330        340        350        360  
ARRGLFFAAR ASRLHELYQQ HASLDEIDPA MRSQIEQKFF RRGFDEIWDE TRRHYASSRP  
 
       370        380        390        400        410        420  
DQIAEIERSP KKKMAAVFRW YFAHSTQLAL SGDDTRLTDF QVHCGPALGA FNRWVRGTPL  
 
       430        440        450        460  
ESWQNRHVAD LAERIMQGTA AWLEARLASM ADSGGQRPSL QLQRQ  
 
N-His6-GbnD1 ACP3 
MGSSHHHHHH SSGLVPRGSH  
       10         20         30         40         50         60  
TATVPTTVTT PTATENDALA ARAIEYFRKW LAAQLKVGAD QLDDDAPLDR YGIDSVRVMQ  
 
        70         80         90        100        110        120  
LTSALESRFG PLSKTLFFEY RNVAELSRHF VQAHRERMLD LLGLASPSAA PLPTSRPAGP  
 





       10         20         30         40         50         60  
PATQRADVRD EITALYRQIQ AGSIERGEAA ARIARLRALA RDGGSDGSSG TDDGPAVPLA  
 
        70         80         90        100        110        120  
AIVEAVKTRV AAVLEVPLAR IEVDAPLDRY GIDSVTVMRL TGEFERELGP LSKTLLFEYR  
 
       130        140        150        160        170        180  
TVGEVSRYFS VSHAASVARW LGVAASAPSA PPGAYQAGAR TMRAMAVATR GLAVPPATAS A  
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N-His6-GbnD2 ACP5 
MHHHHHHGKP IPNPLLGLDS TENLYFQGID PFT 
        10         20         30         40         50         60  
PNPASLSSVP GGQDATRAAS AALLADEALR HVKRQLAAVI RLPVERIDED ASFEEYGIDS  
 
        70         80         90        100        110        120  







        10         20         30         40         50         60  
AQAKPVAGAA PAAAGVPAPA PIADAAELGA RVDAALARAV CEILRIGESD VDAETDFSAY  
 
        70         80         90        100        110        120  
GFDSISLTEF SNRIGERLGV ELLPTIFYEY PSLLALRGFL LAEHGAALAA ALQVQPAAGR  
 
       130        140  
QVEPDPEPHR ESNRESNPGA AAVGLPEG 
 
N-His6-GbnD5 ACP12 
MHHHHHHGKP IPNPLLGLDS TENLYFQGID PFT 
        10         20         30         40         50         60  
VAAGYDGARA AALAAGESTR ASFDEALRRF VTDQLAAQGV ALAGRLGDDT PFFDAGLDST  
 
        70         80         90        100        110  
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        10         20         30         40         50         60  
AGARTMRAMA VATRGLAVPP ATASASLPQD RPEATATGTQ AVAVIGLAGR YPQAADLDAF  
 
        70         80         90        100        110        120  
WENLSTGRDC ITEIPSTRWD HEVYFDARKG QPGKSYSKWG GFLDGVDEFD PSFFSISPRE  
 
       130        140        150        160        170        180  
AQLMDPQERL FLQCAYHALE DAGHTRASLG AARVGVFVGV MYEEYPYHGS PSQGTTQPQA  
 
       190        200        210        220        230        240  
LGGSSASIAN RVSYAFNLNG PSIAMDTMCS SSLTALHLAC QSLRLGECEL ALAGGVNVSI  
 
       250        260        270        280        290        300  
HPNKYLGLSQ GQFASSEGRC RSFGAGGDGY VPSEGVGCVL LRPLAAAEAA GDRILGVIRA  
 
       310        320        330        340        350        360  
SAINHGGRTN GYTVPNPNAQ GELIAEALRA SGVDARAISY LEAHGTGTAL GDPIEIAGLV  
 
       370        380        390        400        410        420  
KAYGAWEGEP GEPGEPGDAR LEPCAIGSVK SNIGHCESAA GIAGLTKVLL QMRHGKLAPS  
 
       430        440        450        460        470        480  
LHAQTLNPLI DFGRTPFRVQ RELAPWRRPR VRVDGVEREM PRLAGISSFG AGGANAHVIV  
 
       490        500        510        520        530        540  
EEYVARAVEA ADARREGQPA IVVLSARSEA QVLIQARNLQ AAIEREAYGE GELAALAHTL  
 
       550        560        570        580        590        600  
QAGREAFEVR LATTVTSMAM LVERLASLAG EAPDYSAWMR GETRRDAADL PAPETVEGWL  
 
       610        620        630        640        650        660  
AQGRVEPLLR AWLDGLAFDW RRLRAADPPI RPLRLPGYPF ARQRYWADPP AAAAPRVARL  
 
       670        680        690        700        710        720  
HPLLHENRST AFEPQFVSHF DGREACLADH RVAHARVLPG AAQLEIARAA AALSLGEAAA  
 
       730        740        750        760        770        780  
LELTEVAWLQ PACFDEQGGS LRIALFVDSE TEAEFDIGSL DGDTVYSQGR LRLREAASPV  
 
       790        800        810        820        830        840  
VLELASLRAA CGQVPLAPEA LYASFAAAGL QYGPAHRAIA ELRTGLDTAG RPQVLARLEV  
 
       850        860        870        880        890        900  
PDGAADEALV LHPSLVDGAI QATIGLLLVP GGARRAMLPA RLGRVGVAAA TPARGWAWLR  
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       910        920        930        940        950        960  
FAEGSGPEDV APRIDLSICD EHGAVALEIE ALTLMPAPVA SQTGVETLWL APAWAEAEAP  
 
       970        980        990       1000       1010       1020  
LDAPRGAAQP TREVFVAGQL PEGVLAALAR RYGESRVHVA PGADAMPLAA GYVAAADALF  
 
      1030       1040       1050       1060       1070       1080  
AIVRERLADV ASGECLFQLL RVEDGTAGAA CLDGLGALLR TASIENPRFA TQSIRIDAAD  
 
      1090       1100       1110       1120       1130       1140  
ATDGETLLAL LDANARERDS REIAYLDGRR RQRRHLELSQ PGGDVPAWPA GTVALITGGL  
 
      1150       1160       1170       1180       1190       1200  
GGIGYRVAES IAASGPGTTL LLCGRSEPAD AAARLGALRA AGANAEFVRT DITDAAATEA  
 
      1210       1220       1230       1240       1250       1260  
LVAGIVARHG RLDTVIHSAG IVRDNFVIRK NASELHAVLA PKVAGLVNLD AATRSLPLRE  
 
      1270       1280       1290       1300       1310       1320  
LIVFSSVSGA FGNAGQADYA CANAFMDAFA AWRATRVAAG ERSGRTLSIG WPLWAEGGMR  
 
      1330       1340       1350       1360       1370       1380  
VDAAVEAKLR RDGLAPLDTA SGLAVLARCR QLPPELTQVV VLAGDAARLR ARHGLAAAAI  
 
      1390       1400       1410       1420       1430       1440  
GAAASAPNRA PNPAPNPASL SSVPGGQDAT RAASAALLAD EALRHVKRQL AAVIRLPVER  
 
      1450       1460       1470       1480       1490       1500  
IDEDASFEEY GIDSVMAVEL TDRLERACGP LSKTLLFEYQ SVRDLTAFLV RHHAEGLGAA  
 
      1510  
LGLGEASSDG ETAKAEV  
 
N-His6-GbnD2 KS6-ACP6a and N-His6-GbnD2 Module6(S941A) 
MGSSHHHHHH SSGLVPRGSH 
       10         20         30         40         50         60  
DGETAKAEVA VAALAAGAVA TARAAGPALA PVAPRTRRRP RGRLPGRESE PPRITAIAVI  
 
        70         80         90        100        110        120  
GLAGRYPQAA DLDAFWENLS TGRDCITEIP STRWDHEAYF DARKGQPGKS YSKWGGFLDG  
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       130        140        150        160        170        180  
VDEFDPFFFN ISPREAQLMD PQERLFLQCA YHALEDAGHT RASLGAVRVG VFVGVMYEEY  
 
       190        200        210        220        230        240  
HLLSDPAGGD LAQTYIPGGY LSSVANRVSY FGNFRGPSFG VDTMCSSSLT ALHLACQSLR  
 
       250        260        270        280        290        300  
LGECELALAG GVNVSIHPNK YLGLSQGQFA SSEGRCRSFG AGGDGYVPSE GVGCVLLRPL  
 
       310        320        330        340        350        360  
AAAEAAGDRI LGVIRASAIN HGGRTNGYTV PNPNAQGELI AEALRASGVD ARAISYLEAH  
 
       370        380        390        400        410        420  
GTGTALGDPI EIAGLVKAYG AWEGEPGEPG DARLEPCAIG SVKSNIGHCE SAAGIAGLTK  
 
       430        440        450        460        470        480  
VLLQMRHGKL APSLHAQTLN PLIDFGRTPF RVQRELAPWR RPRVRVDGVE REMPRLAGIS  
 
       490        500        510        520        530        540  
SFGAGGANAH LIVEEYVARA VEAADARREG QPAIVVLSAR SEAQVLIQAR NLQAAIAREA  
 
       550        560        570        580        590        600  
YGEGELAALA HTLQAGREAF EVRLATTVTS MAMLVERLAS LAGETPDYSA WMRGEARRDG  
 
       610        620        630        640        650        660  
NDALAHFAKD PELNEVLRKW LRAGNPVRIA ELWTRGLDID WAAMQEDGPA PARLRLPGYP  
 
       670        680        690        700        710        720  
FATKRYWMAR ADGSPALAAR AAVPARPEPP TRAAVPPAAV KVLAEVLADA PRVAIVLGEP  
 
       730        740        750        760        770        780  
GGFEARTEGA ARAASIRLAV LDPLDEFEPP AAPAAARQDD GQTAAAARQV PAGIEVSIER  
 
       790        800        810        820        830        840  
LRLSLAQMLC AEAADLGADV PFGELGLDSV VGVEWTRAIG REYGVTLAAA TLYDHPTLTT  
 
       850        860        870        880        890        900  
LAAWLAATVE AGAAIATAGR DVPPRPDAHP VRLVEPDQDV ATPLAAAAAV EGGNEAEVAA  
 
       910        920        930        940        950        960  
GMAMPIEALV ERLAGTLAQA LCAEREEIDP DTPFAELGID SVVGVEWVRD INRAFGTELK  
 
       970        980        990       1000       1010       1020  
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ATVLFDHATV KLLAAHLAPL ACPAPHSVRV DPPAAPVEQL AAASAVPARE LADTARHAGS  
 
      1030       1040  
RGHVQAVEPA APVAKTGNAP  
 
N-His6-IcoA PCP3  
MHHHHHHGKP IPNPLLGLDS TENLYFQGID PFT 
        10         20         30         40         50         60  
RYEAPQGETE QAVAALWAEL LGVERIGRHD NFFALGGHSL LAVRMLNRLR AMQAGDLSLS  
 
        70         80  
SLFDHPTVSA VAQAIDSGSR SVA  
 
N-His6-IcoA Module 3 (C3-C4-A3-PCP3), N-His6-IcoA C4-A3-PCP3 and N-His6-IcoA C4 
MGSSHHHHHH SSGLVPRGSH 
        10         20         30         40         50         60  
MRAHDLVRID RNVTMPLSFA EQRVLAIEAG GTRGAMLNSS RLFILSGRVR EDVLDRALRA  
 
        70         80         90        100        110        120  
VVERHEILRT HYAGDETTGS FVPVIGRSAL FHLERREVAE DDAMPIAQSE AARHLDCFRG  
 
       130        140        150        160        170        180  
PVFGATLFVE SPRRAILMIA IHHIAMDAAS WNIVWRDFRQ AYAALAADEP PALAPLALQY  
 
       190        200        210        220        230        240  
RDYAAWTTKQ VDAERLAQLR QTWRERLAGA PVYLNLPADR PRPDKLSDRA GRIERMLAPE  
 
       250        260        270        280        290        300  
LVQGIRQIAT AYKVTPFIVL ETTLAIACAQ LARSRDIVIG TVTEGRTHAA TEDMVGLFVN  
 
       310        320        330        340        350        360  
TLPLRHRLDR TASVASHLLA TSRELLSALE ASELPFADVV AAVNPPRASS HDPIFQVFCQ  
 
       370        380        390        400        410        420  
FQQGPGKTRE TIADMTIEAI PRTRMARGAD LAVVFLDAGE YLSADVSYSA DLFDAESIDA  
 
       430        440        450        460        470        480  
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LIELFLRFLA ESVQRPDAVV DELWDAGVAS ARAVASGPDV SRLVDRPGSP AETWYALSPA  
 
       490        500        510        520        530        540  
QQAVWLQEQA ARPGTSFFSV AAMRCAPEID RMRLVAASRA LIAQNQAFWI QVSDAGLQCE  
 
       550        560        570        580        590        600  
ASTPTTRFQH FVEPTTMTGE AMRRAVIEWH EKLNEDPRDK SGAVAVFDSP GSVLVALRSP  
 
       610        620        630        640        650        660  
HVQNDGWSAL RYFERIGRNY AALESDPARA FDMDRIFLDT LSLDERYLCS PTYERDAAFW  
 
       670        680        690        700        710        720  
QSACARIDGQ PLVTLVADHA HPVDARGVVR SLRKVFPQTL QERVLNAARK LSLSPAECLT  
 
       730        740        750        760        770        780  
ALTALYLMRV TGERSTVLGV SFLNRTREAL DIPGQFAKVI PLPVSIGQGD IPLSSTLNGI  
 
       790        800        810        820        830        840  
RDAFKDVMQH GRFPFGEMVR RYGFDPRHIE ISVNTLFLRH PVEVGGQPAH VQWLSGPEHG  
 
       850        860        870        880        890        900  
LSFLFTQFGR SAPIDIELRY NGNAFDSESV ERHARRLLDF IERACEDDSV SARGIELVSS  
 
       910        920        930        940        950        960  
EERALLIDAL NATDAPYDRN QYLHGLFEAQ AKRTPEATAL IAGDERLSYA ELDARANRFA  
 
       970        980        990       1000       1010       1020  
RYLVDLGVGP DALVAVCLER STAMVVSLIG ILKAGGAYVP IDPAYPGPRI AHIVSDSAPA  
 
      1030       1040       1050       1060       1070       1080  
VVLVDATGRE ALVDALGDEK LAEYGLIDVS AASTPWNKLS SDSLSSNALG LNPRHLAYVI  
 
      1090       1100       1110       1120       1130       1140  
YTSGSTGMPK GVQNEHDALV NRLTWMQEAY RLGGQDVVLQ KTPFSFDVSV WEFFWTLANG  
 
      1150       1160       1170       1180       1190       1200  
ATLVIAEPGA HRDADYLTEI IAKHGVTTLH FVPSMLAGFL EAQDLTRCKT LSRIICSGEA  
 
      1210       1220       1230       1240       1250       1260  
LPAPIARRCL ERLPHAQLHN LYGPTESAID VTAFTCPPDF DAQAVPIGKP IANTRIYLLD  
 
      1270       1280       1290       1300       1310       1320  
ERQAPVPLGA IGELYIGGVG VARGYLNRAD LTAQRFLADP FARAAGHPEA RMYRTGDLAR  
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      1330       1340       1350       1360       1370       1380  
YLPDGNIVFL GRNDDQVKIR GFRIELGEIE VQLAKHEAVR DAIVIARQDS TGNARLLAYV  
 
      1390       1400       1410       1420       1430       1440  
TPQESASREE LARSLREHLT ARLPEYMVPA AFVVLETLPL TPNGKLDRRA LPEPADDAFV  
 
      1450       1460       1470       1480       1490       1500  
QSRYEAPQGE TEQAVAALWA ELLGVERIGR HDNFFALGGH SLLAVRMLNR LRAMQAGDLS  
 
      1510       1520  
LSSLFDHPTV SAVAQAIDSG SRSVA  
 
 
Protein Mass Spectra 
 
Figure S1 High resolution mass spectrum of N-His6-GbnD1 ER1. 
  
Figure S2 High resolution mass spectrum of N-His6-GbnD1 ACP1-ER1. 
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Figure S3 High resolution mass spectrum of N-His6-SUMO-GbnE 
 
Figure S4 High resolution mass spectrum of N-His6-SUMO-GbnE(H198V) 
 
Figure S5 High resolution mass spectrum of N-His6-GbnD1 ACP3 
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Figure S6 High resolution mass spectrum of GbnD1 ACP3 (His-tag cleaved) 
 
Figure S7 High resolution mass spectrum of N-His6GbnD2 ACP5. 
 
Figure S8 High resolution mass spectrum of N-His6 -GbnD4 ACP10 
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Figure S9 High resolution mass spectrum of GbnD4 ACP10 (His-tag cleaved) 
 
Figure S10 High resolution mass spectrum of N-His6-GbnD5 ACP12 
 
Figure S11 High resolution mass spectrum of N-His6-GbnD2 Module 5 
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Figure S12 High resolution mass spectrum of N-His6-GbnD2 Module 6 
 
 
Figure S13 High resolution mass spectrum of N-His6-IcoA C4 
 
Figure S14 High resolution mass spectrum of N-His6-IcoA C4-A3-PCP3 
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Figure S15 High resolution mass spectrum of N-His6-IcoA C4-A3-PCP3 (H143A) 
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Sequence alignments  
 
Figure S17 Multiple sequences alignment of GbnD1 ER1 domain with integrated ER domains from modular 
PKSs. Ery: erythromycin, Spn: spinosyn, Rap: rapamycin, Lkm: lankamycin, Cur:curicin. ‘ERx’ refer to the ER 
domain in the module x. 
* 
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Figure S18 Multiple sequence alignment of GbnE and trans-acting ERs from trans-AT PKS. Ent: etnangien, Ped: 
pederin, Bat: Batumin/kalimantacin, Pks: dihydrobacillaene, Mln: macrolactin, Mup: mupirocin, Lnm: leinamycin, 
Gdm: gladiostatin. 
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Figure S18 (continue) Multiple sequence alignment of GbnE and trans-acting ERs from trans-AT PKS. Ent: 
etnangien, Ped: pederin, Bat: Batumin/kalimantacin, Pks: dihydrobacillaene, Mln: macrolactin, Mup: mupirocin, 
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Mass spectra of extracted ion chromatograms of gladiolin and related 
derivatives  
 
Figure S19 Comparison of high-resolution mass spectra of EICs at m/z= 777.5153 ± 0.02 Da and 799.4972 ± 0.02 
Da, corresponding to [M+H]+ and [M+Na]+ ions of gladiolin derivatives 33 and 34 in B.gladioli BCC1622 WT and 
32 in B.gladioli BCC1622_ΔgbnD1_ER1 
 
Figure S20 Comparison of high-resolution mass spectra of EICs at m/z= 777.5153 ± 0.02 Da and 799.4972 ± 0.02 
Da, corresponding to [M+H]+ and [M+Na]+ ions of gladiolin derivatives 33 and 34 in B.gladioli BCC1622 WT and 
32 in B. gladioli BCC1622_gbnD1_ER1*(G388S/G388P). 
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Figure S20 Comparison of high-resolution mass spectra of EIC at m/z=779.5309 ± 0.02 Da and 
801.5129 ± 0.02 Da, corresponding to the [M+H]+ and [M+Na]+ ions of gladiolin 7 and iso-gladiolin 
28 in B.gladioli BCC1622 WT and B.gladioli BCC1622_ΔgbnE  
 
Figure S 21 Comparison of high-resolution mass spectra of EICs at m/z= 777.5153 ± 0.02 Da and 
799.4972 ± 0.02 Da, corresponding to [M+H]+ and [M+Na]+ ions of gladiolin derivatives 33 and 34 
in B.gladioli BCC1622 WT and B.gladioli BCC1622_ΔgbnE 
 
 
